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Summary
The consequences of the pharmacological manipulation of metabotropic and AMPA 
glutamate receptor-mediated events in the rat brain were investigated in this thesis. [14C]2- 
deoxyglucose autoradiography was used to explore modifications in physiological brain 
function following the systemic administration of two novel selective agonists with actions 
on group II metabotropic glutamate receptors (mGluRs) and following the intracerebral 
manipulation of the hippocampus using a selective AMPA antagonist. The putative role of 
group II mGluRs in neuroprotection was also examined. An in vivo model of cerebral 
ischaemia together with two in vitro models of neurotoxicity with group II mGluR agonist 
intervention were used to study the potential of group II mGluR agonists in protecting 
cellular elements from neurotoxic insults.
Mapping brain function with group II selective mGluR agonists
Local rates of cerebral glucose use were measured using the [14C]2-deoxyglucose 
autoradiographic technique to examine the functional consequences of the systemic 
administration of the novel mGluR agonist LY3 54740, and a related analogue LY3 79268, 
in the conscious rat.
Both LY354740 (0.3, 3.0, 30 mg/kg) and LY379268 (0.1, 1.0, 10 mg/kg) produced 
dose-dependent changes in glucose utilisation. LY3 54740 produced anatomically 
widespread reductions in glucose use, while LY3 79268 affected a smaller number of brain 
regions which displayed increases in glucose metabolism. After LY354740 (3.0mg/kg) 
administration, 4 out of 42 brain regions demonstrated statistically significant changes from 
vehicle treated controls: red nuclei (-16%), mammillary body (-25%), anteroventral thalamic 
nucleus (-29%) and the superficial layer of the superior colliculus (+50%). An additional 15 
regions displayed significant reductions in function-related glucose use (P<0.05) in animals
xvi
treated with LY354740 (30mg/kg). In contrast, LY379268 (0.1, 1.0, lOmg/kg) produced 
changes in glucose metabolism in only 20% of the brain regions analysed. Significant 
increases in glucose use (P<0.05) were evident in the superficial layer of the superior 
colliculus (+81%), locus coeruleus (+57%), genu of the corpus callosum (+31%), cochlear 
nucleus (+26%), inferior colliculus (+20%) and the molecular layer of the hippocampus 
(+14%). Three regions displayed significant decreases: mammillary body (-34%), 
anteroventral thalamic nucleus (-28%) and the lateral habenular nucleus (-24%). Both 
compounds displayed a similar anatomical pattern of altered glucose metabolism in the 
limbic system. Reductions were noted in the anteroventral thalamic nucleus, lateral 
habenular nucleus, molecular layer of the hippocampus and the mammillary body (P < 0.05) 
following both agonists. Glucose utilisation in components of different sensory systems 
were altered following the activation of mGluR2/3. In animals treated with LY3 54740, 
reductions in function-related glucose use were observed in areas associated with vision, 
while those treated with LY3 79268 demonstrated elevated glucose utilisation in primary 
auditory areas.
This study has demonstrated that the [14C]2-deoxyglucose autoradiographic 
technique provides a reliable means of mapping functional events in the brain. It has 
highlighted fundamental differences in the regional effects of the two agonists and has 
served to demonstrate the important functional involvement of the limbic system together 
with the participation of components of different sensory systems in response to the 
activation of mGluR2 and mGluR3 with LY354740 and LY379268.
Regional mapping of cerebral function following hippocampal manipulation
The [14C]2-deoxyglucose autoradiographic technique was used to investigate 
changes in brain function during, and following, the localised 7 day infusion of the selective 
AMPA/kainate receptor antagonist LY326325 in the conscious rat.
During the period of drug infusion, anatomically circumscribed changes in glucose 
use were measured in animals treated with LY326325 compared with aCSF (artificial 
cerebrospinal fluid) treated control animals. Reductions in glucose utilisation were 
demonstrated in the molecular layer of the dorsal hippocampus (-23%, P<0.002) but not in 
the molecular layer of the ventral hippocampus. The maximal reduction in glucose use 
measured in the molecular layer of the hippocampus was observed adjacent to the implant 
site, along a dorsal axis relative to the implant site. Other than a marked elevation in 
function-related glucose use in the superficial layers of the entorhinal cortex, rates of 
glucose utilisation in the remaining regions of the CNS were minimally affected during the 
period of drug infusion.
Following the period of LY326325 infusion, glucose use in the molecular layer of 
the dorsal hippocampus in animals treated with LY326325 returned to levels comparable 
with aCSF treated animals. The elevation in glucose use observed in the entorhinal cortex 
during the period of drug infusion was also not evident. However, a 17% reduction in 
glucose use was observed in the red nucleus of LY326325 animals. Function-related 
glucose use in aCSF treated animals both during the period of drug infusion and after drug 
infusion did not differ significantly.
This study reveals that intrahippocampal infusions of LY326325 can reduce synaptic 
activity as measured by glucose use selectively in the hippocampus in a reversible manner. 
Infusions of this kind may provide invaluable insight into memory processes that are thought 
to involve the hippocampus.
Neuroprotection in vivo and in vitro using group II mGluR agonists
The effects of LY354740 and LY379268 were assessed in the middle cerebral artery 
occlusion model of focal ischaemia in rats. LY354740 (0.3, 3.0 or 30.0 mg/kg) or 
LY379268 (lO.Omg/kg) were administered subcutaneously 30 minutes prior to and 3 hours
after the induction of ischaemia. Twenty four hours after the ischaemic insult, the brains 
were processed for the evaluation of infarct volumes. No significant reduction in infarct 
volumes was observed in animals treated with LY354740 (30mg/kg) (199 ± 22 mm3) 
compared with vehicle treated controls (191 ± 18 mm3). Similarly, no reduction in infarct 
volumes was seen following LY379268 (lOmg/kg) (97 ± 11 mm3) compared with vehicle 
treated controls (101 ± 8  mm3). These data provide no support for the view that group II 
metabotropic glutamate receptors have a major influence on reducing the volume of 
ischaemic damage in this model.
LY3 79268 treated brain tissue in animals in which the middle cerebral artery (MCA) 
had been occluded was assessed together with vehicle treated MCA-occluded animals at a 
cellular level using immunohistochemistry to determine whether any cellular or mechanistic 
changes were distinguishable from the vehicle-treated group. Immunohistochemical analysis 
carried out at one coronal level (anterior co-ordinate 7.19 mm), using markers for amyloid 
precursor protein (APP), transforming growth factor-pi (TGF-|31), TGF-P2, fragment end 
labelling of DNA and for mGluR2/3, demonstrated no changes in APP accumulation score 
or in the number of mGluR2/3 immunoreactive cells. However, labelling for TGF-pi 
demonstrated a significant reduction in the number of immunoreactive cells at the core of 
the ischaemic lesion following LY3 79268 compared with vehicle treated controls. In 
contrast, TGF-P2 immunoreactivity was increased by 25% at the boundary of the ischaemic 
lesion compared to vehicle treated controls. In addition, animals treated with LY3 79268 
displayed significant reductions in the number of terminal deoxynucleotidyl transferase 
(TdT) labelled cells both at the boundary and at the core of the lesion, compared with 
vehicle treated controls. This data provides evidence that activation of mGluR2/3 by 
LY379268 reduces apoptotic-like cell death and results in the increased production of TGF- 
P2. To establish whether astrocytes were involved in the production of TGF-P2, primary
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cultures were incubated with the agonists LY354740 and LY379268. The results showed 
that astrocytes were capable of producing and secreting TGF-02 following treatment with 
LY354740 and LY379268. This response was abolished in cultures simultaneously 
incubated with the mGluR2/3 selective antagonist LY341495 indicating that the response is 
specifically mediated through mGluR2/3.
In a separate series of experiments in vitro, the neuroprotective effects of 
LY354740 and LY379268 were explored using staurosporine-induced toxicity in neuronal 
cell cultures. Both LY354740 and LY379268 (1pm) significantly reduced lactate 
dehydrogenase (LDH) efflux, a marker of cell damage and death, caused by staurosporine.
Collectively, these data provide evidence that group II mGluRs may not have a 
neuroprotective role in focal models of cerebral ischaemia, where damage to cells occurs 
quickly, but that their activation may reduce cell death in instances where the slowly 
evolving cellular damage is protracted to allow defensive intracellular events to take place. 
In addition, such defensive intracellular events are likely to involve glial-neuronal signalling.
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CHAPTER 1 
INTRODUCTION
1.1 Glutamate in the CNS
Glutamate, together with aspartate, are excitatory amino acids found in great 
abundance in the brain. They have well established roles in protein synthesis, as key 
intermediates in ammonia metabolism, and as precursors for other neurotransmitters such as 
y-aminobutyric acid (GABA). A transmitter role for glutamate and aspartate was first 
proposed in the 1950s after observations that sodium glutamate could activate central 
nervous system (CNS) neurones (Hayashi, 1954). Since then, the role of glutamate as a 
neurotransmitter in the CNS, and the elucidation of excitatory amino acid receptors have 
been extensively studied. The availability of potent and selective excitatory amino acid 
agonists and antagonists together with the advent of molecular biological techniques has 
resulted in the discovery of distinct receptor types.
At least 4 classes of receptors exist. Three are ion-channel linked receptors, or 
ionotropic receptors (iGluR) and are named after their preferred agonists:- N-methyl-D- 
aspartate (NMD A), kainate-preferring (KA), and a-amino-3-hydroxy-5-methyl-4- 
isoxazolepropionic acid (AMPA). The remaining class of receptor are the metabotropic 
receptors (mGluR), which are coupled to second messenger systems. While the properties 
of all the receptor types will be outlined, attention will be focused on the metabotropic 
glutamate receptors.
1.2 Ionotropic glutamate receptor classification
The ionotropic glutamate receptor subtypes are traditionally defined by the actions 
of specific agonists and are divided into NMDA and non-NMDA receptors (AMPA and 
kainate receptors). Through DNA cloning, the clear separation between the NMDA 
receptors and non-NMDA receptors that was demonstrated pharmacologically was given a
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molecular basis (Hollman et al., 1989). The protein sequences between the subunits of the 
NMD A receptors and the non-NMDA receptors differed substantially (Hollman et al., 
1989; Moriyoshi et al., 1991; Monyer et al., 1994). Moreover, studies demonstrated that 
there is no significant sequence homology or receptor structure similarity between 
glutamate receptors and other ligand-gated ion channels including the GABAa, nicotinic 
acetylcholine, glycine or serotonin receptors. Unlike other ionotropic receptors which have 
4 transmembrane domains (TMD) and an extracellular C-terminus, the ionotropic glutamate 
receptors appear to have an intracellular C-terminus and only three ‘real’ TMD. (Hollman et 
al., 1994; Kuryatov et al., 1994; Wo & Oswald, 1994). In this model, rather than crossing 
the membrane fully, the second TMD is considered to lie in close proximity to the 
intracellular surface of the plasma membrane or make a hairpin turn in the membrane.
The following sections outline the functional characteristics, pharmacology and 
molecular biology of these receptors.
1.2.1 The NMD A receptor
The availability of specific agonists and antagonists and the use of radioligand 
binding studies has led to extensive studies over the last 40 years that have provided 
detailed characteristics of NMD A receptors. At resting membrane potentials the channel is 
voltage-dependently blocked (at potentials more negative than -20 or -30 mV) by Mg2+ 
ions. Activation of the receptor by glutamate, aspartate or related amino acids leads to a 
voltage-dependent conductance in neurones resulting from the removal of the Mg2+ 
blockade and the opening of the cation-permeable ion channel (Na+, K+ and Ca2+). Thus 
NMDA receptor-induced synaptic currents are characteristically slow in onset and have a 
long duration, decaying over several hundred milliseconds. This type of activation results in
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a large influx of Ca2+ into the cell which can elicit long-term metabolic or structural 
changes.
Compounds that act on NMDA receptors are classified according to their site of 
action. The competitive NMDA antagonists, such as 3-(2-carboxypiperazin-4-yl)propenyl- 
1-phosphonoate (CPP-ene), act on the glutamate/NMD A recognition site. In conjunction 
with the glutamate recognition site, drugs can act at:
a) a regulatory site which binds glycine (strychnine insensitive). NMDA receptor activity is 
not possible without glycine. D-serine and D-alanine are active at this binding site and act as 
co-agonists at the NMDA receptor. Modulation of the glycine site has been used to 
experimentally manipulate NMDA receptor activity (e.g. 3-amino-l-hydroxy-2-pyrolidone, 
HA-966).
b) a site within the channel that binds phencyclidine and related compounds. Agents which 
act on this site are classed as non-competitive NMDA antagonists (e.g. MK-801) as the 
responses mediated are voltage- and use-dependent. Other ligands include dissociative 
anaesthetics such as phencyclidine and ketamine. They have a low therapeutic ratio as the 
side effects associated with these compounds are psychotomimetic and cardiovascular in 
nature (Muir & Lees, 1995).
c) the polyamine modulatory binding site where the polyamines spermine and spermidine act 
as agonists and putrescine and arcaine act as antagonists.
d) an inhibitory divalent cation site that binds Zn2+. In contrast to Mg2+, the inhibition by 
Zn2+ is not voltage-dependent and interacts at a different site. One function of this site could 
be to modulate NMDA function because of the high concentrations of Zn2+ present in nerve 
terminals.
Activation of the NMDA receptor is also subject to modification by H* 
concentration and redox state. Acidic pH inhibits NMDA receptor activation while reducing
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agents enhance NMDA receptor activation and Ca2+ influx (Levy et al., 1990; Sucher et al., 
1990). Compounds that act on NMDA receptors selectively are outlined in table 1.1.
Molecular biology o f the NMDA receptors
NMDA receptors exist in multiple forms and most probably as pentameric 
assemblies. Expression studies have revealed that NMDA-receptors are composed 
heteromerically of two subunits, the NR1 subunit (103 kDa) and the NR2 subunit (133 
kDA) (Moriyoshi et al., 1991). The NR1 subunit is a fundamental component of all native 
NMDA receptors and can be assembled into homomeric NR1 receptor channels (albeit with 
a small current response). The NR1 subunit has 8 possible splice variants, NR1A-NR1H 
(Zukin & Bennett, 1995), that arise from the permutations of a short insertion near the N- 
terminus (4 variants) or a deletion in the C-terminus (3 variants) together with the main 
isoform (Westbrook, 1994). Four NR2 subunit types exist, NR2A-NR2D, which form the 
native NMDA when co-expressed with the NR1 receptors (Gasic & Hollman, 1992). The 
NR2 subunits are modulatory subunits that have no NMDA activity but potentiate and 
differentiate the NMDA receptor activity depending on which of the NR2 subunits are 
incorporated. For example, NR1-NR2A and NR1-NR2B channels are more sensitive to the 
Mg2+ blockade and display the highest affinity sites for glycine binding compared with other 
heteromeric channels (Monyer et al., 1992). Both the Ca2+ permeability and Mg2+ block in 
the NMDA receptor channel are determined by a site corresponding to the TMD2 RNA 
editing site in the AMPA receptor. Pharmacological diversity of the NMDA receptors is 
affected by subunit composition. For example, eliprodil and ifenprodil are NR2B specific 
antagonists.
The binding sites for glutamate and glycine on recombinant NR1-NR2B receptors 
have been identified using site-directed mutagenesis studies (Kuryatov et al., 1994). In both
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subunits, the binding sites have significant and structural homology with the bacterial 
amino-acid proteins that bind protein or ions first recognised in AMPA receptors. The 
subunits possess two domains similar to that of bacterial periplasmic binding proteins. One 
domain is homologous with the leucine, isoleucine, valine binding protein (LIVBP) and the 
other is homologous with the lysine, arginine, ornithine binding protein (LAOBP). A 
schematic representation is illustrated in figure 1.2. The similarities to bacterial binding 
proteins are discussed in section 1.3.
1.2.2 The non-NMDA receptors
Until very recently, the lack of pharmacological tools to discriminate between 
AMPA and KA receptors caused much confusion regarding the functionally distinct actions 
mediated by each receptor. Consequently, the kainate receptor is the least characterised of 
the glutamate receptors.
The AMPA receptor has at least three separate binding sites at which agonists or 
antagonists can act;
a) the glutamate binding site, e.g. 2,3-Dihydro-6-nitro-7-sulfamoyl-benzo(F)quinoxaline 
(NBQX).
b) the desensitisation site; AMPA receptors show rapid desensitisation.
c) the intra-ion channel binding sites where certain substances such as the Joro spider toxin 
acts to block the ion channel (Ozawa et al., 1998).
Agonists acting on the AMPA receptor lead to the activation of conductance 
channels that exhibit little voltage-dependence, are permeable to Na+ and K+, and which 
may be permeable or impermeable to Ca2+ depending on the receptor structure. Receptor 
activation by KA results in the opening of a cation channel permeable to Na+, and 
sometimes to Ca2+.
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A distinctive characteristic of non-NMDA receptors are their rapid desensitisation to 
glutamate. This is thought to play a role in the shaping of synaptic currents and in synaptic 
depression at some synapses (Trussell & Fishbach, 1989; Trussell et al., 1993). At AMPA 
receptors, AMPA and glutamate but not KA induce a rapid and strong desensitising 
response in the receptors, while desensitisation is marked at KA receptors following KA 
activated currents. A number of agents have been shown to reduce this rapid 
desensitisation. Concanavalin A (ConA) blocks rapid glutamate desensitisation at native and 
recombinant KA receptors (Huettner, 1990; Partin et al., 1993). ConA is less potent at 
AMPA receptors but the diuretic agent cyclothiazide (CTZ) and also aniracetam blocks 
desensitisation at native and recombinant AMPA receptors with no effect at KA receptors 
(Wong & Mayer, 1993; Yamada & Tang, 1993). A recent compound 4-[2-(phenyl- 
sulfonylamino)ethylthio]-2,6-difluoro-phenoxyacetamide (PEPA) which is structurally 
distinct from the pyrrolidinones such as aniracetam, and the benzothiazide compounds such 
as CTZ, has been found to potentiate AMPA receptor responses (Sekiguchi et al., 1997).
Characterisation of the AMPA receptor has been advanced greatly with the aid of 
the competitive antagonist 2,3-Dihydro-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) 
the most potent centrally active AMPA antagonist. This was the first AMPA/KA receptor 
antagonist with selectivity and systemic activity. Receptor binding studies and 
electrophysiological studies demonstrated that it has a 30-fold higher affinity for AMPA 
receptors over KA receptors in the CNS, and no affinity for NMDA receptor binding sites 
(Sheardown et al., 1990). Subsequently, a second class of AMPA antagonists has emerged, 
that are non-competitive and do not exhibit voltage- or use-dependency, e.g. GYKI 52466 
and GYKI 53655. They act to increase the rate of desensitisation of AMPA receptors by 
binding to the CTZ binding or a neighbouring site (Palmer & Lodge, 1993). GYKI 53655 
has made possible the functional isolation of KA receptors. The antagonist 5-nitro-6,7,8,9-
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' v  'a t
High-affinity 
[3H]-kainate binding 
sites
KA>DA>Glu»AMPA
Low-affinity 
[3H]-kainate binding 
Sites
DA>KA>Glu»AMPA
DA>KA>Glu»AMPA
Kainate Receptors
[3H]-AMPA binding sites
AMPA»KA
DA|AMPA>Glu>KA
V
AMPA Receptors
Figure 1.1. Structural relationship among cloned A M PA  and kainate receptor 
subunits.
The line length separating the subunits represents their evolutionary distance.
Order of low affinity binding, KD = 50-100 nM, high affinity binding, KD = 5 nM. 
KA=kainate; DA=domoate; Glu=L-glutamate.
(From Bettler & Mulle, 1995)
7
tetrahydrobenzo[g]indole-2,3-dione-3-oxime (NS102) is routinely used at kainate receptors, 
but has poor selectivity. A newly developed glutamate analogue, 2S,4R-4-methylglutamate 
(SYM 2081), is a promising ligand that has demonstrated the ability to desensitise KA 
receptor mediated currents selectively and potently (Wilding & Huettner, 1997). The agents 
that selectively act on AMPA and KA receptors are summarised in table 1.1 (for a 
comprehensive review of AMPA receptor pharmacology, see Gill & Lodge, 1997). In 
hindsight, comparing the properties of the recombinant KA receptors with the native 
receptors, most of the electrophysiological actions of KA described in the brain have been 
attributed to AMPA receptors rather than KA receptors. Only in rare instances has it been 
possible to find pure populations of kainate receptors in vivo and even now the 
physiological role of kainate receptors remain obscure. The characterisation of KA 
receptors has not been easy because of their desensitising properties and the masking of 
their currents by the larger AMPA receptor-mediated currents (Lerma et al., 1993). 
Investigation of the physiological roles of KA-preferring receptors is just starting in earnest 
(Castillo eta l., 1997; Clarke e ta l., 1997; Rodriguez-Moreno e ta l., 1997; Lerma, 1997).
Molecular biology o f AMPA and KA receptors
The first glutamate receptor was cloned in 1989 and was named GluRl (Hollman et 
al., 1989). It is generally believed that 4 genes encode AMPA receptor subunits (GluRl-4) 
and 5 encode KA receptor subunits. The kainate receptors comprise of GluR5-7, known as 
the “low affinity” subunits and the “high affinity” KA1-2 (Bettler et al., 1992; Lomeli et al., 
1992). All non-NMDA glutamate receptor subunits are approximately 900 amino acid 
residues in length of about 100 kDa and the sequence relationship of these genes reflect the 
traditional pharmacological classification (figure 1.1). AMPA receptors exist either as 
homomeric or heteromeric oligomers of the different subunits. The different assemblies of
the subunits results in major changes in the functional properties of the native AMPA 
receptors.
Molecular analysis has provided evidence for much structural and functional 
diversity. Many splice variants have been described in the N- and C-terminals of AMPA and 
KA receptor subunits (Bettler & Mulle, 1995). For instance, each KA subunit is subject to 
splicing and the GluRl/-2/-3/-4 subunits exist in alternatively spliced ‘flip’ and ‘flop’ 
variants which are spatially and temporally regulated (Monyer et al., 1991). The isoforms 
differ in their expression in cells and have different kinetic properties (Sommer et al., 1990). 
They have been shown to differ in their time course of desensitisation. Channels assembled 
with flop variants generally show a faster desensitisation than those with flip forms 
(Mosbacher et al., 1994). Also their response to drugs modifying desensitisation differ 
(Partin et al., 1993).
The functional properties of AMPA and KA receptors can also be altered by RNA 
editing (Sommer et al., 1991; Kohler et al., 1993). This manifests as variations in the 
conductance levels of a receptor subtype according to the subunits present (Swanson et al., 
1997). For example, recombinant expression studies show that the subunit GluR2 gives rise 
to heteromeric receptors low in Ca2+ permeability, characteristic of most native AMPA 
receptors (Hollman et al., 1991). This contrasts with homomeric and heteromeric receptors 
assembled from the GluRl/-3/-4 subunits that are relatively permeable to Ca2+. This 
property has been mapped to a single residue. The change in a single amino acid at the 
‘Q/R’ site in the TMD2 segment of subunits determines the Ca2+ permeability. Mutagenesis 
studies have shown that this site also determines the sensitivity of the ion channels to spider 
and wasp toxins such as argiotoxin and Joro spider toxin, which have less effect on GluR2 
containing receptors and serve as probes to detect the presence or absence of GluR2 
subunits (Blaschke et al., 1993). The change in this amino acid is the product of an RNA
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editing mechanism that converts the glutamine codon (CAG) present into an arginine codon 
(CGG). The positive charge of arginine prevents the permeation of divalent cations in 
AMPA receptors. GluRl/-3/-4 subunits have the glutamine residue (Q), whereas the GluR2 
subunit has the arginine residue (R). GluR5 and GluR6 subunits can also be edited to have 
the arginine residue. RNA editing of the Q/R site in the second domain has also been 
observed for the KA receptor subunit GluR6 and produces a similar effect on rectification 
as the AMPA subunits (discussed below), but an opposite effect on calcium permeability. 
Those that have the arginine residue have a higher calcium permeability than GluR6 with 
glutamine. However, this depends on additional RNA editing of 2 codons in TMD1 (Kohler 
et al., 1993). The corresponding site in NMDA receptors is also responsible for Ca2+ and 
Mg2+ permeability. Recently, editing at another site was identified in the extracellular 
TMD3-TMD4 loop of GluR subunits which determines a switch from the encoded arginine 
(R) to glycine (G) (Lomeli et al., 1994). Editing at this site is specific for GluR2, 3 and 4, 
and is about 80-90% complete in adult rat brain. Immediately adjacent to this editing site is 
the flip/flop splicing site. Similar to the flip/flop site, this RNA editing site is involved in 
controlling desensitisation and recovery rates of AMPA receptor responses, and edited 
forms show a slower desensitisation rate(Seeburg, 1996).
Using heterologous expression systems it was demonstrated that AMPA subunits 
can assemble into both homomeric and heteromeric receptor configurations with distinct 
functional properties (Boulter et al., 1990; Keinanen et al., 1990). Homomeric receptors of 
GluRl, GluR3 and GluR4 are Ca2+ permeable and show inwardly rectifying I/V relations 
whereas GluR2 form Ca2+ impermeable channels with linear I/V relations (Hume et a l,
1991). When GluR2 is co-expressed with any of the other AMPA receptor subunits, 
channels with properties similar to GluR2 are formed (Hollman et al., 1991). It also seems 
that only a very few cells lack the GluR2 subunit. Examples are the Bergmann glia cells
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Figure 1.2 Schematic representation of the topology of an iGluR.
The channel pore domain is highlighted in black
LIVP = Leucine, isoleucine, valine binding protein; LAOBP = Lysine, arginine, ornithine 
binding protein; TMD = transmembrane domain
(Adapted from Pin & Bockaert, 1995)
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Table 1.1 Ionotropic glutamate receptor pharmacology.
RECEPTOR
CLASSES
Agonists Antagonists Comments / References
NMDA
transmitter site NMDA CPP
L-Glutamate CPP-ene
Methanoglutamate D-AP5
L-Aspartate D-AP7
Ibotenate
Quinolinate
homocysteate
CGS-19755
Channel PCP
MK-801
TCP
Ketamine 
SKF 10047 
CNS 1102 
dextromethorphan 
memantme
Glycine site Glycine HA-966 (P)
D-Serine Kynurenate
D-Alanine 7 -Cl-Kynurenate
D-Cycloserine (P) ACEA 1011, 1021
Polyamine site Spermine Ifenprodil
Spermidine Arcaine
Histamine Eliprodil
AMPA AMPA NBQX
L-Glutamate CNQX
Quisqualate DNQX
Kainate LY293558
Willardiines GYKI 52466 
GDEE 
Argiotoxin 
Joro spider toxin
Kainate AMPA CNQX
Kainate DNQX
L-Glutamate NS-102
Domoate
Quisqualate
Willardiines
Methahexitone
Curtis & Watkins, 1963
Clineschmidt et al., 1982; Kemp et al., 
1987.
Davies & Watkins, 1973; Kulagowski et al., 
1994
Spermine and Spermidine enhance the 
affinity for MK-801
Eliprodil/ifenprodil NR2B selective
GYKI 52466 is non-competitive and 
inhibits GluR6
Argiotoxin is use-dependent channel 
blocker - no block in receptors with 
edited GluR2 subunit
Haldemann & McLennan, 1972; 
Krogsgaard-Larsen et al., 1980; Omstein et 
al., 1993; Sheardown et al., 1990
AMPA agonist at GluR5, GluR6/KA- 
2 and dorsal root ganglion neurones
Methahexitone active on AMPA and 
GABA receptors
CNQX less potent at GluR6 than at 
other receptors
Agents are not necessarily ranked in order of potency. (P) = partial agonist.
AMPA: a-amino-3-hydroxy-5-methylisoxazole proprionate; CGS-19755: (+)cis-4-phosphonomethyl-2- 
piperidinecarboxylate; CNQX: 6-cyano-7-nitro-quinoxaline-2,3-dione; CPP: 3-3(2-carboxypiperazin-4- 
yl)propyl-l-phosphate; CPP-ene: 3-(2-carboxypiperazin-4-yl)propenyl-l-phosphonoate; D-AP5: (D-)2- 
amino-5-phosphopentanoate; DNQX: 6,7-nitro-qunoxaline-2,3-dione; GDEE: glutamic acid diethyl ester; 
GYKI 52466: l-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine; HA-966: 3-amino- 
1-hydroxy-2-pyrolidone; LY293558; MK-801: dibenzocycloheptene-imine; PCP: phecyclidine, TCP: 1-(1- 
thienyl- cyclohexyl)-piperidine
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(Bumashev et al., 1992) and a subset of hippocampal neurones (type II cells) (Bochet et al., 
1994).
Only KA receptor subunits GluR5 and GluR6 form functional homomeric receptors 
(Bettler et al., 1992; Sommer et al., 1992; Kohler et al., 1993) and can also assemble as 
heteromeric receptors in pairwise combination with the KA-1 or KA-2 subunits (Herb et al., 
1992; Sakimura et al., 1992). GluR5 and GluR6 exhibit fast desensitisation kinetics to 
KA/glutamate while the inclusion of KA subunits into GluR6 and GluR7 receptors make 
them sensitive to AMPA (Herb et al., 1992). Additionally, heteromeric GluR5/KA-2 
receptors present faster inactivation kinetics than homomeric GluR5 receptors.
Despite extensive research, all attempts to incorporate GluR7 subunit into a 
functional recombinant receptor has been unsuccessful until recently. Schiffer et al. (1997) 
have cloned and characterised a novel carboxy-terminal splice variant of GluR7, named 
GluR7b. They have demonstrated that these two subunits can generate functional 
homomeric kainate receptors with distinct pharmacological properties. GluR7 showed 
approximately a 10 fold higher EC50 for glutamate compared to other cloned AMPA or 
kainate receptors. In addition, GluR7 could be co-expressed with KA-1 and KA-2 subunits 
to form functional heteromeric receptors. Interestingly, these receptors were insensitive to 
domoate, unlike all other non-NMDA receptor subunits. The authors concluded that this 
receptor may play a unique role under conditions of strengthened neurotransmission in the 
CNS. Although reports suggest that KA receptor subunits do not form mixed channel 
complexes with AMPA receptor subunits, both types of receptors can be expressed in the 
same neurone or glial cell and may localise in different subcellular sites (Vickers et al., 
1993; Patneau et al., 1994; Wenthold et al., 1994). The model of glutamate binding is 
thought to be the same as for NMDA receptors (figure 1.2) and the TMD2 domain of each
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subunit is thought to contribute directly to the lining of the cation channel (Sucher et al.,
1996).
1.2.3 Current concepts of ionotropic glutamate receptor subunit identification
In order to understand all the roles of these receptors, there is undoubtedly a need to 
identify all the subunits that make up the subtypes, so that the individual characteristics of 
each subunit may be differentiated and the nature of the subunit co-assemblies understood. 
Although this identification process has progressed rapidly, there is recent evidence that 
suggests many more discoveries are to be made. For example, the expression of 
recombinant NMDA receptors can exhibit different properties from the native NMDA 
receptors on neurones, such as pharmacology or antibody reactivity. This may well be due 
to unidentified native partner subunits (Sucher et al., 1996; Barnard, 1997). Additional 
evidence also suggests that types of ionotropic glutamate receptors exist in the mammalian 
CNS that have not yet been identified. The cloned 81 and 82 subunits (Lomeli et al., 1993) 
which have a 15-25% sequence homology to NMDA and non-NMDA receptor subunits 
have failed to express functionally alone or with any other known subunit.
Further subunits have been described recently. The non-NMDA receptors have an 
extracellular N-terminal. Distinct from the established non-NMDA receptors, structurally 
related subunits of -50 kDa have been reported that have most of the extracellular N- 
terminal domain missing (Wo & Oswald, 1994). These are kainate binding proteins found in 
abundance in non-mammalian vertebrates. These proteins bind selectively to KA and not 
AMPA and occur on neurones in frogs (Wada et al., 1989). From the Xenopus laevis toad, 
a short GluR-like protein was purified which binds to AMPA and KA with high affinity, and 
upon reconstitution in a lipid bilayer, could participate in a glutamate-activated channel 
(Henley et al., 1992). This subunit has been termed XenUl and is unlike the kainate-binding
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proteins and all previously known non-NMDA subunits. In addition, XenUl does not 
replace the conventional receptors because Xenopus also contains the known receptor 
subunits for AMPA and KA which have been demonstrated to be >95% identical to their rat 
equivalents (Ishimaru et al., 1996). Expression data suggests however that a partner subunit 
is required for XenUl and a novel subunit has been cloned from Xenopus - XenNRIG 
cDNA (Soloviev et al., 1996). This encodes a 99.6 kDa subunit closely related to the NR1 
subunit seen in mammalian NMDA receptors. When expressed alone, no functional 
response was evident, but after co-expression of XenNRIG and XenUl, consistent and 
strong current responses to NMDA and non-NMDA receptor agonists were obtained. 
Electrophysiological studies have provided evidence that these receptors exist as a new type 
of ionotropic glutamate receptor (Soloviev et al., 1996). It has been termed a ‘unitary 
receptor’ for glutamate, i.e. one that combines the agonist sites of NMDA and non-NMDA 
receptors on different subunits, but in one heteromeric receptor molecule. These receptors 
exhibit the fundamental attributes of the NMDA receptor-channel complex; a voltage- 
dependent Mg2+ block and glycine dependence, but are stimulated by non-NMDA agonists, 
and may exist in mammals. These receptors, together with the 6-subunits identified, 
illustrate that the full repertoire of ionotropic glutamate receptors is still unknown.
1.3 Metabotropic glutamate receptor classification
The existence of metabotropic glutamate receptors mGluRs was only discovered in 
1985 when it was reported that glutamate stimulated phospholipase C in cultured striatal 
neurones via a receptor that did not belong to the NMDA, AMPA or KA families 
(Sladeczek et al., 1985). Independently, L-AP4 had previously been recognised as a specific 
ligand for a new glutamate receptor subtype (Foster & Fagg, 1984). Subsequent research 
revealed L-AP4 to act as an agonist on presynaptic glutamate receptors, depressing
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glutamate release at excitatory synapses and shown to be coupled to G-proteins (Koemer & 
Johnson, 1992; Nawy & Jahr, 1990). It is now recognised that the then named L-AP4 
receptor is a member of the mGluR family. Unlike the ionotropic glutamate receptors, early 
characterisation and classification of the mGiuRs resulted from molecular biological 
techniques. Pharmacologically, mGiuRs were distinguished from the ionotropic glutamate 
receptors by the use of the non selective (mGluR subtype) agonist trans-1- 
aminocyclopentane-l,3-dicarboxylic acid {trans-KCVD), or its IS, 3R-isomer, which 
modifies inositol phosphate (IP) metabolism (Palmer et al., 1989; Schoepp et al., 1991).
Molecular biology o f the metabotropic glutamate receptors
The first mGluR cDNA was cloned independently by two groups and is now 
generally named mGluRla (Masu et al., 1991; Houamed et al., 1991). Its deduced amino 
acid sequence revealed that this receptor shared no sequence homology with any other G- 
protein coupled receptor. The ensuing search for mGluR-related cDNA has led to the 
isolation of 7 other genes and several splice variants that encode mGiuRs and are named 
mGluR 1 -mGluR8.
Splice variants have been demonstrated for mGluRl, mGluR4 and mGluR5 (Tanabe 
et al., 1992; Pin et al., 1992; Minakami et al., 1994). To date, the human homologues of 
mGluRla, b and d, mGluR2, mGluR3, mGluR4, mGluR5a, b, mGluR7 and mGluR8 have 
been cloned (Minakami et al., 1994; Laurie et al., 1996; Desai et al., 1995; Flor et al., 
1995a, 1995b; Emile et al., 1996; Daggett et al., 1995; Wu et al., 1998). The primary 
sequence of the human receptors show 93-99% homology with the rat homologues, while a 
mGluR cloned from Drosophila melanogaster called DmGluRA shows 45% sequence 
homology with the mammalian mGluR3 (figure 1.3). The mGiuRs also show significant 
homology with the recently cloned GABAb receptor (Kaupmann et al., 1997).
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The 8 mGiuRs can be subdivided into three groups principally on the basis of their 
amino acid sequence, but also in terms of their pharmacological properties and transduction 
mechanisms (figure 1.3). mGiuRs of the same group show about 70% sequence identity, 
whereas between groups this decreases to around 45%. The receptors are much larger than 
all previously identified G-protein coupled receptors and do not share any sequence 
homology, thus defining a new family of receptors. This new family of receptors may not be 
restricted to glutamate receptors and may include additional members. Evidence for this 
comes from the isolation of a Ca2+-sensing receptor cDNA from a bovine parathyroid 
cDNA library. It has a 30% sequence identity with the mGiuRs but is not sensitive to 
mGluR agonists but to cations such as Mg2+, Gd3+ and neomycin (Brown et al., 1993).
All the mGiuRs possess a large N-terminal extracellular domain, seven putative 
TMDs separated by short intra- and extra-cellular loops and a cytoplasmic C-terminal 
domain variable in length (figure 1.4). The role of the C-terminal domain is not known, but 
may be the target of various kinases due to the numerous phosphorylation sites and 
serine/threonine residues present that could regulate receptor activity. The model of the 
glutamate binding site emerged from the molecular modelling of the N-terminal domain of 
mGluRl (O’Hara et al., 1993). Nakanishi et al. (1990) first noticed that there were 
similarities in sequence between the N-terminal domain of AMPA receptors and bacterial 
periplasmic glutamine-binding proteins, especially with the leucine, isoleucine, valine 
binding protein (LIVBP). The mGluR 1 N-terminal domain also exhibited homology with 
the bacterial binding protein. This similarity is not evident at the primary sequence level, but 
is prominent when the sequences are aligned with respect to their three-dimensional 
compatibility. The resulting model of the N-terminal domain displays 2 globular lobes 
connected by hinge regions that close like a clamshell on binding of the ligand. By 
constructing chimeric receptors, it was demonstrated that the second intracellular loop of
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mGiuRs is critical in G-protein coupling specificity (Pin et al., 1994; Gomeza et al., 1996). 
The mechanism by which a ligand induces the conformational changes required for G- 
protein activation remain to be discovered. For a comprehensive review of the structure of 
the mGiuRs, see Conn & Pin, (1997).
Like the iGluRs, evidence suggests that novel mGiuRs may also exist that have not 
been discovered as yet. For example, in cortical slices, there appears to be an mGluR that 
couples to phosphoinositide hydrolysis that does not correspond to any of the previously 
cloned mGluR subtypes (Chung et al., 1998). Furthermore, a novel mGluR is thought to 
exist that couples to the activation of phospholipase D (Holler et al., 1993; Boss et al.,
1994).
1.3.1 Group I receptors
Cloned group I mGiuRs, including the splice variants (mGluRla-c,e and mGluR5a 
and b), stimulate phospholipase C (PLC), demonstrated by the hydrolysis of 
phosphatidylinositol (PI) (Masu et al., 1991; Houamed et al., 1991). Hydrolysis of the 
membrane phosphatidylinositol-4,5-bisphosphate by PLC produces two second messengers; 
diacylglycerol (DAG) which activates protein kinase C (PKC) and inositol 1,4,5- 
trisphosphate (IP3) which leads to the release of calcium from intracellular stores. 
Stimulation of cAMP formation has also been reported for mGluRla and it has been 
attributed to a direct coupling to adenylate cyclase (AC) through Gs-protein (Aramori & 
Nakanishi, 1992), though this is not certain. In addition, it is not known whether this 
heterologous coupling is a result of the expression of the receptors at high levels in non­
neuronal cells or is due to low G-protein selectivity in neurones. It has also been reported 
recently that mGluR activation (suggested to be mGluR 1) increases cGMP levels in 
cerebellar slices and that the response can be blocked by nitric oxide synthase inhibitors
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(Okada, 1992). While no functional differences have been detected between the expressed 
splice variants mGluR5a and mGluRSb, the mGluRla variant has been shown to generate 
faster responses and activate AC when compared with the truncated isoforms mGluR lb and 
mGluRlc (Pin et al., 1992; Pickering et al., 1993) It is thought that the functional 
difference is caused by a difference in the coupling efficiency of the receptors to the G- 
proteins (Prezeau et al., 1996). A pre-synaptically located mGluR shown to couple to PI 
hydrolysis is thought to exist that enhances the release of glutamate, but only in the 
presence of arachidonic acid (Herrero et a l, 1992).
For both clonal cell lines and native receptor-mediated responses, group I receptors 
are selectively activated by the compound 3-5-hydroxyphenylglycine (DHPG). Other 
selective agonists are summarised in table 1.2. Although qualitatively similar, the potencies 
of the majority of these agonists are significantly greater upon mGluR5 receptors. Selective 
antagonists for this group of receptors are emerging. Recently, the synthesis of substituted 
derivatives of a prototypic mGluR antagonist, 4-carboxyphenylglycine (4-CPG) has 
produced compounds LY367385 and 2-methyl-4C3HPG that possess improved selectivity 
for mGluRla over mGluR5a (table 1.2). However, these agents have been demonstrated to 
activate group II receptors at higher concentration.
1.3.2 Group II receptors
Expression of cloned group II mGiuRs (mGluR2 and 3) is coupled to the inhibition 
of adenylate cyclase (Tanabe et al., 1992). This response is inhibited by pertussis toxin 
which suggests the involvement of a Gi-type of G-protein. They have also been shown to 
inhibit N-type Ca2+ channels through a pertussis toxin sensitive pathway (Ikeda et al.,
1995). Consistent with studies in expression systems, activation of group II mGiuRs inhibits 
forskolin-induced increases in cAMP accumulation in brain slices and cultures (Schoepp et
20
LIVP-like
domain
Cysteine nch 
domain
7-TMD
G-protein
coupling
Unknown
functions
Figure 1.4 Schematic representation of the topology of an mGluR.
The region rich in cysteine residues is indicated with black circles. The segment in the 
second intracellular loop is important for G-protein coupling specificity is indicated in black. 
LIVP = Leucine, isoleucine, valine binding protein 
TMD = transmembrane domain
(From Conn & Pin, 1997)
al., 1995a; Wright & Schoepp, 1996). However, as the measurement o f inhibition o f cAMP 
has been through the AC activator forskolin, rather than responses o f receptors that activate 
AC to agonists, it is not clear whether group II mGiuRs actually couple to inhibition of 
neurotransmitter-induced increases in cAMP accumulation in native systems. Indeed, there 
is evidence to suggest that that the activation o f group II potentiates rather than inhibits 
cAMP accumulation resulting from Gs-coupled receptor agonists (e.g. vasoactive intestinal 
polypeptide, the (3-adrenergic receptor agonist isoproterenol) in the hippocampus (Winder 
& Conn, 1996).
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Group II mGiuRs are selectively activated by (2R, 4R)-4-
aminopyrrolidinedicarboxylic acid, (2R, 4R)-APDC (Schoepp et al., 1995a). Other agonists 
which result in the activation of mGluR2 and mGluR3 are presented in table 1.2. 
(2S,2’R,3,R)-2-(2’3’-dicarboxycyclopropyl) glycine (DCG-IV) is the most widely used 
group II agonist, but is not wholly selective for these receptors. The novel group II agonists 
LY3 54740 (Bond et al., 1997) and LY379268 (Monn et al., in press) used in this thesis are, 
at present, the most potent compounds for this class. They are the first mGluR agonists to 
be bioavailable following systemic administration, and are potent at nanomolar 
concentrations. The structure of the ligands are given in figure 1.5. The pharmacology of 
these agonists are discussed extensively in chapter 8, section 8,1. Selective antagonists for 
group II receptors are also available. For the majority of the antagonists, their activities 
have been reported only for mGluR2 and not mGluR3 receptors, but differences may 
emerge in native receptors where both the receptors may contribute to the pharmacological 
responses.
1.3.3 Group HI receptors
Group III mGiuRs (mGluR4, 6, 7 and 8) are also negatively coupled to adenylate 
cyclase via a pertussis toxin sensitive G-protein when expressed in certain cells and in native 
systems (Nakajima et al., 1993; Okamoto et al., 1994). The inhibition observed in 
expression systems is often smaller than that seen with the group II mGiuRs and it has been 
suggested that this is because this transduction pathway is not the preferred pathway. For 
example, mGluR6 and possibly mGluR8 are likely to negatively couple to a cGMP 
phophodiesterase in its native environment of the retina (Shiells & Falk, 1992). Unlike the 
group II mGiuRs, the group III mGiuRs have been shown to couple to the inhibition of Gs- 
activated adenylate cyclase in the hippocampus (Wright & Schoepp, 1996).
22
c o o -
Glutamate
+H3N
LY3 54740
LY379268
Figure 1.5 Structure of glutamate, LY354740 and LY379268.
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While this group contains the largest number of receptors, they are the least well 
characterised pharmacologically. The pharmacology of group HI receptors differs 
tremendously from groups I and II and they are selectively activated by L-amino-4- 
phosphonobutyrate, L-AP4 (Nakanishi, 1992). The actions of L-AP4 are mimicked by the 
structurally related (and endogenous to the CNS) L-serine-O-phosphate (L-SOP) (Thomsen 
& Suzdak, 1993). Interestingly, mGluR4 receptors are largely unaffected by any of the 
broad spectrum phenylglycine derivatives, the structure upon which most of the mGluR 
ligands are based. Table 1.2 summarises the selective agonists and antagonists of group III 
mGiuRs.
1.4 Distribution and physiological roles of glutamate receptors
1.4.1 Ionotropic glutamate receptors
Distribution o f the ionotropic glutamate receptors
The distribution of the different receptors has been extensively studied. The general 
distribution of the NMDA receptors in the rat CNS has been mapped using radiolabelled 
NMDA antagonists (Maragos et al., 1986; Monaghan & Cotman, 1985). This method 
permits the identification of the location of binding sites but does not allow a measure of 
functional receptor activity. NMDA receptors are found predominantly in the forebrain with 
the highest levels of NMDA binding sites to be found in the hippocampal CA1 region. 
Moderate levels of NMDA binding sites are present in the dentate gyrus and the CA3. 
NMDA receptors are widespread in the cortex, but particularly in the frontal, anterior 
cingulate and pyriform cortices. However, a laminar pattern of receptor density exists in the 
cortex; two bands of receptors are seen in cortical layers I-III and V. High levels of NMDA 
receptors are present in sub-cortical regions such as the dorsal-lateral septum, amygdala, 
striatum and nucleus accumbens. Brain regions associated with sensory functions also
contain a moderate level of NMDA receptors, including visual structures such as the 
superior colliculus superficial layer and lateral geniculate body and auditory structures such 
as the medial geniculate body and cochlear nucleus. Low levels of NMDA receptors are 
found in motor regions, for example the red nucleus and the pontine nucleus. The 
distribution of the different NR subunits have been determined by in situ hybridisation 
(Monyer et al., 1992; Moriyoshi et al., 1991). While NR1 is widely distributed, NR2 
subunits are differentially distributed in the CNS. For example NR2C expression levels are 
present in the cerebellum only, while NR2A and NR2B are found predominantly in the 
hippocampus, cortex and thalamus and NR2D is found mainly in the olfactory bulb (Monyer 
et al., 1992; Buller et al., 1994; Salt & Eaton, 1996). Expression patterns of NR2 subunits 
are also regulated developmentally in rodents suggesting that different spatial and temporal 
patterns of expression of NR2 allow for the fine tuning of NMDA receptor functions.
AMPA receptors are distributed abundantly and widely throughout the CNS. Using 
radioligand binding studies, the highest levels were seen in the hippocampal CA1 and CA3 
regions. High levels of binding were also seen in the molecular layer of the dentate gyrus 
and superficial layers of the cerebral cortex. Other brain regions found to be rich in 
[3H]AMPA binding included the striatum, nucleus accumbens, septum and amygdala 
(Monaghan et al., 1984; Rainbow et al., 1984). AMPA receptors are also present in several 
types of glial cells (Bowman & Kimelberg, 1984; Bumashev et al., 1992; Muller et al.,
1992). Following the molecular identification of the receptor subunits, AMPA receptor 
distributions have been localised at the mRNA level and at the protein level (Rogers et al., 
1991; Petralia and Wenthold, 1992; Martin et al., 1993). As a result of these studies, 
GluRl-4 were shown to have regional expression patterns. In the cortex, GluR2 mRNA is 
expressed uniformly in all layers while GluRl, 3 and 4 mRNAs differ among layers. In the 
hippocampus, GluRl, 2 and 3 mRNAs are abundantly expressed in the pyramidal cell layer
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and dentate gyrus. Studies indicate that AMPA receptor subunits are expressed 
predominantly in the flop forms in the adult brain (Sommer et al., 1990) and that only a few 
neuronal types lack the GluR2 subunit. Indeed, a recent study has provided evidence that 
calcium permeable AMPA receptors in the hippocampus (i.e. GluR2 lacking) are found 
exclusively at mossy fibre synapses (Toth & McBain, 1998). In addition, it is believed that 
in the hippocampus distinct AMPA receptors are expressed on single neurones that are 
associated with specific afferent pathways. This suggests that information is likely to be 
transmitted onto the postsynaptic cell in a synapse specific manner (Toth & McBain, 1998).
Radioligand binding studies using [3H]kainate have revealed that binding sites are 
abundant throughout the entire CNS. Brain areas such as the hippocampal CA3 region and 
cerebellar granular layer show intense labelling. KA receptor densities are high in cortical 
layers V and VI, the reticular nucleus of the thalamus, striatum and hypothalamus 
(Monaghan & Cotman, 1982). The anatomical distribution of KA receptor subunits has also 
been determined more recently using in situ hybridisation (Bahn et al., 1994; Bischoff et al., 
1997). All 5 subunits are expressed by the majority of brain cells. KA2 mRNA appears to be 
almost universally expressed while KA1 transcripts are seen mainly in the CA3 and dentate 
gyrus of the hippocampus. GluR5 mRNA expression is seen in the cingulate and piriform 
cortex while GluR6 is most abundantly expressed in cerebellar granule cells. Evidence 
suggests KA receptors can coexist with AMPA receptor subunits on the same cells but do 
not co-assemble with one another (Mackler & Eberwine, 1993).
Ionotropic glutamate receptor mediated responses
AMPA receptor subunits are found clustered at postsynaptic sites and a major role 
of the ionotropic glutamate receptors is the transmission of normal synaptic activity along 
excitatory pathways. Glutamate mediated excitatory post-synaptic potentials (EPSPs) are
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made up of 2 components. Stimulation of the AMPA receptors are responsible for the 
stimulatory fast EPSP (Davies et al., 1989), while the NMDA receptor is activated only 
after depolarisation and because of its slower conductance appears to be involved in the 
amplification of excitatory responses. Together, they underlie excitatory synaptic currents. 
Several lines of evidence suggest that AMPA and NMDA receptors are co-localised and are 
commonly activated by a near instantaneous rise and rapid decay of glutamate (Jones & 
Baughman, 1991) Therefore, it seems likely that the AMPA receptor has a relatively low 
affinity and becomes unbound very quickly after the clearance of glutamate whereas NMDA 
receptors have a higher affinity which results in a prolonged binding (Lester et a l, 1990). 
Because of the multitude of combinations of receptor subunits, large differences in the 
kinetics of non-NMDA synaptic currents that have been observed between different 
neuronal populations may result from differential clearance of glutamate from the synaptic 
cleft (Livsey & Vicini; 1992; Barbour et a l, 1994) but may also reflect the differences in the 
functional properties of the receptors such as desensitisation characteristics (Viklicky et al.,
1991). As already mentioned, the role of KA receptors is less clear because the synaptic 
responses have been difficult to demonstrate (Castillo et al., 1997; Vignes & Collingridge,
1997). This is largely due to the finding that KA produces large non-desensitising current 
responses at AMPA receptors. However, the presence of functional KA receptors in the 
hippocampus suggests the involvement of KA receptors in fast glutamatergic transmission. 
Electrophysiological data supports the idea that NMDA and AMPA or KA receptors work 
together to mediate post-synaptic excitation.
Physiological roles o f the ionotropic glutamate receptors
Given their widespread distribution, they are involved in virtually all central nervous 
system functions. The ionotropic glutamate receptors not only mediate fast excitatory
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transmission but also participate in brain plasticity. NMDA receptors are proposed to be 
involved in the mechanisms of synaptic plasticity in the developing and mature brain. For 
example, NMDA receptors are involved in the developing visual and olfactory systems 
(Cline et al., 1987; Lincoln et al., 1988) and have been linked to neuronal survival and 
differentiation (Headley & Grillner, 1990). A multitude of evidence indicates that the 
NMDA and AMPA glutamate receptors are important in the hypothetical cellular 
mechanisms of memory formation - long-term potentiation (LTP) and long-term depression 
(Collingridge & Bliss, 1987; Thompson, 1986). LTP is a long lasting increase in synaptic 
transmission evoked by either a high frequency stimulation of synaptic pathways, or by 
pairing presynaptic activity with postsynaptic depolarisation (Bliss & Lomo, 1973). The 
former is most commonly used and LTP is induced by delivering a high frequency tetanus 
(such as 10 bursts of 200 Hz for 75 ms, with an interburst interval of 10 s is frequently used 
for in vivo experiments).The potentiation of synaptic efficacy is dependent on an increase in 
intracellular Ca2+. Because of the voltage-dependent feature of NMDA receptors, they are 
thought to be essential to the induction and maintenance of LTP (Bliss & Collingridge
1993).
The hippocampus has been implicated in memory formation and all excitatory 
projection pathways to, within, and from the hippocampus, use glutamate as a transmitter. 
The involvement of NMDA receptors in the hippocampus in learning and memory in rats 
has been previously demonstrated. Studies have shown the importance of NMDA receptors 
in the induction of LTP in the Schaffer collateral-CAl field of the hippocampus and is 
commonly known as NMDA-dependent LTP (Bliss & Collingridge, 1993). The high 
frequency stimulation of the Schaffer collaterals leads to an association between NMDA 
receptor activation and postsynaptic depolarisation. This allows the removal of the Mg 
block of the NMDA receptor associated channel. The Ca2+ influx resulting from the opening
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of the NMDA receptor activates postsynaptic Ca2+ sensitive enzymes which leads to the 
potentiation of the synaptic efficacy by either pre- or post-synaptic modifications. Similarly 
Ca2+ permeable AMPA receptors are expected to provide a synaptically activated route for 
Ca2+ entry for the modulation of LTP, and GluRl subunits are thought to be particularly 
important for LTP (Vanderklish et al., 1992). Traditionally, LTP is thought to result from 
an increase in transmitter release and an enhanced postsynaptic AMPA/KA response (Bliss 
& Collingridge, 1993). Recent studies using GluR2 KO mice have suggested that LTP in 
the CA1 occurs post-synaptically and results from a recruitment of new AMPA receptors or 
an increase in the conductance of receptors (Mainen et al., 1998). NMDA receptor 
involvement in learning and memory has also been demonstrated behaviourally using spatial 
memory tasks (Morris et al., 1986). More recently, using cre-lox transgenic technology, 
Tsien et al. (1996a) were able to produce mice where the NR1 gene was disrupted in CA1 
pyramidal cells but was normally expressed in other parts of the brain. Together with 
finding that NMDA receptor-mediated currents and LTP were abolished in the CA1 
synapses, the mice exhibited impaired spatial memory (Tsien et al., 1996b; McHugh et al., 
1996). Not all memory processes are dependent on LTP, and NMDA receptors have been 
shown to be involved in these LTP-independent processes. For example, NMDA receptor 
antagonists interfere with working memory (Adler et al., 1998), which is a short-lasting 
form of memory that is maintained by neuronal activity rather than synaptic modification 
(Funahashi et al., 1989). Recently, Lisman et al. (1998) showed that the voltage-dependent 
excitatory postsynaptic potentials produced by NMDA receptors can lead to selective 
excitation of neurones in the prefrontal cortex that is needed to maintain novel items in 
working memory.
KA receptors are believed to have presynaptic roles. Studies have implicated KA 
receptors in generating epileptiform activity at CA3 mossy fibre terminals and the
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suppression of synaptic release of glutamate at CA1 synapses. Although other groups have 
reported that KA enhances transmitter release (Ozawa et al., 1998), reports have suggested 
that KA receptor activation, specifically GluR5 subunits, downregulates GABAergic 
inhibition in hippocampal CA1 pyramidal neurones (Clarke et al., 1997; Rodriguez-Moreno 
etal., 1997).
Finally, glutamatergic pathways from the cerebral cortex to the striatum appear to 
be involved in the regulation of voluntary motor behaviour. Indeed, there is evidence of the 
involvement of cortico-striatal, cortico-subthalamic and subthalamic-pallidal/nigral 
glutamatergic projections in Parkinson’s disease (Greenamyre & O’Brien, 1991)
1.4.2 Metabotropic glutamate receptors
Distribution o f the metabotropic glutamate receptors
In situ hybridisation and immunohistochemical studies of the rat brain have 
demonstrated that the mGluRs are expressed in neuronal and glial populations throughout 
the brain. The receptor subtypes show distinct patterns of distribution with differential 
expression both regionally and between cell types within a region. The distribution of each 
group of mGluRs is discussed in turn below.
mGluRl expression has been demonstrated in many of the target areas of putative 
glutamatergic projection fibres such as the hippocampus - especially CA2-CA4, striatum, 
olfactory tubercle, thalamus (except reticular nucleus), substantia nigra, red nucleus, 
superior colliculus, cochlear nucleus and Purkinje cells of the cerebellum (Shigemoto et al.,
1992). mGluR5 are distributed differently from mGluRl mRNA. They are specifically 
localised to pyramidal cells throughout the CA1-CA4 and granule cells of the dentate gyrus 
and Golgi cells in the cerebellum (Abe et al., 1992). Both mGluRla and mGluR5 are 
localised at the periphery of postsynaptic densities and therefore respond to concentrations
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of glutamate that are sufficiently high to spread away from the central region of the synapse 
(BaudQetal., 1993; Shigemoto etal., 1996).
Studies have revealed that mGluR2 are essentially localised to the main and 
accessory olfactory bulb, cerebral cortices (particularly in the entorhinal cortex), striatum, 
molecular layers of the hippocampus and dentate gyrus, mammillary body, medial habenular 
nucleus, thalamic (reticular, anterior and midline) nuclei and cerebellar Golgi neurones 
(Ohishi et al., 1993a & b, 1994; Hayashi et al., 1993; Neki et al., 1996a & b; Petralia et al., 
1996). Through these studies, there is evidence to suggest that mGluR2 are located 
presynaptically at perforant and mossy fibres of the hippocampus, as well as 
postsynaptically. Additionally they appear to be discretely localised to presynaptic terminals 
of GABAergic granule cells. The localisation of mGluR3 reveal that they are distributed 
more widely in forebrain neurones and glia. They are prominently expressed in neurones in 
the cerebral cortex, reticular thalamic nucleus, striatum, caudate putamen, dentate gyrus and 
in glial cells throughout the brain (Tanabe et al., 1993; Petralia et al., 1996). Moderate 
expression of mGluR3 are also seen in the superficial layer of the superior colliculus, lateral 
amygdaloid nucleus and Golgi cells of the cerebellum (Ohishi et al., 1993b). mGluR3 are 
also distributed in white matter where they are expressed in oligodendrocytes. In contrast to 
mGluR2, they are only weakly expressed in the olfactory bulb. A recent in vitro binding 
study was able to characterise rat mGluR2 and mGluR3 more selectively with the group II 
specific agonist LY354740 (Schaffhauser et al., 1998). They found that the distribution of 
binding sites for [3H]LY3 54740 in sections of rat brain correlated well with mGluR2 over 
mGluR3 when compared to previous immunohistochemical or in situ hybridisation studies. 
In particular, the highest density of binding was seen in the anteroventral thalamic nuclei, 
cerebellar granule layer, retrosplenial cortex and in the molecular layer of the hippocampus.
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Of the group in  receptors, in situ hybridisation studies have shown that mGluR8 
mRNA expression is seen in the main olfactory bulb of the mouse and that they are located 
presynaptically (Kinoshita et al., 1996a). Of the remaining receptors, mGluR4 is most 
intensely expressed in the cerebellar granule cells (especially mGluR4a) and are thought to 
act as autoreceptors on axon terminals of parallel fibres (Kinoshita et al., 1996b). They are 
also found in the superficial layers of the entorhinal cortex, mammillary body and thalamic 
nuclei. The distribution of mGluR7 mRNA in the rat brain has been shown to be more 
widely distributed than mGluR4 mRNA (Ohishi et al., 1995). They are present on axon 
terminals of the mitral/tufted cell in the main olfactory bulb, cortical regions, CA1 and 3 of 
the hippocampus, granule cells of the dentate gyrus and locus coeruleus. They are also 
expressed in the regions displaying mGluR4 mRNA mentioned above. The mGluR6 is 
unique among glutamate receptors and displays the most restricted expression of all the 
mGluRs. This receptor appears to be exclusively expressed at an appreciable level in the 
inner layer of the retina, at ON-bipolar cells (Nakajima et al., 1993). Moreover, it appears 
that this receptor is the only example of a G-protein coupled receptor responsible for fast 
synaptic transmission in the CNS (Nakanishi, 1994).
Within any brain region, differential expression of receptor subtypes is also seen. For 
example, in situ hybridisation has revealed that the most dominant subtypes in the CA1 of 
the hippocampus are mGluR5 and mGluR7 on neurones and apical dendrites, while mGluRl 
are found in abundance on the stratum oriens. In the CA2 region, mGluR4 and mGluR7 are 
widely expressed and the CA3 expresses mGluRl, mGluR5 and mGluR7 on neurones with 
a lower amount of mGluR2. mGluR4 are seen to be located presynaptically on mossy fibre 
terminals. Also in the cerebellum there is prominent expression of three subtypes; mGluRl 
are found predominantly in Purkinje cells, mGluR2 in Golgi cells, while mGluR4 are seen in 
the granule cells. In addition, within the cerebellum, two separate populations of Golgi cells
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have been demonstrated. The majority of cells contain mGluR2 and are segregated from 
Golgi cells possessing mGluR5. No cells were demonstrated to show mGluR2 and mGluR5 
simultaneously (Ohishi et al., 1993a, 1994, 1995; Neki et al., 1996b). This precise 
segregation of the mGluRs seems to suggest that the individual subtypes have specialised 
functions.
mGluR mediated responses
As the mGluRs couple to second messenger systems, they could conceivably affect 
many aspects of cell function. They have been shown to modulate voltage-dependent and 
voltage-independent ion channel function, increasing or decreasing excitability along with 
potentiating or inhibiting synaptic transmission.
Potassium channels are common targets for modulation by mGluRs which can result 
in a dramatic increase in cell excitability, attributed to mGluR 1 and mGluR5 (Davies et al., 
1995; Gereau & Conn, 1995b), or an inhibitory effect, due possibly to group I or II 
receptors (Rainnie et al., 1994). The receptors are capable of exerting direct excitatory 
effects on neurones by activating non-selective cation channels including the Na+/Ca2+ 
exchanger, and the activation of a Ca2+- activated non-specific cation current (Crepel et al., 
1994; McBain et al., 1994). There is also some evidence to suggest that mGluRs may 
couple to cation channels by a G-protein independent mechanism (Zheng et al., 1995). The 
activation of mGluR are thought to reduce currents through the various voltage-dependent 
calcium channels. Inhibition of N-type currents in cortical neurones are likely to be mediated 
by both group I and II mGluRs (Choi & Lovinger, 1996), while group II mGluRs mediate 
the inhibition of Ca2+ channels in cultured granule cells (Chavis et al., 1995).
Glutamatergic circuits can be modulated through the activation of mGluRs. The 
mGluRs provide a mechanism by which glutamate can modulate or fine-tune activity at the
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same synapses at which it elicits fast synaptic responses. One of the most prominent 
physiologic effects of mGluR agonists throughout the CNS is the reduction of transmission 
at glutamatergic synapses. This is typically mediated by the presynaptic mGluRs that serve 
as autoreceptors to reduce glutamate release. mGluRs of all three groups can act as 
autoreceptors in different brain regions. In the adult hippocampal CA1, the autoreceptors 
were revealed to be group I and III mGluRs, most likely the mGluR5 and mGluR7 subtypes 
(Gereau & Conn 1995a & b; Manzoni & Bockaert, 1995). Other examples of autoreceptors 
can be found at the mossy fibre synapses (group II and HI involvement) and cortico-striatal 
synapses (group II) (Manzoni et al,, 1995; Lovinger & McCool, 1995).
The mechanisms by which autoreceptors regulate glutamate release from 
presynaptic terminals is not clear. One mechanism could result from the reduction of 
voltage-sensitive calcium currents (VSCCs). Alternative mechanisms could be due to the 
direct modulation of presynaptic Ca2+ currents that trigger exocytosis, or modulation of the 
exocytotic machinery itself, or the activation of presynaptic potassium currents. Evidence 
exists for these mechanisms. For example, IS, 3R-ACPD was found to reduce transmission 
at excitatory synapses in the visual cortex, and this effect was blocked by the K+ channel 
blocker 4-aminopyridine (Sladeczek et al., 1993). However, more recent work has revealed 
that transmitter release is through direct modulation of the Ca2+ current (Takahashi et al.,
1996).
A novel mechanism by which mGluR activation can reduce transmission at 
glutamatergic synapses in the hippocampus has been discovered in recent years. Winder & 
Conn (1996) concluded that co-activation of mGluRs and p-adrenergic receptors leads to 
an increase in cAMP which results in the activation of presynaptic adenosine receptors at 
the Schaffer collateral terminals. However, this response was found to be initiated in glia 
(accumulation of cAMP) rather than in neurones. Thus, the group II mGluRs (most
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probably mGluRS) located on glia are involved in a novel form of glial-neuronal 
communication and could be pivotal in regulating synaptic transmission in the hippocampus 
when noradrenergic inputs are active. In contrast, presynaptic mGluR activation can 
increase glutamate release under certain conditions. This has been seen when mGluRs are 
activated in the presence of arachidonic acid (Herrero et al., 1992; Collins & Davies, 1993). 
Increased glutamate release has been demonstrated at the Schaffer collateral-CAl synapse 
where autoreceptors are also present. Thus it seems the potentiation of glutamate release, 
which occurs when mGluRs are activated in the presence of arachidonic acid, is sufficient to 
overcome the autoreceptor mediated depression of transmission at this synapse.
As well as serving as autoreceptors, mGluRs can serve as presynaptic heteroceptors 
at GABAergic synapses, reducing GABA release and inhibitory synaptic transmission. 
Again, it seems that members of all three groups are capable of this function. Of the brain 
regions studied, group II mGluRs can reduce transmission at inhibitory synapses in the 
accessory olfactory bulb and thalamus (Salt & Eaton, 1995; Hayashi et al., 1993). This 
property has also been seen for group I and group III mGluRs in the CA1 area of the 
hippocampus and thalamus respectively (Gereau & Conn, 1995a; Salt & Eaton, 1995). 
Another role of the mGluRs is their ability to regulate excitatory and inhibitory transmission 
by modulating the currents through the glutamate and GABA receptor channels. They have 
been demonstrated to potentiate and reduce currents through both NMDA and non-NMDA 
receptors. This action is highly variable in different cell populations and suggests unique 
roles for mGluRs in regulating synaptic transmission in different brain regions (Bleakman et 
al., 1992; Ceme & Randic, 1992; Colwell & Levine, 1994).
There is now increasing evidence for the specific subcellular localisation of mGluRs 
on neurones and synaptic terminals (Pin & Duvoisin, 1995). Group I receptors are generally 
located at postsynaptic sites, whereas group II and III receptors can occur at both
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presynaptic and postsynaptic sites. More specifically, it appears that functional receptors 
can be found located at the periphery of synapses. The mGluR la receptors are thought to 
be localised at the periphery of the post-synaptic membrane (Baude et al., 1993), unlike the 
iGluRs which occupy the ‘core’ of the synapse. Also, mGluR2 has been shown to be 
located pre-terminally on axonal processes and in the rat hippocampus, and presynaptic 
mGluR7 is located within the synaptic grid where vesicle docking and exocytosis takes 
place (Shigemoto et al., 1996). Thus, they are only expected to be activated by excessive 
amounts of glutamate such as that released during synaptic hyperactivity and not during 
normal synaptic transmission. Indeed, recent work by Scanziani et al. (1997) has provided 
evidence for this at hippocampal mossy fibre synapses in the guinea pig. Using mGluR 
antagonists MCPG (a-methyl-4-carboxy-phenylglycine) and MCCG (2S, 3S, 4S)-methyl-2- 
(carboxycyclopropyl)-glycine) to block the receptors, synaptic responses were measured at 
two different frequencies. It was shown that the antagonist increased the amplitude of 
synaptic responses during a 1 Hz train, but not during the control 0.05 Hz stimulation. This 
indicated that the modulation was mediated by mGluR2 and that they were activated only 
during the higher frequency stimulation. Thus, as mGluR agonists are known to depress 
transmission at mossy fibre synapses, the removal of the block resulted in a rapid inhibition 
of transmitter release. This use-dependent activation of presynaptic mGluRs represents a 
negative feedback mechanism for controlling the strength of synaptic transmission.
The group I receptors mGluR 1 and mGluR5 have been shown to exhibit distinct 
intracellular calcium responses in transfected cells. Electrophysiological studies have 
demonstrated that glutamate evokes a single-peaked, non-oscillatory [Ca2+]i in mGluRl 
expressing cells and oscillatory [Ca2+]i response in mGluR5 expressing cells (Kawabata et 
al., 1996). This is thought to result from a single amino acid substitution at the G protein 
interacting carboxy-terminal domain and that the oscillatory response is determined by a
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Figure 1.6 Schematic view of the putative roles of mGluRs at glutamatergic 
synapses.
Presynaptically, mGluRs may potentiate the release o f glutamate by activating protein 
kinase C (PKC) or by potentiating the activity o f the calcium channels. They may also 
inhibit the release o f glutamate by inhibiting N-type voltage sensitive calcium channels 
(VSCCs). Arachidonic acid (AA) can act as a retrograde messenger after being released by 
diacylglycerol (DAG) and act on group I mGluRs to enhance glutamate release. 
Postsynaptically, mGluRs can modulate the activity o f NMDA and AMPA receptors, 
different potassium channels (calcium activated, inward rectifier channel), and VSCCs.
G = G protein; IP3 = inositol 1,4,5-trisphosphate; PLC = phospholipase C.
specific PKC phosphorylation at the threonine residue of mGluR5 (Kawabata et al., 1996). 
Thus, the two closely related mGluR subtypes mediate diverging intracellular signalling in 
glutamate transmission (Nakanishi et al., 1998). This again hints at specialised functions for 
the different receptors.
Physiological roles o f the metabotropic glutamate receptors
As a consequence of the discovery of better agonists and antagonists, and the 
development of gene-knockout techniques, the mGluRs have been shown to be involved in 
many brain functions.
A substantial body of evidence indicates that mGluRs also have important roles in 
development and plasticity. For example, in development, the peak of excitatory amino acid 
stimulated PI hydrolysis is seen between 6 and 12 days of age in neonatal rats and this 
correlates well with periods of intense synaptogenesis (Palmer et al., 1990). Their 
involvement in memory and learning is provided by studies of synaptic plasticity.
Receptors such as mGluRs that are capable of enhancing NMDA receptor activity 
and increase the intracellular Ca2+ concentration are expected to facilitate the induction of 
LTP, or even to induce LTP, as experiments have shown that hippocampal long-term 
potentiation requires the influx of Ca2+ through receptors and additional activation of PLC 
and AC dependent signal cascades (Blitzer et al., 1995; Collingridge & Bliss, 1995). 
Moreover, an increase in the levels of IP3 is also thought to be important in LTP since it can 
release Ca2+ from internal stores. Indeed, studies suggested that NMDA receptor activation 
appeared not to be sufficient to induce LTP. Several reports have demonstrated that 
NMDA-dependent LTP in the hippocampus requires the activation of mGluRs in vivo 
(Bashir et al., 1993; Manahan-Vaughan & Reymann, 1996; Manahan-Vaughan et al., 
1996). Of the 8 cloned mGluRs, receptors of group I have been implicated most strongly in
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LTP (Pin & Duvoisin, 1995). Early reports yielded conflicting results. The potentiation of 
NMDA/AMPA mediated currents have been described in which a broad-spectrum mGluR 
ligand was used to induce LTP in CA1 and CA3 of the hippocampus, but these results were 
not reproduced by others (Chinestra et al., 1993; Manzoni et al., 1994). Experiments in 
'knock-out' mice have provided evidence for the involvement of mGluRs in LTP. 
Independent groups have found that in these animals LTP is reduced, but with ambiguous 
results (Conquet et al., 1994; Aiba et al., 1994).
Evidence for the role of the group I subtypes in LTP and memory is beginning to be 
elucidated from studies using gene-targeting techniques. Recent work with mutant mice that 
express no mGluR5 but normal levels of the other glutamate receptors suggest mGluR5 
plays a regulatory role in NMDA receptor dependent LTP, such as that seen in the CA1 
region and dentate gyrus of the hippocampus (Lu et al., 1997). Consistent with this, they 
found that LTP remained intact in the mossy fibre synapses on the CA3 region which is an 
NMDA receptor independent pathway. Behaviourally, the mutant mice were also impaired 
in two different spatial learning tasks which are known to depend on an intact hippocampus 
- the water maze and contextual fear conditioning (Morris, 1981; Philips & LeDoux, 1992). 
In contrast, previous studies using a mutated mGluRl gene revealed that LTP was impaired 
in the NMDA-independent pathways in the hippocampus (mossy fibre synapses of the CA3) 
(Aibaefa/., 1994).
Behaviourally, the impairment of spatial memory has been observed after MCPG 
(non selective mGluR antagonist) injection in the hippocampus, i.c.v injection of IS, 3R- 
ACPD, and in mGluRl knock-out mice (Riedel et al., 1994; Conquet et al., 1994; Aiba et 
al., 1994; Pettit et al., 1994). Spatial memory acquisition, which is believed to be 
hippocampus dependent, requires the modulation of mGluRs as the blockade of these 
receptors during learning causes amnesia (Riedel & Reymann, 1996). Also, it was observed
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that the effect of blockade of mGluRs is limited to a time window during and shortly after 
the acquisition learning as blocking the receptors hours after the learning event does not 
interfere with memory formation nor memory recall (Riedel & Reymann, 1996).
In the cerebellum, long-term depression (LTD) of parallel fibre Purkinje cell 
synapses is a well defined phenomenon. A role for PLC-coupled mGluRs, especially 
mGluRl which is highly expressed in Purkinje cells, has been suggested here (Linden,
1994). It is thought to arise from the co-activation of AMPA and mGluR receptors together 
with an increase in the concentration of intracellular Ca2+ induced by Purkinje 
depolarisation.
The activation of mGluRs also appears to be important for NMDA-independent 
LTP, such as VSCC-dependent LTP (Little et al., 1995). Recent work has demonstrated 
that the group I antagonists MCPG and 4-CPG were effective at blocking both NMDA and 
VSCC-dependent LTP (Manahan-Vaughan et al., 1998). As both forms of LTP activate 
multiple second messenger pathways, it is thought that these two forms of LTP share some 
common induction pathways which involve mGluRs.
The involvement of group II receptors in LTP has also been studied. Behnisch et al. 
(1998) provided evidence that while mGluR2 and mGluR3 are not essential for the 
induction of long term potentiation in the CA1 region of the hippocampus, they may be 
involved in feedback mechanisms in long-term potentiation. Group II receptors are thought 
important in other forms of learning. For example, mGluR2 are predominantly expressed 
presynaptically on granule cells of the accessory olfactory bulb. Activation of these 
receptors leads to the suppression of GABAergic inhibition and the enhancement of 
olfactory memory (Kaba et al., 1994).
LTD (long term depression), like LTP is also thought to be a fundamental process 
involved in learning and memory (Bliss & Collingridge, 1993). In the hippocampus,
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repetitive low frequency stimulation can reverse LTP by a process known as depotentiation 
(Barrionuevo et al., 1980). A similar type of homosynaptic depression can also be induced 
without first inducing LTP known as homosynaptic LTD (Dudek & Bear, 1992). Given the 
widespread expression of mGluR2 presynaptically on mossy fibres the role of these 
receptors was explored in synaptic plasticity in CA3 by targeted disruption of the mGluR2 
gene (Yokoi et al., 1996). It was demonstrated that LTP induced by tetanus was not 
impaired, but homosynaptic LTD induced by low frequency stimulation was almost totally 
abolished. However, the mutants performed normally in water maze learning tasks.
It is speculated that the role mGluRs play in the participation of memory formation 
is to modulate the signal-to-noise ratio of the CNS; that is, they set a ratio in order to filter 
out unimportant information and amplify important information. Under normal conditions, 
spontaneous neuronal activity is supposed to constitute a ‘noise’. During a particular 
learning event, activation of mGluRs might produce a signal, and this increase in the signal- 
to-noise ratio is transformed into memory. Blockade of group I mGluRs by MCPG for 
example, prevents the changes in the signal-to-noise ratio and thus leads to amnesia. Other 
mGluRs might reduce the noise and generate signals. Stimulation of group II or III mGluRs 
may depress excitation due to the inhibition of voltage-activated Ca2+ channels or the 
presynaptic reduction of transmitter release (Glaum & Miller, 1993).
The mechanisms involved in the induction and early expression of LTP are currently 
extensively studied. Less is known about the maintenance of LTP which appears to be 
critically dependent on protein synthesis and mRNA synthesis. Study into LTP maintenance 
has led to the hypothesis that the induction of LTP is associated with the setting of a 
‘synaptic tag’ at activated synapses whose role is to sequester plasticity-related proteins that 
go on to serve to stabilise temporary synaptic changes and extend their persistence (Frey &
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Morris, 1998). It has been speculated that the presently unknown identity of the tag may 
interact with mGluRs and aid in the sequestration of proteins.
With the exclusive localisation of mGluR6 in the retina, the mGluRs have an 
important role in visual transmission (Nomura et al., 1994). Electrophysiological evidence 
indicates that mGluR6 mediates postsynaptic responses on ON-bipolar cells (i.e. excitation 
of ON pathway following light exposure) by enhancing cGMP hydrolysis, analogous to that 
of signal transduction in photoreceptors (Nawy & Jahr, 1990).The mGluRs have also been 
demonstrated to be involved in the central control of cardiac activity (Pawloski-Dahm & 
Gordon, 1992). The microinjection of 1SR,3RS-ACPD into the nucleus tractus solatarius 
was demonstrated to induce cardiovascular responses that mimic the baroreflex response 
(e.g. hypotension and bradycardia). It is believed that mGluRs could provide novel centrally 
acting agents for the treatment of high blood pressure (Pawloski-Dahm & Gordon, 1992).
1.5 Glutamate and neurodegeneration
In addition to being crucially involved in physiological circumstances, glutamate also 
appears to be involved in acute and chronic neurological disorders. Knowledge that 
glutamate was toxic to neurones dates back to 1957 (Lucas & Newhouse). It was not until 
14 years later that the investigation of the action of glutamate and glutamate analogues led 
to the hypothesis of excitotoxicity (Olney et al,. 1971) and the concept that the excessive 
activation of glutamate receptors can mediate neuronal degeneration and cell death (Olney, 
1969). Support for the excitotoxicity hypothesis grew when the neuronal pathology induced 
by glutamate and glutamate analogues were revealed to be similar to that associated with a 
wide range of neurological insults such as ischaemia and epilepsy (Rothman, 1984; Auer et 
al., 1984; Olney et al., 1986). In accordance with this, a massive release of glutamate as
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well as other neurotransmitters (e.g. aspartate, GABA, glycine) was demonstrated during 
and following experimental ischaemia models (Benveniste et al., 1984; Globus et al., 1988; 
Andine et al., 1991; Mitani & Kataoka, 1991). Although glutamate is also believed to be 
involved in several forms of chronic neuronal degeneration, such as Alzheimer’s disease or 
Huntingdon’s disease (Meldrum & Garthwaite, 1990; Beal, 1992). The literature 
concerning chronic degeneration is not reviewed because the focus of the thesis was on 
acute excitotoxicity associated with ischaemia.
The question of the mechanisms of glutamate neurotoxicity has since been addressed 
both in vitro and in vivo by the development of models of cerebral ischaemia (Choi, 1988; 
Macrae, 1992; McAuley, 1995). There are several main types of in vivo ischaemia models, 
grouped into global and focal models (transient and permanent and partial and complete). 
Global models have often been stated to be models of cardiac arrest producing selective cell 
death, while focal models are said to be of greater relevance to acute ischaemic stroke 
producing brain infarction (Macrae, 1992). Focal ischaemia differs in a variety of ways from 
global ischaemia. A major difference is that focal ischaemia has a dense core of ischaemic 
tissue that is destined to die, together with a therapeutically susceptible zone at the 
periphery of the lesion called the penumbra, where the potential for collaterization exists 
(Ginsberg & Pulsinelli, 1994). Models in which the middle cerebral artery (MCA) of the rat 
is occluded are extensively used to study focal cerebral ischaemia because of their relevance 
to the human clinical setting as this vessel is most often occluded in man (Mohr et al., 
1986). In addition, the rat is the species of choice not only because of economical 
considerations but also because the cranial circulation in the rat is proposed to be similar to 
that in humans (Yamori et al., 1976), especially when compared with other species such as 
the cat, dog and gerbil.
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Of the numerous models of focal ischaemia (for review of models see Macrae, 1992; 
McAuley, 1995), the subtemporal approach with diathermy originally described by Tamura 
and co-workers (1981) has emerged as the standard method of MCA occlusion. The MCA 
is electrocoagulated proximal to the origin of the lateral lenticulostriate artery and results in 
the severe reduction in cerebral blood flow (<25ml/100g/minutes) within the territory of the 
MCA known as the ischaemic core (cortex, caudate putamen, globus pallidus, regions of 
the internal capsule and adjacent white matter) with blood flow reduced to a lesser degree 
(20-25% normal flow) at the penumbra (Hossman, 1994). The ischaemic penumbra 
disappears as the duration of the ischaemia increases and after a certain time will no longer 
be receptive to therapeutic intervention. Certain factors can complicate the outcome of the 
ischaemic insult and have to be taken into consideration. These include the animal species, 
strain, sex, age, nature of the ischaemia (global/focal, temporary/permanent), physiological 
variables such as temperature and blood pressure. Consequently, some neuroprotection 
studies have reported conflicting results.
In vitro models of ischaemia and neurotoxicity have been developed and used 
successfully to provide valuable information about the cellular mechanisms of injury not 
possible in vivo. For example, in vitro ischaemia is generated by severe energy depletion, 
either by the direct removal of vital substrates, or by a pharmacological intervention such as 
Iodoacetate, an inhibitor of glycolysis (Goldberg et al., 1997). The direct removal of the 
energy substrates oxygen and glucose is usually preferred, as it avoids problems associated 
with metabolic inhibitors such as the difficult removal of the agents from cells. It has been 
demonstrated that when neuronal cultures are deprived of both oxygen and glucose, they 
are killed approximately 10-fold more rapidly than in the absence of either oxygen or 
glucose alone (Goldberg et a l, 1997). The cell death seen following an acute insult such as 
hypoxia and hypoglycaemia is characterised by cell body swelling, early membrane lysis and
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random DNA breakage and is generally categorised as necrosis. Recently, increased 
attention has been focused on neuronal apoptosis (marked by cell body shrinkage, 
membrane blebbing, chromatin condensation and intemucleosomal fragmentation of cellular 
DNA) because of suggestions that it may contribute to neuronal loss in certain disease 
states, including hypoxia/hypoglycaemia and neurodegenerative diseases (Linnik et al.,
1993). Staurosporine-induced cell death is considered to be mediated primarily through the 
activation of apoptotic pathways (Koh et al., 1995). Staurosporine acts as a broad spectrum 
inhibitor of cAMP-dependent protein kinase, Ca2+-calmodulin kinase type II, tyrosine 
kinases and protein kinase C. Previous studies have demonstrated the ability of 
staurosporine to induce apoptosis in non-neuronal cell types and in cells of the CNS (Koh et 
al., 1994).
1.5.1 Ionotropic glutamate receptors and mechanisms of excitotoxicity
The exact mechanisms that lead to cell death are still unclear but it is well 
recognised that Ca2+ plays a critical role. In 1977, Nicholson et al. demonstrated that anoxia 
triggered the rapid translocation of Ca2+ from extracellular to intracellular spaces of 
cerebellar tissues. This and subsequent work led to the hypothesis of calcium-mediated cell 
death in ischaemia, hypoxia, hypoglycaemia and status epilepticus (Siesjo, 1981). It was 
originally assumed that only certain populations of neurones with high densities of calcium 
channels were vulnerable to these insults. However, an important step forward was made 
when the subsequent work of Choi (1987) demonstrated that cultured neurones exposed to 
glutamate showed a delayed cell death that was calcium mediated, and that removal of 
extracellular calcium protected the neurones. The conclusion drawn was that the excitotoxic 
hypothesis and the calcium hypothesis of cell death were intimately linked.
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Much of the interest in mechanisms of neurotoxicity has been focused on the 
NMDA receptor, reflecting its high Ca2+ permeability and it’s ability to mediate abnormal 
rises in intracellular Ca2+. Much evidence also exists for the involvement of non-NMDA 
receptors in pathological processes because of their appreciable Ca2+ permeability. AMPA 
receptors lacking the GluR2 subunit may play a role in the vulnerability of hippocampal 
neurones to ischaemic injury. Thus Pellegrini-Giampietro et al. (1992) reported that 
transient global forebrain ischaemia induced a selective decrease in GluR2 mRNA levels in 
the hippocampus and this preceded any histological signs of cell damage. This would lead to 
the increased formation of Ca2+-permeable AMPA receptors. The hypothesis predicts that 
Ca2+ entry through GluR2-lacking AMPA receptors in neurones that normally express Ca2+- 
impermeable channels contributes to the delayed cell death seen in global ischaemia because 
such channels do not intrinsically have any compensatory mechanisms for Ca2+ buffering 
(Pellegrini-Giampietro e ta l., 1997).
Under normal physiological conditions, calcium fluxes are tightly regulated by 
means of the 3Na+-Ca2+ exchange and by an ATP regulated Ca2+-2H+ exchanger (Blaustein, 
1988; Carafoli, 1987). In order to maintain calcium homeostasis, mechanisms must also 
exist for terminating both glutamate and calcium transients. These include the re-uptake of 
glutamate through an electrogenic NaVglutamate symporter, ATP-dependent Ca2+ pumps in 
the endoplasmic reticulum (ER), reuptake by glia, Ca2+- or ATP-dependent K+ channels and 
GABA-activated Cl' channels (Attwell & Mobbs, 1994; Pellerin & Magistretti, 1994; 
Kennedy, 1989; Erecinska & Silver, 1994). Thus with the concentration of intracellular 
calcium maintained, [Ca2+]i is only seen to rise transiently during cell activation. For 
example, glutamate (AMPA) receptor activation results in the passage of Na+ into the cell, 
which in turn leads to the depolarisation of the postsynaptic membrane. The depolarisation 
has two possible effects; 1) it relieves the Mg2+ block of the calcium permeable channel
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gated by the NMDA receptor and 2) it opens voltage-sensitive calcium channels (VSCCs). 
In addition, there may be mobilisation of intracellular calcium stores following mGluR 
mediated activation of IP3 and Ca2+-permeable AMPA receptors. Therefore, elevations in 
[Ca2+]i can be induced by a number of pathways.
The prolonged elevations of [Ca2+]i that follow pathological insults such as 
ischaemia can damage neurones in many ways. In ischaemia, the reduction in blood flow 
causes a decline in ATP levels and leads to the failure of the Na+/K+ pump, which in turn 
results in depolarisation and the activation of glutamate receptors. The depolarisation leads 
to the opening of VSCC and calcium influx into the cell. The increase in intracellular 
calcium also causes a release of glutamate that results in the prolonged exposure of post­
synaptic receptors to glutamate and to further influx of Na+ and Ca2+ ions. Re-uptake of 
glutamate becomes impaired through the suppression of ATP levels and this can lead to 
non-vesicular release of glutamate. This results in the accumulation of intracellular calcium 
in neurones followed by the destabilisation of the ATP-driven Ca2+-2H exchanger. It can 
also result in the reversal of the Na+/Ca2+ exchanger due to the Na+ influx through voltage- 
gated channels and also as a result of activating AMPA receptors. While levels of free 
calcium within a cell are very low (O.lpmol/L), the total cell calcium content is about 10 
000 times higher and calcium is found bound to proteins or phospholipids, or sequestered 
into the ER, calciosomes and mitochondria. It is clear that the cell contains enough calcium 
to substantially increase [Ca2+]i if it becomes released into the cytosol or displaced from its 
binding sites. Calcium can also be released by PLC-coupled events, mediated by receptors. 
Furthermore, the re-sequestration of calcium back into the ER requires ATP (Kristian & 
Siesjo, 1998). Increasing levels of calcium eventually activate immediate early genes and 
proteases such as calpains, which lead to the destruction of cytoskeletal components (Siman 
& Noszek, 1988) and also activation of phospholipases and endonucleases leading to the
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membrane damage and DNA fragmentation. Calcium also affects the activity of protein 
kinases (e.g. PKC, PKA), phosphatases, and activates enzymes that give rise to the 
production of reactive oxygen species such as hydrogen peroxide (H2O2), the superoxide 
anion (0 2'")» and nitric oxide (NO) (Tymianski & Tator, 1996; Choi, 1988) which in turn 
can modulate [Ca2+]i directly (Siesjo et al., 1994).
The mechanism described above is a well recognised scheme implicated in 
excitotoxicity. However, in recent years, research interests have focused on calcium 
metabolism of the mitochondria. It is well known that calcium accumulation leads to 
mitochondrial damage (Nicholls, 1985). It is assumed that following an insult of limited 
duration, a sustained perturbation of cell calcium metabolism leads to a slow gradual rise in 
[Ca2+]i (Deshpande et al., 1987). The rise in calcium eventually exceeds a ‘set point’ for 
calcium sequestration in the mitochondria, and they start to accumulate calcium until they 
are overloaded and become dysfunctional (Martins et al., 1988). The damage triggered was 
originally thought to indicate the activation of mitochondrial phospholipase A2 (PLA2) 
which broke down the lipid backbone of the inner mitochondrial membrane to produce a 
non-specific increase in mitochondrial membrane permeability (Gunter & Pfeiffer, 1990). 
Recent evidence suggests that the increase in permeability involves the assembly of a 
proteinaceous pore - the MPT (mitochondrial permeability transition) pore which allows the 
passage of ions and molecules (Gunter & Pfeiffer, 1990; Zoratti & Szabo, 1995; Duchen et 
al., 1993; Bemardi & Petronilli, 1996).
The neuropathological state that has been described following the exposure of 
neurones to glutamate, or a glutamate analogue, is one of cellular swelling - in particular 
swelling of the mitochondria. This has been causally linked with chloride influx (Rothman, 
1985), but the swelling process is now thought to reflect the assembly of an MPT pore in 
the inner mitochondrial membrane which allows the release of Ca2+ and Mg2+ along with
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other compounds. A consequence of this is the abrupt production of reactive oxygen 
species. MPT pore formation is triggered by a number of factors, but is thought to occur 
principally as a result of oxidative stress and calcium accumulation (Duchen et al., 1993; 
Crompton et al., 1988; Richter et al., 1995). Studies in vitro have demonstrated that 
cyclosporin A inhibits the MPT pore (Zoratti & Szabo, 1995). While in vivo, it was 
discovered that cyclosporin A, provided it could pass the blood-brain barrier, dramatically 
reduces CA1 damage following a brief forebrain ischaemia (Uchino et al., 1995). However, 
these results have to be interpreted with caution as cyclosporin can produce other effects 
(e.g. immunosuppression, modulation of NO production). Of the reactive oxygen species 
produced following an increase in [Ca2+]i, NO and peroxynitrite predispose to an MPT pore 
and could potentially act as triggers of a pore opening in partially calcium loaded 
mitochondria (Schweizer & Richter, 1994; Packer & Murphy, 1995).
A second hypothesis involves the synthesis of the respiratory complexes in the 
mitochondria (Abe et al., 1995). Briefly, the enzymes (i.e. the respiratory complexes) 
required to allow the passage of electrons along the respiratory chain and extrude FT are 
encoded for by mitochondrial and nuclear DNA. For this process, the mitochondria must 
therefore be transported to the nucleus along the cytoskeletal elements, such as dynorphin 
and kinesin. The suggestion put forward is that this process grinds to a halt when the 
cytoskeleton is broken down by calcium activated proteases and calcium-dependent 
disassembly of the microtubules (Siman et al., 1996). This would result in reduced activities 
of the mitochondrial enzymes and a subsequent depletion in the generation of ATP.
Free radicals play an important role in excitotoxic and ischaemic processes (Watson 
& Ginsberg, 1989). Free radicals are produced predominantly in the mitochondria and also 
in the arachidonic acid cascade of phospholipid metabolism. The production of free radicals 
leads to lipid peroxidation and degradation of proteins which may subsequently compromise
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intracellular calcium regulation (Floyd & Carney, 1992). Thus, free radicals promote the 
elevation of [Ca2+ ]i, which in turn increases free radical production by mechanisms 
involving the production of arachidonic acid (Sanfeliu et al., 1990; Verity, 1993). The 
production of the free radical NO is increased in response to increased [Ca2+]i. It has been 
shown the NOS containing neurones (1-2% of all neurones in the cortex) are resistant to 
NMDA toxicity (Koh & Choi, 1988; Uemura et al., 1990). Calcium stimulates constitutive 
nitric oxide synthase (cNOS) through Ca2+-calmodulin which results in the formation of 
NO. Therefore, the activation of NMDA glutamate receptors can trigger NO synthesis via 
the associated influx of calcium. NO may be cytotoxic directly by inhibiting enzymes in the 
mitochondria, resulting in perturbations in energy metabolism and in enzymes involved in 
DNA synthesis, such as ribonucleotide reductase activity (Dawson et al., 1992; Kwon et 
al., 1991). A major pathway through which NO mediates cell death is thought to be its 
interaction with O2' anion and the subsequent formation of peroxynitrite (ONOO*) 
(Beckman et al., 1991; Koppenol et al., 1992). Peroxynitrite also decomposes to other 
reactive oxygen species thus activating lipid peroxidation. Other studies using knockout 
mice have identified the specific NOS isoforms important to ischaemic injury. Animals 
deficient in neuronal NOS (nNOS) appear to be more resistant to ischaemic tissue damage 
than wild types (Huang et al., 1994). However, the involvement of NO in the 
pathophysiology of brain injury remains controversial. Studies have also provided evidence 
that NO is not involved (Demerle-Pallardy et al., 1991). Studies by Lipton et al. (1993) 
suggest that the dual roles of NO in excitotoxicty may depend upon its redox state. The 
reduced ion, nitrogen monoxide (NO') is thought to be responsible for the neurotoxic action 
of NO via a reaction with superoxide leading to the formation of peroxynitrite. Conversely, 
the oxidised nitrosonium ion (NO+) is believed to react with the redox modulatory site of 
the NMDA receptor and block neurotransmission.
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1.5.2 Existing neuroprotective strategies for glutamate-induced toxicity
In order to effectively treat neurotoxic insults, in this case ischaemia, an appreciation 
of the mechanisms involved in causing cell damage and death is required. Thus, a number of 
pharmacological strategies have been proposed as possible mechanisms for attenuating the 
neurotoxic actions of glutamate and have been studied in models of excitotoxic and 
ischaemic cell death in vitro and in animal models of acute ischaemic stroke.
The post-synaptic manipulation of glutamate receptors has been the most obvious 
line of consideration. Initial efforts concentrated on NMDA receptor subtypes because of 
their Ca2+ permeability. Functional inhibition of NMDA receptors can be achieved through 
actions at different sites such as the primary transmitter site, the glycine binding site, 
polyamine site and PCP site. Glutamate receptor antagonists have been demonstrated to 
effectively reduce neuronal damage in experimental models of ischaemia and hypoxia. In 
global ischaemia, NMDA receptor antagonists provide little protection. However, the 
competitive antagonists CGS19755 and CPP have been shown to provide neuroprotection 
when given before the ischaemic insult (Boast et al., 1988). NMDA receptor antagonists of 
all types, for example the non-competitive antagonists MK-801, dextromethorphan, 
CNS1102 and eliprodil, appear to be effective in providing neuroprotection in models of 
focal ischaemia (Gotti et al., 1988; Park et al., 1988, 1992; Toulmond et al., 1993). 
However, inhibition of these different sites can lead to serious side effects and behavioural 
profiles such as loss of memory, limiting their clinical utility.
AMPA receptors can also be inhibited by both allosteric and competitive 
antagonists. The potent AMPA antagonist NBQX was a candidate used to examine the role 
of non-NMDA receptors in ischaemia (Gill & Lodge, 1991), but due to its 
pharmacokinetics, chemical properties and side effects (such as renal precipitation), it was 
not developed further. The administration of AMPA receptor antagonists alone or in
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combination with NMDA are neuroprotective in models of global ischaemia (Sheardown et 
al., 1990; Kaku et al., 1991; Mosinger et al., 1991). AMPA antagonists have been shown 
to provide partial protection against damage induced by global ischaemia when given post- 
ischaemically (Buchan et al., 1991a; Li & Buchan, 1993). However, in focal ischaemia, 
AMPA antagonists of both types, e.g. LY293558 and GYKI 52466, also diminish the 
volume of infarction (Buchan et al., 1991b; Bullock et al., 1994; Gill et al., 1992; Smith & 
Meldrum, 1992; Degraba et al., 1994). By blocking AMPA receptors, membrane 
depolarisation is prevented, which in turn will attenuate NMDA receptor activation and 
voltage-sensitive Ca2+ channels, thereby reducing Ca2+ entry. AMPA antagonists appear to 
be more potent neuroprotectants against the delayed neuronal death seen after severe 
forebrain ischaemia (4 vessel occlusion). A rationale for the neuroprotective effects of 
AMPA antagonists against delayed neuronal degeneration is the possible alteration in the 
expression of the receptors after ischaemia. It has been shown that there is a decrease in the 
expression of GluR2 following severe forebrain ischaemia. As the GluR2 subunit determines 
the calcium permeability of the AMPA receptors, this would result in increased calcium 
permeability, and cell damage. The use of AMPA antagonists may inhibit this response. 
Alternatively, AMPA receptors may become more responsive after ischaemia and are 
upregulated, as seen during the maintenance phase of LTP (Davies et al., 1989).
In view of the importance of calcium in mediating neuronal damage and death, 
calcium channel antagonists (compounds that block calcium fluxes through voltage- 
operated calcium channels) have been investigated for their usefulness in neuroprotection. 
Initial studies used compounds that had been optimised for their anti-hypertensive 
properties such as nimodipine (Alps et al., 1988). The results from these calcium 
antagonists are conflicting. For example, nimodipine has been reported to be 
neuroprotective in some but not all focal ischaemia studies in the rat, and global ischaemia
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models (Bielenberg et al., 1990; Alps et al., 1988). It is thought that the conflicting data 
may be due to in part the confounding effects of systemic hypotension. The neuronal VSCC 
antagonist SB201823A which has reduced cardiovascular effects, has been shown to be 
neuroprotective in both global and focal cerebral ischaemic models (Barone et al., 1995; 
Ginsberg, 1995). Following on from this, studies have demonstrated that calpain inhibitors 
(enzyme activated by high levels of intracellular calcium) reduce ischaemic damage and 
infarct volume in focal ischaemia (Rami & Krieglstein, 1993).
Oxygen free radicals are important in the cascade of cellular events leading to cell 
death following cerebral ischaemia. By conjugating the enzyme responsible for removing 
superoxide, superoxide dismutase (SOD), to polyethylene glycol the circulation half-life of 
SOD can be increased by many hours. Liu et al. (1989) demonstrated that this reduced 
infarct volume in permanent MCA occlusion by around 25%. In addition, compounds that 
inhibit lipid peroxidation (e.g. tirilizad) also provide neuroprotection in various experimental 
models (Hall et al., 1994). Nitrone-based free radical traps are also possible strategies for 
neuroprotection. Using these compounds, free radicals are intercepted and incorporated 
into the nitrone agents to form a spin adduct that can no longer undergo other reactions. 
The potential of these agents in cerebral ischaemia arose serendipitously following studies 
with phenyl-tert-butylnitrone (PBN) with little or no side effects (Carney & Floyd, 1991). 
Evidence suggests that the action of PBN is not wholly attributable to trapping free radicals. 
Zhao et al. (1994) demonstrated that brain infarct volume was reduced following MCA 
occlusion, even when administered 3 hours post-ischaemia. Thus it seems that PBN may 
block neurodegenerative processes initiated by, that are temporally separate from, the post- 
ischaemic burst of oxyradicals which is most likely thought to be genomic regulation 
(Hensley et al., 1997).
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Another possible approach to the protection of neurones in ischaemia is to modulate 
Na+ channels (down-modulate) and K+ channels (opening of channels). The down regulation 
of Na+ channels during periods of limited oxygen supply appears an effective way of 
reducing energy expenditure because a large proportion of energy consumed by excitable 
cells is used to maintain the Na+ and K+ gradients across the membrane. Cell membranes are 
selectively permeable to K+ under physiological conditions and for this reason the activation 
of K+ channels opposes depolarisation and thus will reduce membrane excitability and 
neuronal activity (Suzuki et al., 1995). The down regulation of Na+ channels remains 
beneficial even after the ischaemia. Lamotrigine and its derivatives act on Na+ channels and 
have been demonstrated to protect against ischaemic damage (Wiard et al., 1995; Smith & 
Meldrum, 1995). Other agents such as riluzole, lubeluzole (Pratt et al., 1992; De Ryck et 
al., 1994) are also capable of protecting against ischaemic damage. The transport of L- 
glutamate may also represent a site at which excitatory transmission may be controlled. 
More specifically, in the presence of high levels of glutamate, the increased transport of 
glutamate away from the synaptic cleft could serve as a protective mechanism to prevent 
excitotoxic damage.
On the basis of the exciting experimental data showing neuroprotection in the 
various animal models of cerebral ischaemia, a multitude of clinical trials have been carried 
out in ischaemic stroke patients. However, out of all the studies completed, only the USA 
trial for the thrombolytic agent recombinant tissue plasminogen activator (rt-PA) has 
proved successful (Adams etal., 1996).
Presently, there is much interest in secondary neuronal death, such as that seen with 
CNS inflammatory processes which occur days after an ischaemic insult. An emerging 
strategy for the treatment of stroke is directed at inflammatory cytokines (Feuerstein et al., 
1996). Various experimental studies have implicated roles for several inflammatory
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molecules in the pathophysiology of stroke. The dramatic expression of cytokines has been 
detected after an ischaemic insult. These include tumour necrosis factor-a, TNF-a (Wang et 
a l,  1994), interleukin-lp, IL-lp (Liu et a l,  1993), transforming growth factor-P, TGF-P 
(WieBner et a l, 1993) and interleukin-6, IL-6 (Wang et al., 1995), as well as various 
chemokines. While some cytokine-suppressive drugs have been suggested as a possible 
therapeutic targets in stroke (Elford et al., 1995; Loddick & Rothwell 1996), recent studies 
have shown that the production of certain cytokines may be beneficial in limiting neuronal 
cell death associated with excitotoxicity, such as the TGF-ps (McNeill et a l, 1994). The 
TGF-ps are expressed abundantly in the nervous system and are multifunctional, pleiotropic 
molecules with major roles in the control of cell differentiation and proliferation, 
extracellular matrix metabolism, cellular migration and immunosuppression. In addition to 
the interest in the inflammatory response following ischaemia, it is increasingly recognised 
that white matter in the CNS is highly vulnerable to cerebral ischaemia (Pantoni et a l, 
1996) and its protection should be considered alongside that of grey matter. Amyloid 
precursor protein (APP) is a transmembrane glycoprotein associated with the cytoskeleton. 
It is ubiquitously expressed in the nervous system and undergoes fast anterograde axonal 
transport in the peripheral nervous system. Disruption of APP transport is believed to 
reflect axonal injury; it has been demonstrated to be a sensitive marker of axonal damage in 
head injury (Blumbergs et a l, 1994; Gentleman et a l, 1995) and accumulation of APP has 
been shown as a result of ischaemic insults (Kalaria et a l, 1993; Stephenson et a l, 1992).
1.6 Emerging roles of metabotropic glutamate receptors in brain 
pathology
Due to the ubiquitous distribution of mGluRs, they have the potential to participate 
in a wide variety of functions in the CNS. Because of this, they may also be involved in a
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wide range of neurologic and psychiatric disorders. The involvement of mGluRs in 
pathology was initially suggested when enhancements of excitatory amino acid stimulated 
PI hydrolysis were demonstrated in brain slice preparations subjected to various stimuli 
(Iadorola et a l, 1986; Nicoletti etal., 1987; Seren et a l, 1989).
mGluRs may have a role in chronic neurodegenerative disorders. Recent evidence 
indicates that mGluRs may be potential drug targets for the therapy of Parkinson’s disease 
(Greenamyre et a l,  1994). The activation of mGluRs is also thought to interfere with the 
pathophysiological events underlying Alzheimer’s disease. Activation of recombinant 
mGluRla has been shown to increase the release of soluble forms of amyloid precursor 
protein APP (Lee et a l, 1995). This might be accompanied by a reduction in P-amyloid 
production (Gabuzda et a l, 1993). In contrast, apoptosis induced by P-amyloid is 
substantially reduced by agonists of group II and group III mGluRs (Copani et a l,  1995).
Hypothetically, one of the most potential and beneficial effects of mGluR agonists 
and antagonists is their use in reducing of excitotoxic neuronal damage that occurs after 
stroke or traumatic brain injury. From the putative mechanisms described above, selective 
antagonists of mGluRs involved in potentiating responses to the activation of iGluRs could 
be effective in reducing excitotoxicity, as could agonists at mGluR autoreceptors.
As previously described, the role of ionotropic glutamate receptors in excitotoxic 
insults such as ischaemia prompted the search for neuroprotective agents. Protecting against 
excitotoxicity using iGluR antagonist therapy has revealed serious shortcomings, such as 
compromised fast excitatory synaptic transmission (Ginsberg, 1995). Metabotropic 
glutamate receptors are possible targets for neurodegenerative disorders as they have the 
potential to overcome the limitations associated with agents active at ionotropic glutamate 
receptors. Evidence shows that they are expected to mediate excitatory synaptic 
transmission only under certain circumstances, such as synaptic hyperactivity (Conn et a l,
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1995). Thus, mGluRs could influence both the induction and the progression of neuronal 
degeneration without hampering the efficiency of fast excitatory synaptic transmission.
When this thesis was first undertaken, interest in the involvement of mGluRs in 
acute excitotoxicity was still in its infancy due to the absence of good pharmacological 
tools. Preliminary studies had revealed that NMDA-induced neurotoxicity in cortical 
cultured cells was attenuated with fraws-ACPD (active isomer is 1S,3R-ACPD), and that 
this observation was extended to a mouse model of permanent focal ischaemia (Koh et al., 
1991; Chiamulera et al., 1992). However, the local or intracerebroventricular infusion of 
trans-kCPT) resulted in the degeneration of striatal and hippocampal neurones (McDonald 
& Schoepp, 1992), while intrahippocampal injections resulted in limbic seizures and 
hippocampal cell loss (Sacaan & Schoepp, 1992). The dichotomy in results can be 
attributed to the fact that trans-ACPD has a broad spectrum of activity and is able to 
activate various mGluR subtypes. This has led to the hypothesis that individual mGluR 
subtypes can differentially affect the processes associated with neurodegeneration and has 
resulted in a succession of predominantly in vitro studies exploring the roles of mGluRs in 
excitotoxicity. Studies with the mGluR2/3 selective agonists 2R,4R-APDC and DCG-IV, 
and group III selective agonists L-AP4 and L-SOP, also demonstrated protective effects 
against hypoxic- and NMDA-induced excitotoxic neuronal cell death (Bruno et al., 1994; 
Buisson & Choi, 1995; Buisson et al., 1996). Similarly, in vivo studies demonstrated that 
intraventricular injections of DCG-IV produced anticonvulsive and neuroprotective effects 
against kainic acid induced excitotoxicity (Miyamoto et al., 1997). Thus it is generally 
assumed that the activation of group II or III receptors will facilitate neuroprotection by 
reducing synaptic excitation (Nicoletti et al., 1996).
The situation with group I receptors however is still not entirely clear. It is thought 
that the activation of mGluRl or mGluR5 will increase neuronal excitation and excitability,
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and therefore exacerbate neuronal damage. Activation of an mGluR coupled to PI 
hydrolysis could increase calcium levels either by IlVmediated release of calcium from 
intracellular stores, such as the ER, or by DAG activation of PKC leading to the facilitation 
of calcium currents through NMDA receptors. This is believed to be a consequence of 
excessive mGluR-mediated potentiation of NMDA currents through the ability of PKC to 
remove the Mg2+ block. Consistent with this idea, Bruno et al., (1995b) demonstrated that 
agonists selective for group I mGluRs led to the amplification of NMDA-induced neuronal 
degeneration in cultured cortical cells, and also that the activation of mGluRl exacerbated 
post-traumatic neuronal injury (Mukhin et al., 1996). Similarly MCPG, a broad spectrum 
mGluR antagonist, was shown to protect hippocampal CA1 neurones from hypoxia and 
hypoglycaemia in vitro (Opitz et al., 1994). In contrast, Ferraguti et al. (1997) provided 
evidence to suggest that the inactivation of mGluRl does not prevent excitotoxic neuronal 
damage following MCA occlusion in the mouse. Again, the apparent contradictory results 
can now be explained by the involvement of these agents with more than one mGluR 
subtype. This however does not explain the absence of neuroprotection demonstrated 
following the targeted gene disruption of mGluRl (Ferraguti et al., 1997).
Recent studies using the new and selective group I mGluR antagonists, AIDA and 
LY367385, appear to substantiate the hypothesis that activation of mGluRl and mGluR5 
are detrimental to the CNS (Strasser et al., 1998; Bruno et al., 1999). Neuroprotection may 
also be subject to the timing of group I mGluR manipulation (Schroder et al., 1999). 
Although there has been limited in vivo data because of the lack of systemically active, 
centrally bioavailable, mGluR selective ligands with which to explore the involvement of 
these receptors in excitotoxicity, the absence of mGluRs in target organs of the autonomic 
nervous system suggests they should be devoid of major peripheral side effects and mGluRs 
may be promising drug targets. Recent evidence for the role of group II mGluRs in
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excitotoxicity is further discussed in context within the results section of this thesis in 
chapter 8, section 8.4.
1.7 Imaging cerebral function with [14C]2-deoxyglucose 
autoradiography
[14C]2-deoxyglucose autoradiography ([14C]2-DG) allows functional activity within 
the brain to be assessed quantitatively. Through the measurement of local rates of glucose 
utilisation, this technique permits the visualisation and the quantitation of glucose 
metabolism in discrete anatomical regions throughout the CNS. Inferences about cerebral 
function can be drawn using the [14C]2-DG autoradiographic technique for two reasons. 
Firstly, under normal physiological conditions, the energy requirements of cerebral tissue 
are derived almost exclusively from the aerobic metabolism of glucose. Secondly, functional 
activity and energy metabolism in the CNS are directly and intimately associated (SokolofF, 
1977).
The technique takes advantage of the biochemical characteristics which result from 
the modification of the glucose molecule to 2-deoxyglucose, which differs only in the 
substitution of the hydroxyl group on the second carbon atom to a hydrogen atom. The 
entry of 2-deoxyglucose from the blood into the brain is mediated by the same saturable 
carrier that transports glucose across the blood-brain barrier. In the CNS, both sugars 
compete for hexokinase which result in their phosphorylation, and it is at this point in the 
biochemical pathway that the metabolism of the two diverge. Glucose-6-phosphate is 
metabolised further via the glycolytic and tricarboxylic acid cycle pathways eventually to 
produce C 02 and water. The product 2-deoxyglucose-6-phosphate however, is not a 
substrate for glucose-6-phosphate dehydrogenase or glucose-6-phosphate isomerase and its 
catabolism ceases at this point. Therefore, once 2-deoxyglucose-6-phosphate is formed, it is
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essentially trapped and accumulates as it is formed in the cerebral tissues (the hydrolysis of 
2-deoxyglucose-6-phosphate back to 2-deoxyglucose does not present a problem as levels 
of glucose-6-phosphatase are present only in very low levels), thus allowing the application 
of the quantitative autoradiographic technique.
Sokoloff et al. (1977) developed a theoretical model based on the biochemical 
properties of 2-deoxyglucose (figure 1.8) in which the relationships can be mathematically 
defined and an operational equation derived if the following assumptions are made:
1) Plasma glucose concentration and the rate of glucose consumption are constant 
throughout the period of the procedure.
2) Each tissue compartment is homogeneous, and that the concentrations of [14C]2-DG 
and glucose within each compartment are uniform and exchange directly with the 
plasma.
3) [14C]2-DG is present only in tracer concentrations (molecular concentrations of free 
[14C]2-DG essentially equal to zero).
The operational equation which defines Ri, the rate of glucose consumption per unit 
mass of tissue ‘i* in terms of the measurable variables 1) arterial plasma [14C]2-DG 
concentration (Cp*) and arterial plasma glucose levels (Cp) at specified times (t) throughout 
the experiment to the time of killing (T), and 2) the total concentration of [14C] in the tissue 
(Ci) at the time of killing (T), is illustrated in figure 1.9. The rate constants Ki*, K2* and 
K3*, which define the distribution of tracer between plasma and brain tissue compartments, 
and the lumped constant (k, O and kinetic constants for hexokinase) which maintains the 
steady state rates of [14C]2-DG and glucose phosphorylation in the brain, are not measured 
in each experiment. The values for these constants were previously determined in animals by 
Sokoloff et al. (1977) in the original description of the method.
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Figure 1.8 Schematic representation of the biochemical behaviour of [14C]2- 
deoxyglucose in the brain.
Cp* and Cp represent the concentrations of [14C]2-deoxyglucose and glucose in arterial 
plasma respectively.
Ce* and Ce represent their respective concentrations in tissue precursor pools that serve as 
substrates for hexokinase.
Cm* and Cm represent the concentrations of [14C]2-deoxyglucose-6-phosphate and glucose- 
6-phosphate in tissue respectively.
Ki(*}, K2(*}, K3(*} represent the rate constants for carrier mediated transport of [4C]2- 
deoxyglucose from plasma to tissue, from tissue back to plasma, and phosphorylation by 
hexokinase respectively.
(From Sokoloff et al., 1977)
Different energy-dependent processes contribute to the rate of glucose utilisation 
within neurones, including processes involved with neurotransmitter synthesis and release 
and the maintenance of ionic gradients by ionic pumps. The different cellular elements 
within cerebral tissue will also have varying requirements for energy consumption. It has 
been estimated that neurones account for approximately 75% of the total oxygen 
consumption in the CNS (Siesjo, 1978). The dynamic alterations in glucose utilisation 
reflect predominantly nerve terminal electrical activity (Schwartz et al., 1979). The
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Figure 1.9 The operational equation of the [14C]2-deoxyglucose method.
The rate of glucose utilisation Ri in any region of cerebral tissue is calculated from the 
operational equation. All symbols are the same as those defined in figure 2.1 
X represents the ratio of tissue distribution volumes for deoxyglucose and glucose, O equals 
the fraction of glucose which, once phosphorylated, will continue to be metabolised via the 
glycolytic pathway, Km(*) and Vm(*) represent the Michaelis-Menten constants of 
hexokinase for deoxyglucose^ and glucose.
(From Sokoloff et al., 1977)
remainder of energy consumption in the brain relates to ionic fluxes and ionic transport 
which can be manipulated only after the inhibition of electrical activity (i.e. flat EEG) 
(Crane et al., 1978; Astrup et al., 1981).
As alterations in glucose use correspond to the activity in axonal pathways, changes 
in glucose use will not be restricted to receptor localisation, but also the neuronal pathways 
connected to those regions. For this reason, the technique has been successfully applied to 
many diverse situations. For an extensive review of the applications of the [14C]2-DG 
technique, interested readers should refer to the review by McCulloch (1982). A major 
application of the [14C]2-DG technique has been to characterise the functional consequences 
associated with a particular neurotransmitter system, either by the administration 
(systemically/locally) of putative receptor agonists or antagonists, or by using 
stereotaxically placed lesions. Over the past 20 years, the [14C]2-DG technique has provided 
much insight into the circuitry associated with the majority of the known neurotransmitter
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systems in the CNS. A small number of studies are briefly outlined here to present a few of 
the applications of the [14C]2-DG technique. The most extensively studied system has been 
that of dopamine. Dopaminergic systems have been manipulated sytemically, through the 
use of agonists and antagonists, and also locally by stereotaxic lesions of dopaminergic 
pathways. Such studies have demonstrated that changes in glucose metabolism are 
restricted in their anatomical distribution. The systemic administration of dopaminergic 
agonists led to elevations in glucose use in regions containing dopamine receptors, such as 
the substantia nigra and striatum. However, alterations in glucose utilisation were also 
demonstrated in brain regions lacking dopamine receptors but which are influenced by 
dopaminergic activity, such as the inferior olivary nucleus and thalamic nuclei. Intracerebral 
approaches such as the lesioning of dopaminergic pathways or injecting dopaminergic 
agents directly into brain regions, have also been used to manipulate neuronal activity. For 
example, a combination of systemically administered apomorphine and lesions of retinal 
input to primary visual structures helped in determining the involvement of retinal 
dopaminergic receptor activation in visual processes (McCulloch et al., 1980).
Extensive studies have been carried out to investigate the consequences of GAB A 
receptor manipulation. Using the systemic administration of the GABAa agonists muscimol 
and 4,5,6,7-tetrahydroisoxazole[5,4-c]pyridin-3-ol (THIP), these ligands were 
demonstrated to depress glucose utilisation throughout the CNS (Kelly & McCulloch, 
1982, 1984; Kelly et al., 1986). An interesting application of the autoradiographic technique 
has been the use of a ranking function ( f  function) to allow the systematic and objective 
interpretation of data obtained (Ford et al., 1985). This approach was applied to studies 
investigating GABAergic manipulations. Through the use of the /  function, regional 
heterogeneity in the metabolic responses of brain structures to GABA ligands were
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revealed. Differences in the cerebral functional effects of the benzodiazepine, diazepam, was 
separated from the effects of the GABAa agonists muscimol and THIP.
Since glutamate is widely used in the CNS as a neurotransmitter, and is associated 
with the pathogenesis of a variety of neurodegenerative disorders, the functional 
consequences of glutamate receptor manipulations have also been studied extensively. 
Selective NMDA receptor antagonists together with selective AMPA receptor antagonists 
have been used to examine cerebral function in both physiologic and pathologic conditions.
Systemic pharmacologic manipulations using NMDA receptor antagonists have been 
carried out extensively. Using a variety of competitive antagonists (e.g. CPP, CGS 19755 
and CGS 37849) and non-competitive antagonists (e.g. MK-801, ketamine and PCP), 
studies have revealed that the functional consequences after receptor blockade both at the 
glutamate recognition site and in the receptor ion channel are essentially the same. The non­
competitive NMDA antagonists result in selective and substantial increases in function- 
related glucose use in cortical and subcortical limbic structures and basal ganglia, while the 
competitive NMDA antagonists result in more modest reductions in glucose use in these 
areas (Meibach et al., 1979; Nelson et al., 1980; Hargreaves et al., 1993; Sharkey et al.,
1994).The differences in the magnitude of the responses displayed by the different NMDA 
receptor antagonists has been attributed to the use-dependent nature of the glutamate 
receptor blockade of MK-801 or PCP, which is intensified by increasing glutamatergic 
transmission.
The systemic antagonism of AMPA receptors by agents such as NBQX and 
LY293558 result in alterations in glucose use that differ from the effects produced by the 
competitive and non-competitive antagonists of the NMDA receptors. AMPA antagonists 
produce marked, anatomically widespread and dose-dependent reductions in glucose use 
throughout the brain, unlike the selective changes seen following NMDA receptor
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manipulation (Suzdak & Sheardown, 1993; Browne & McCulloch, 1994). The 
consequences of the pharmacologic manipulations of NMDA and AMPA receptors are 
discussed in relation to findings obtained in this thesis in chapter 8.
1.8 Aims of thesis
The extensive study of ionotropic glutamate receptors has revealed a multitude of 
functions in the brain and led to speculation about their involvement in the pathology of 
neurodegenerative diseases such as ischaemia. While it has been demonstrated that NMDA 
and AMPA receptor antagonists such as MK-801 and NBQX are potent neuroprotectants, 
the use of such agents in the clinical setting has not proved possible. Similarly, the roles of 
mGluRs in the CNS are thought to be as diverse, and thus could have the potential to 
influence the therapy of a variety of CNS disorders. However, progress has been hindered 
due to a lack of subtype-specific and systemically active ligands.
The aims of this thesis are to investigate the consequences of metabotropic and 
AMPA glutamate receptor activation in the rat brain using selective ligands with an 
emphasis on group II mGluR activation. The consequences of antagonism were also 
examined for AMPA. The studies examine the impact of glutamate receptor activation 
following pharmacological manipulations under physiological and pathological conditions 
using a variety of in vitro and in vivo techniques.
Aim 1: To investigate the effects on cerebral function following glutamate receptor
manipulation using two novel, systemically active metabotropic receptor agonists that have 
been demonstrated to be highly potent and selective for group II mGluRs in vitro, 
LY354740 and LY379268. Using [14C]2-deoxyglucose autoradiography, the effects of 
these agents on glucose utilisation in the rat brain will be examined and compared. In
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addition, the study will investigate if the effects following the systemic administration of 
LY354740 and LY379268 are similar to those displayed following systemic NMDA and 
AMPA receptor antagonists.
Aim 2: To investigate the consequences of cerebral function following the selective
modification of neuronal activity by direct intracerebral injection of the selective AMPA 
antagonist LY326325. [14C]2-deoxyglucose autoradiography will also be used in this study 
to determine whether AMPA receptor blockade in the hippocampus is similar to that seen 
following intracerebral blockade of NMDA receptors.
Aim 3: To explore the neuroprotective role of group II mGluRs in cerebral
ischaemia. A model of permanent cerebral ischaemia together with LY3 54740 and 
LY379268 drug intervention will be used to test the hypothesis that activation of group II 
mGluRs are neuroprotective. Together with the traditional histological analysis to measure 
infarct volume, immunohistochemical analysis of ischaemic brain tissue treated with 
LY3 79268 will also be carried out to determine cellular changes in the brain following 
permanent cerebral ischaemia.
Aim 4: To explore the possible mechanisms of actions of group II mGluRs in acute
excitotoxicity using cell culture models of neurotoxicity. This study will use two 
mechanistically disparate challenges of hypoxia/hypoglycaemia and staurosporine-induced 
neurotoxicity to investigate the events involved in mediating neuroprotection by LY3 54740 
and LY379268. In addition, astrocytes will also be used to determine their possible role in 
the protection mechanism.
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CHAPTER 2 
METHODS
2.1 In vivo [14C] 2-deoxyglucose autoradiography
2.1.1 Preparation of animals for [14C]2-deoxyglucose measurement
Male adult rats were placed in a perspex chamber and anaesthetised initially with 5% 
halothane in a nitrous oxide and oxygen gas mixture (70:30). Maintenance of anaesthesia 
was achieved using 0.8-1.0% halothane, administered via a face mask. The right femoral 
blood vessels were exposed by blunt dissection and polyethylene cannulae containing 
heparinised saline (5 IU/ml) were inserted 0.5cm into the right femoral artery and vein to 
allow the sampling of blood and the injection of [14C]2-deoxyglucose, respectively. The 
cannulae were secured in place using 4/0 silk thread and a small quantity of adhesive 
(superglue) was applied as a precautionary measure. By making a small cut through the skin 
at the nape of the neck, the cannulae were passed subcutaneously and externalised using a 
sterilised stainless steel guide cannula (International Market Supply, UK). Xylocaine® 
anaesthetic gel was applied liberally to the femoral incision site and the incision site sutured. 
The externalised cannulae were secured in place by sutures, and again a small quantity of 
adhesive was applied. The cannulae were trimmed to a shorter length, out of the reach of 
the animal, and plugged. The halothane anaesthesia was discontinued and the rats allowed 
to recover from the effects of the anaesthetic for a minimum of two hours before any further 
manipulation. Arterial blood pressure and rectal temperature were monitored continuously 
throughout the surgical procedure and heating lamps were used to maintain normal body 
temperature.
2.1.2 Cannulae preparation
Cannulae (Portex Ltd., UK) were prepared manually at least 24 hours before they 
were required for use in [14C]2-DG autoradiography experiments. A length (approximately 
2cm) of cannula with an external diameter 0.96mm, internal diameter 0.58mm, was inserted
69
(1mm) into a cannula (cut to approximately 20cm) with an external diameter 1.4mm, 
internal diameter 0.63mm. The join was then sealed with standard Araldite epoxy adhesive 
and allowed to air-dry.
2.1.3 The [14C]2-deoxyglucose procedure
Local cerebral glucose utilisation was measured in fully conscious, freely moving 
rats by means of the [14C]2-DG technique originally described by Sokoloff et al. (1977). 
The period of measurement of cerebral glucose utilisation was initiated by the 
administration of an intravenous pulse of 50pCi [14C]2-DG (specific activity 55.0 mCi/mol; 
Amersham Life Science) in 0.7ml saline, injected over 30 seconds. Timed arterial blood 
samples (approximately lOOpl) were drawn at fixed time points over the next 45 minutes. 
The blood samples were immediately centrifuged (Microfiige E; Beckman) and the arterial 
plasma aliquots assayed to determine the concentrations of 14C and glucose by means of 
liquid scintillation counting and semi-automated glucose oxidase enzyme assay (Glucose 
Analyser 2, Beckman), respectively. Forty-five minutes after the isotope administration, the 
rats were sacrificed with halothane and their brains were removed quickly and carefully. The 
brains were then frozen in isopentane at -42°C for 10 minutes, mounted onto swivel headed 
microtome chucks and embedded in Lipshaw matrix ready for processing for quantitative 
autoradiography.
2.1.4 Liquid scintillation analysis
In order to calculate the plasma integral required in the operational equation for the 
determination of rates of local cerebral glucose utilisation, the plasma history of [14C]2-DG 
over the experimental period of 45 minutes had to be measured. A plasma sample of 20pl 
from each of the blood samples obtained at each time point was pipetted into a scintillation
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vial containing 1ml distilled water. To each vial, 10ml scintillation fluid was added 
(Ecoscint, National Diagnostics) and shaken thoroughly. A vial containing 20pl of 14C- 
standard of known specific activity was also counted to act as an internal control. 
Radioactivity was counted in a refrigerated scintillation counter (Packard Tri-Carb, 
1900CA) and the mean disintegrations per minute (dpm) were calculated from triplicate 
counts of 4 minutes each.
2.1.5 Preparation of autoradiograms
Previously mounted brains were stored at -20°C for as short a period as possible 
(less than 2 days). The brains were cut serially into 20pm thick coronal cryostat sections at 
-22°C. Triplicate sections were collected according to the cutting schedule utilised (cutting 
schedules varied between studies depending on the regions of specific interest), mounted 
onto 20mm x 40mm glass coverslips and dried rapidly on a hotplate at 60°C. The coverslips 
were then glued onto thin card in sequence. Autoradiograms were generated by exposing 
the brain sections with medical X-ray film (Biomax™ MR film, Eastman Kodak Company) 
in light-tight cassettes for 3 days, together with a series of precalibrated [14C]-methyl 
methacrylate standards (range 44-1475nCi/g tissue equivalents). After 3 days, the films 
were developed (developer 5 minutes, stop bath 1 minute, fixer 10 minutes, followed by half 
an hour in running water).
2.1.6 Quantitative densitometric image analysis
Local rates of glucose utilisation were determined from the [14C]2-DG 
autoradiograms with quantitative densitometric analysis using a computer based 
densitometer (Micro Computer Imaging Device; MCID, Imaging Research Inc., Ontario, 
Canada). Densitometric measurements represent the amount of digital signal collected from
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the sample, in this case X-ray film, and are expressed initially as grey levels from 0 
(represents black) to 255 (represents white). The image analyser then converts the 
measured grey levels into optical density values ranging from 0 (white) to 2.4 (black). After 
raw data input and calibration to the 14C film standards (figure 2.1), which relates optical 
density to the known concentrations of radioactivity (nCi/g), the quantification of isotope 
concentrations and consequently local cerebral glucose use (pmol/1 OOg/minutes) were 
measured in discrete brain regions in each animal. Measurements were made by placing the 
autoradiographic sections under the camera (at the same magnification and light intensity as 
that used for the calibrations) and positioning a frame over each anatomical region of 
interest. The size of the measuring frame varied (1mm2- 9mm2), depending on the 
anatomical region (e.g. 1mm2 for small nuclei such as the locus coeruleus; 9mm2 for large 
anatomical regions such as the caudate nucleus). For each anatomical region of interest, the 
mean optical density was calculated from readings made in 3-6 sections per animal 
(maximum n=12). Anatomical structures in the rat brain were defined with reference to a 
stereotaxic atlas (Paxinos & Watson, 1986).
2.2 Hippocampal stereotaxic surgery
The study utilising stereotaxic surgery in this thesis was carried out in collaboration 
with the University of Edinburgh and Universite de Bordeaux I. I would like to thank 
Professor Richard Morris, Dr. Gemot Riedel and Dr. Jacques Micheau for performing the 
stereotaxic surgery described in this thesis.
2.2.1 Intrahippocampal stereotaxic placement of cannulae
The chronic implantation of cannulae and minipumps into the hippocampus was 
performed under general anaesthetic using standard stereotaxic techniques.
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IMale adult rats (Harlan Olac, Bicester, UK) were placed in a perspex chamber and 
anaesthetised with 5% halothane in a nitrous oxide and oxygen gas mixture (70:30). 
Anaesthetic was maintained by intraperitoneal (i.p.) injections of Avertin (tribromoethanol, 
10 ml/kg). The fur on the skull cap was shaved and the animal placed on a stereotaxic frame 
(Electromedical) with the head placed horizontally (tooth bar at -3.5mm). The skull and 
bregma were exposed by making a longitudinal midline incision in the scalp and the skin 
was moved out of the way with tweezers. Any connective tissue on the skull surface was 
removed with a scalpel. The co-ordinates of the cannulae placement were identified and 
marked in pencil on the skull surface, with respect to the bregma position. Two small burr 
holes were made through the skull with a drill at the respective locations. After perforating 
the dura with a syringe needle, previously prepared L-shaped 27 gauge-tipped stainless steel 
infusion cannulae connected to 7 day minipumps (ALZA 1007D, pumping rate of 0.5 pl/hr 
for 7 days) by flexible polyethylene tubing, were implanted bilaterally in the dorsal 
hippocampus at bregma co-ordinates of AP -4.5mm, L/R ±3.0mm, to a depth of -3.0mm 
below the dura. In order to keep the cannulae fixed in place, three additional burr holes 
were drilled above frontal and occipital regions into which small stainless steel screws were 
anchored. Dental cement was then applied to the skull, cannulae, and screws, to secure the 
whole apparatus. The minipumps were placed in a cavity below the skin of the neck. Finally, 
the skin flaps were folded back and sutured. To avoid infections, the wound was cleaned 
and a topical antibiotic (Aureomycin) was applied liberally over the wound. Animals were 
allowed to recover from the anaesthetic under heating lamps until consciousness was 
regained. Animals were then placed individually into cages lined with post-operative pads 
together with a small quantity of rat chow softened with water. The animals were returned 
to their normal housing conditions and examined regularly for the next 24 hours to check on
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their recovery. On subsequent days, animals were given replacement softened diet, and 
checked daily to monitor their recovery.
All surgical tools were cold sterilised in Novasapa while cannulae and screws were 
sterilised in ethanol (96%).
2.2.2 Avertin preparation
A concentrate of tribromoethanol was first prepared. In complete darkness, 62ml of 
tertiary-amyl-alcohol was added to lOOg of tribromoethanol crystals. This was mixed 
thoroughly and stored in a brown-tinted bottle in the dark as the concentrate is very 
sensitive to light. For a working preparation of the anaesthetic, 5ml of absolute alcohol was 
added to 62.5ml of 0.9% saline and mixed thoroughly. To this mixture, 1.25ml of the 
previously prepared concentrate was added and stirred overnight. The final anaesthetic 
solution should be clear in appearance and the concentrate should be thoroughly dissolved.
2.3 Focal cerebral ischaemia in the rat
The surgical procedure of MCA occlusion in the rat described in this thesis was 
performed by Dr. Marc Soriano.
2.3.1 Preparation of animals
All the experiments were carried out in adult male Fischer 344 rats (250-350g body 
weight) obtained from Harlan Olac, Bicester, UK. Animals were kept under 12-hour light- 
dark cycle and allowed free access to food and water.
Male adult rats were placed in a perspex chamber and anaesthetised initially with 5% 
halothane in a nitrous oxide and oxygen gas mixture (70:30). When the animal was deeply 
anaesthetised, i.e. loss of righting reflex, non-surgical tracheal intubation was performed.
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For this, a cork board was sandwiched upright between two lead bricks. A length of silk 
thread was knotted to form a loop and secured at the top of the cork board and suspended 
over the side of the board. The rat was then suspended onto the loop of silk thread by its 
top teeth to open the mouth and trachea. The tongue was gently held out of the way using 
forceps and the rat was intubated by introducing a 16G intubation tube into the trachea 
(Quik-Cath II; 51 mm L, Baxter; the stainless needle is blunted down to sit within the tube). 
Once in place, the needle was removed and rats were attached to a ventilator (Linton 
Instruments) and anaesthetic was maintained with 1.5% halothane. The femoral artery was 
cannulated with a polythene catheter for monitoring physiological variables. Blood pressure 
(Gould Instruments), blood gases (pC02 and p 0 2)and pH were monitored throughout the 
surgical procedure (288 Blood Gas System, Ciba-Corning), while glucose samples were 
taken immediately after cannulation, pre-occlusion and 10 minutes post-occlusion (Glucose 
Analyser-2, Beckman).
2.3.2 Middle cerebral artery occlusion
Left MCA occlusion was carried out according to the method of Tamura et al. 
(1981) with minor modifications. The animal was placed on its side and the left eye was 
closed with a suture. Following a vertical scalp incision between the eye and the ear (using 
the whisker closest to the ear as an anatomical landmark), the temporalis muscle was 
divided along the plane of its fibre bundles and retracted in order to expose the zygomatic 
arch, which was kept intact (figure 2.2). With the aid of an operating microscope, a 
subtemporal craniectomy was carried out using a dental drill. To ensure that overheating of 
the skull and brain did not occur, the craniectomy was kept cool with sterile saline solution. 
After exposure of the left MCA, the dura was cut and removed with micro-scissors. The 
MCA was electrocoagulated using diathermy immediately over the olfactory tract and the
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Figure 2.2 Middle cerebral artery exposure.
Sites of proximal (A) and distal (B) middle cerebral artery occlusion. 
(From McAuley, 1995)
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coagulation was extended proximally to the origin of the lenticulostriate arteries. The MCA 
was bisected with micro scissors to ensure the complete cessation of blood flow, and 
wounds were sutured with 4/0 silk thread. A subcutaneous (s.c.) injection of sterile saline 
(2ml) was given to prevent dehydration. Halothane anaesthesia was discontinued and the 
animal was then ventilated on pure oxygen until signs of consciousness were evident, and 
extubated. Throughout the surgical procedure, body temperature was monitored with a 
rectal probe and maintained at 37.5 °C with a heating blanket. Animals were placed in an 
incubator during initial recovery period and then returned to their normal housing 
conditions. Any animals which displayed adverse signs of suffering were withdrawn from 
the study and humanely killed.
2.3.3 Tissue processing
Twenty four hours following the MCA occlusion, the animals were sacrificed with 
5% halothane and the brains were carefully removed and frozen in isopentane at -42°C for 
10 minutes. The brains were cut into 20 pm thick serial coronal cryostat sections at -22°C 
at the 8 pre-selected coronal levels per animal, from anterior 10.5 mm to posterior 1.02 mm 
(Osborne et al., 1987). Triplicate sections were mounted onto microscope slides and stained 
with haematoxylin and eosin (H & E) (appendix 3) for histological lesion assessment. Figure
2.3 presents the 8 stereotaxic levels at which histopathological assessment is carried out.
2.3.4 Measurement of the volume of infarction
Ischaemic damage is most widely identified by quantitative histopathology. This 
method allows the distribution and area (and consequently the volume) of ischaemic damage 
to be assessed at 8 coronal levels throughout the MCA territory (Osborne et al., 1987).
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Figure 2.3 Stereotaxic levels for the histopathological assessment of ischaemic 
damage in the rat.
The minimum number o f  stereotaxic levels which must be assessed to yield accurate 
volumetric measurements o f  infarction is 8 (Osborne et al., 1987). The levels are 
represented here along with their respective anatomical landmarks.
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Areas of ischaemic damage and brain swelling were assessed using a computer based image 
analysis system (MCID, Imaging Research Inc.). As this system involves the counting of 
discrete pixels which make up the projected image in question, area measurements are 
obtained by counting the pixels enclosed within a target outline. Therefore, in order for data 
to be expressed in real spatial units, the pixels were referenced to a spatial reference scale. 
Calibrations were made using a cross-hair calibration graticule of 40mm. Both vertical and 
horizontal axes were calibrated, with distance displayed as a function of pixels/mm. Area 
measurements were made by placing the H & E stained coronal sections under the camera 
(at the same magnification as that used for the calibrations) and drawing round the 
boundary of the ischaemic area projected onto the monitor. The mean area was calculated 
from the triplicate sections at each coronal level. The approximate volumes of ischaemic 
damage for each animal were then attained by integrating each of the 8 areas of damage 
measured (mm2) with the known distance between the stereotaxic co-ordinates of these 
levels.
All analyses were carried out in a blinded fashion.
2.4 In vitro models of neurotoxicity
2.4.1 Primary cortical astrocyte culture
Dissection
The method for obtaining cultures of mixed glia from neonatal rat cerebral cortices 
is based on that of McCarthy & de Vellis (1980). Neonatal rat pups (day 0-3) were killed by 
decapitation, and the heads were kept moist with 70% ethanol. These were secured in place 
with straight watchmaker’s forceps, and the brains removed by cutting a ‘V’ into the skull, 
from a point at its base to the eyes, on both sides. The skull was removed to expose the 
dorsal surface of the brain. With a pair of curved watchmaker’s forceps, the brains were
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gently lifted out and placed into small petri dishes (Falcon) containing Ca2+-and Mg2+-free 
Hank's Balanced Salt Solution (HBSS-CFMF). The cerebellum was held in place with 
forceps and the cerebral cortices were detached from the body of the brain and transferred 
to fresh HBSS-CFMF. With the aid of a dissecting microscope, the hippocampus was 
removed by dissecting along the extension of the lateral ventricles. The caudate and septal 
nuclei were also removed to leave a cortical cup. The meninges were removed from the 
surface of the cortices. The cortices were placed into a sterile petri dish containing a fresh 
volume of HBSS-CMF.
Dissociation, plating and maintenance o f cells
The cortices were cut into small cubes (0.5mm3) with a scalpel and the fragments 
were placed into a 50ml centrifuge tube (Falcon). The tissue fragments were incubated with 
collagenase (2000 U/ml solution, diluted 1:3) and 0.25% trypsin (1:3 dilution) for 20 
minutes at 37°C. Following enzymatic digestion, soya bean trypsin inhibitor and DNase 
(SBTI-DNase; see appendix 2), were added to inactivate the trypsin and digest any free 
DNA. The fragments were first triturated gently through a 10ml serological pipette (lOx). 
Trituration was repeated carefully to avoid frothing using a 21G needle and a 23 G needle 
(4x). The cell suspension was centrifuged for 10 minutes at 1000 rpm (Universal 16/16R; 
Hettich). The supernatant was discarded, and the cells re-suspended in a known volume of 
culture medium (20% foetal calf serum in Dulbecco’s Modified Eagles Medium (20% FCS- 
DMEM), containing 2mM glutamine, 25pg/ml gentamicin) and counted using a 
haemocytometer. The cell solution was diluted 1:10 for counting, together with the addition 
of trypan blue (20%) to exclude the inclusion of non-viable cells. The cells were diluted to a 
final concentration of 1.5 x 106 cells/ml and plated into 75cm2 Primaria culture flasks 
(Falcon), 10ml per flask. Cultures were kept at 37°C in a humidified 5% CC>2/95% air
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incubator. After 3 days in culture, the medium was replaced with 10% FCS-DMEM. Cells 
were then subsequently fed twice a week with 5% FCS-DMEM. Once the cells reached 
confluence, they were purified using the shaking method of McCarthy & de Vellis (1980).
Purification o f specific cell types from mixed astroglial cultures
After approximately 12 days in culture, the confluent mixed cultures were used to 
prepare purified cultures of type 1 astrocytes via the shaking method (McCarthy & de 
Vellis, 1980). Mixed glial cultures consist of process-bearing cells (0-2A progenitors, 
oligodendroglia and type 2 astrocytes) growing on top of a confluent layer of type 1 
astroglia. The shaking process detaches the process-bearing cells from the bed layer to leave 
an enriched population of type 1 astrocytes. The procedure for generating primary cultures 
of 02-A progenitors, microglia, oligodendroglia, type 2 or type 1 astrocytes is provided in 
figure 2.4.
Prior to shaking, the caps of the culture flasks were tightened to retain the 5% 
C 02/95% air atmosphere and shaken on a bench top orbital shaker (Forma Scientific, Life 
Sciences International) at 260 rpm for 1V2 hours at 37°C. The medium was discarded and 
10ml fresh 5% FCS-DMEM was added to each flask. The flasks were then returned to the 
incubator for 1 hour to equilibrate C 02 with the fresh medium. The flasks were returned to 
the bench top orbital shaker following the incubation period, where they were shaken at 260 
rpm for 18 hours at 37°C. The medium from each flask was removed, the adherent cells 
were rinsed with unsupplemented DMEM, and the cells subcultured to a plating density of 3 
x 106 cells/ 75cm2 flask. The enriched type 1 astrocyte cultures were then returned to the 
incubator, and maintained by feeding with 5% FCS-DMEM twice a week. Cells were used 
in experiments at least 3 weeks after the initial plating.
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Day 0-12 Mixed brain cell culture from rat cerebral cortex
Day 12 Preshake (260 rpm, 1.5 hr), collect nonadherent cells
I________________
Shake (260 rpm, 18 hr) Incubate 37 C, 1 hI
Collect adherent cellsI
Microglia-enriched culture
Day 13 Adherent, flat cells Nonadherent, process-bearing cells
Contains 0-2A progenitor cells
5% FCS-DMEM
Type 1 astroglia-enriched 
culture
5% FCS-DMEM 
CMT Chemically defined diummec
Type 2 astroglia-enriched 
culture
Oligodendroglia-enriched
culture
Figure 2.4 Schematic representation of the protocol used to prepare type 1 and 
type 2 astroglia, oligodendroglia and microglia.
(Modified from Levison & McCarthy, 1991)
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2.4.2 Primary cortical neuronal cultures
Dissection
Neuronal cortical cultures were obtained from the method of Rose et al. (1993). 
Time-mated female rats (Bantin & Kingman, Hull, UK) were euthanased by CO2 followed 
by cervical dislocation. Embryos at day 16-18 of gestation (E l6-18) were released from 
their placentas into a large square petri dish (Sterilin) containing ice-cold HBSS-CFMF. The 
embryos were decapitated and the heads placed into fresh HBSS-CFMF medium on ice. For 
each head, a sterile 30mm upturned petri dish lid was used as a stand. Each head was placed 
gently onto the lid and placed under a dissecting microscope. The heads were anchored in 
place and the skin and developing bone were cut from the base of the head up, towards the 
dome and nose, in a straight line. Using straight and curved watchmaker’s forceps, the 
membranes were teased aside to expose the brain and the cortices were removed from the 
skull to leave the cerebellum behind. An arc of cortex was then removed from both 
hemispheres (parallel to midline) with a scalpel. As much of the meninges were removed as 
possible and the cortical tissue fragments were transferred to a universal containing ice cold 
dissecting medium (DMEM - 4500g/l glucose; 1% v/v nystatin).
Dissociation, plating and maintenance o f cells
Dissecting medium was added to the tissue fragments to give a volume of 9ml. To 
this, 1ml 2.5% trypsin was added and the mixture was incubated for 30 minutes at 37°C. 
The enzymatic digestion was stopped by replacing the medium with 9ml serum-containing 
medium together with 1ml DNase I (0.5mg/ml). The fragments were triturated gently with 
flamed glass Pasteur pipettes and the cell suspension was centrifuged at 1000 rpm for 8 
minutes at 15°C. The supernatant was discarded and the cells were re-suspended in 20ml 
culture medium (10% v/v non dialysed heat inactivated FCS, ImM glutamine, 1% v/v
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gentamicin and 1% v/v nystatin in Neurobasal medium) and counted using a 
haemocytometer. Cells were cultured at a final plating density of 6 x 105 cells/ml onto 24 
well plates (0.5ml/well) previously treated with poly-D-lysine (5pg/ml prepared in sterile 
distilled water). 1ml was added to each well for at least 1 hour. The poly-D-lysine was 
aspirated and the plates used directly. Cultures were kept at 37°C in a humidified 5% 
CC>2/95% air atmosphere. After two days in culture, non-neuronal division was halted by 
exposure to 5pM cytosine arabinoside in serum-free medium containing B27 supplement. 
Subsequent to this, half the culture medium was replaced at 3-5 day intervals and the 
cultures were maintained for 10-14 days prior to use in experiments.
2.4.3 Induction of hypoxia and glucose deprivation
After the appropriate time in culture in 24 well plates, cells were deprived of glucose 
and oxygen to produce an in vitro model of hypoxia and glucose utilisation. Glucose free 
PBS Dulbecco's Balanced Salt solution (PBS-DBSS) containing 1% v/v HEPES was 
sonicated for approximately 10 minutes to remove the majority of dissolved oxygen in the 
medium. This was followed by gassing the balanced salt solution with N2 gas for at least an 
hour. The existing cell culture medium was aspirated and the medium was replaced with 
495pi of the N2-gassed PBS Dulbecco's balanced salt solution. The plates were replaced 
into a 5% 0 2/5% CO2/90% N2 hypoxic incubator for the required length of time. Following 
the oxygen and glucose deprivation, the media were replaced with 495pi serum free 
Neurobasal medium (no extra glucose added) and the plates incubated in a 5% CO2/90% air 
atmosphere. The media were removed for assay of LDH levels 24 hours after the initial 
insult.
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For neuroprotection studies, 5 pi of 100X concentration of ligand was added to the 
appropriate cultures for the duration of the oxygen and glucose deprivation and again for 
the following incubation in glucose-supplemented and normoxic conditions.
2.4.4 Induction of staurosporine induced neurotoxicity
After the appropriate time in culture in 24 well plates, the existing culture medium 
was aspirated and replaced with 490ul Neurobasal medium (serum and glucose free with 
1% HEPES, 1% glutamine and lOuM glycine). 5pi of lpM  staurosporine (in DMSO) was 
added to the appropriate wells. The plates were replaced into the incubator for 48 hours and 
the supernatants were removed for the assessment of neuronal injury. For neuroprotection 
studies, 5 pi of the 100X concentration of agonist was added to the wells 15 minutes prior 
to the addition of staurosporine.
2.5 Immunohistochemistry
In this section, the immunohistochemical techniques used in this thesis will be 
described. Due to the different requirements of the studies undertaken, the staining 
techniques employed for in vivo and in vitro material are dealt separately.
2.5.1 In vivo material
Immunostaining was carried out using the standard method used in our laboratory, 
the avidin-biotin method (figure 2.5). Avidin has a high affinity for biotin, and this technique 
exploits this highly efficacious and specific reaction. Biotin molecules are conjugated to 
antibodies, which are then bound to a complex comprising of avidin and a biotinylated 
enzyme to produce an amplified signal at the antigen binding site. Immunostaining for the
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detection of DNA fragmentation was carried out using a commercially available kit with 
separate instructions for use. This procedure is also described.
All immunohistochemistry was carried out in 4% paraformaldehyde fixed, paraffin- 
embedded tissue. Sections were first de-waxed thoroughly in histoclear for 10 minutes. The 
process of rehydration of the sections of tissue was initiated by immersion into absolute 
alcohol for 10 minutes. This was repeated with fresh absolute alcohol for another 5 minutes. 
Endogenous peroxidase within the tissue was removed by incubating the tissue in 3% 
hydrogen peroxide in methanol for 30 minutes. The slides were then washed in water for 10 
minutes, followed by a rinse in 50mM phosphate buffered saline (PBS). If necessary, the 
slides were treated with a proteolytic enzyme (0.4% pepsin in 0.01M HC1), or detergent 
(0.2% Triton-X in PBS) depending on the antigen to be demonstrated. Any excess PBS was 
blotted carefully from around the sections and the slides were placed individually into a 
humidity chamber. Using a hydrophobic marker pen, an outline was drawn around each 
section on the slide to limit the volume of solutions to be applied. Each section of tissue was 
incubated with 300pl blocker containing normal serum from the animal species used to 
prepare the secondary antibody (5% bovine serum albumin (BSA), 10% normal serum in 
PBS) for 1 hour at room temperature. The excess blocker was removed and the sections 
were covered with optimally diluted primary antibody. Antibodies were diluted in 0.1% 
BSA and 1.5% normal serum in PBS. The sections were incubated with the primary 
antibody overnight at 4°C. Following overnight incubation, the antibody solution was 
removed and the sections washed thoroughly in PBS for 2 x 5 minutes. Each section was 
incubated with 300pl of the appropriate secondary antibody (directed against the 
immunoglobulin from the species used to prepare the primary antibody), diluted 1:100 in 
PBS for 1 hour at room temperature. During this incubation, the avidin-biotin horseradish
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Figure 2.5 The avidin-biotin complex immunolabelling method.
(Adapted from Jackson & Blythe, 1993)
peroxidase complex (ABC complex) was prepared (1 drop solution A and B in 4.9ml PBS; 
Vector), mixed and allowed to stand for 1 hour. The sections were washed in PBS for 2 x 5 
minutes and then incubated with the ABC complex for 1 hour. The sections were then 
washed with PBS for 2 x 5 minutes and the peroxidase reaction was developed using the 
chromogen diaminobenzidene (DAB) to produce a brown coloured end product (2 drops 
buffer, 2 drops H20 2 and 4 drops DAB; Vector). The reaction was stopped after a 
maximum incubation time of 5 minutes (inter-study development times variable) with PBS. 
The sections were washed with PBS (2 x 5 minutes) followed by water ( 2 x 5  minutes). The 
sections were then counterstained with H & E (see appendix 3 for protocol), dehydrated
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through alcohol (70%, 90% and 100%), cleared with histoclear and mounted in synthetic 
mounting medium, DPX.
Negative controls were generated following the described method, but omitting the 
primary antibody incubation (figure 2 .6).
Fragment end labelling o f DNA using terminal deoxynucleotidyl transferase (TdT)
Staining for DNA fragmentation was carried out using the commercially available kit 
obtainable from Oncogene Research Products, Calbiochem (TdT-FragEL™). In principle, 
TdT binds to exposed 3’-OH ends of DNA fragments and catalyses the addition of biotin- 
labelled and unlabelled deoxynucleotides. Biotinylated nucleotides are detected using a 
streptavidin-horseradish peroxidase conjugate. The chromogen DAB reacts with the 
labelled sample to generate an insoluble brown substrate at the site of DNA fragmentation. 
The sections are subsequently counterstained with methyl green.
Sections were first de-waxed in a similar fashion to the method described for the in 
vivo material. Slides were immersed in histoclear for 5 minutes followed by immersion into 
absolute alcohol for 5 minutes. This was repeated using fresh absolute alcohol for another 5 
minutes. Sections were then rehydrated by immersing consecutively into 90%, 80% and 
70% ethanol for 3 minutes each. The slides were then rinsed briefly with IX TBS (20mM 
Tris pH 7.6, 140mM NaCl). To limit the volumes applied to the slides, each section was 
encircled using a hydrophobic slide marker and placed in a humidity chamber. Sections were 
permeabilised by incubation with 20 pg/ml proteinase K, 100 pl/section for 20 minutes (1 pi 
of 2 mg/ml Proteinase K in lOmM Tris pH 8, added to 99 pi lOmM Tris per section). It is 
important at this step not to overincubate. Slides were rinsed with IX TBS and any excess 
buffer was blotted and the slides carefully dried around each section. Endogenous 
peroxidase was inactivated by incubating the tissue in 3% hydrogen peroxide in methanol
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Figure 2.6 Iminunohistochemistry; generation of negative controls.
Representative example of methodological negative control (arrow). This demonstrates 
the methodological non-specificity of the immunolabelling technique employed. 
Negative controls were generated using the method describes in section 2.5.1, but 
omitting the primary antibody incubation step.
for 5 minutes. The slides were rinsed again in TBS and dried carefully.
Equilibration and labelling of TdT was carried out by incubating each section with 
100 pi of IX TdT equilibration buffer for 30 minutes (dilution of 5X TdT equilibration 
buffer - 1M sodium cacodylate, 0.15 M Tris, 1.5 mg/ml BSA, 3.75mM C0CI2, pH 6.6 - 
with distilled water). During this incubation, the TdT labelling reaction mixture was 
prepared on ice by mixing 57 pi of TdT labelling reaction mixture (mixture of labelled and 
unlabelled deoxynucleotides at an optimal ratio) with 3 pi of TdT enzyme for each section. 
The equilibration buffer was blotted carefully and the labelling reaction mixture was applied 
immediately to each section and incubated at 37°C for 1.5 hours. Following the incubation, 
the slides were rinsed with TBS. The labelling reaction was terminated by incubating the 
slides with 0.5 M EDTA, pH 8 for 5 minutes. The slides were rinsed with TBS and excess 
buffer blotted carefully. Sections were blocked by incubating with 4% BSA in PBS for 10 
minutes. This was carefully blotted and IX streptavidin peroxidase conjugate (prepared in 
4% BSA/PBS) was immediately applied to each section. The sections were incubated at 
room temperature for 30 minutes. DAB solution was freshly prepared 5 minutes before the 
end of the incubation (1 DAB tablet, 1 H202/urea tablet in 1 ml of tap water). Following 
incubation with the conjugate, slides were rinsed with TBS and each section was incubated 
with the DAB for 10-15 minutes. The slides were rinsed with distilled water and 
counterstained with 0.3% methyl green for 3 minutes. The counterstain was removed and 
the slides were dipped 2-4 times into absolute ethanol. Slides were blotted briefly and the 
slides were dipped again into fresh absolute alcohol. The slides were blotted again and then 
dipped 2-4 times into histoclear. Excess histoclear was wiped away and the slides were 
mounted in DPX and left to dry for 24 hours.
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2.5.2 In vitro material
For the visualisation of cultured cells, immunofluorescent techniques were 
employed, where the labelled antibody is visualised directly from its emitted fluorescence. 
The method described was used for the simultaneous identification of two antigens. The 
cells were grown on poly-l-lysine coated glass coverslips (5pg/ml prepared in sterile 
distilled water, 1 hour incubation) in 4 well plates (Nunc, GibcoBRL) for at least three 
weeks as detailed in section 2.4.1. The cells were rinsed with PBS and fixed with 4% 
paraformaldehyde containing 4% sucrose for 20 minutes followed by a 10 minutes 
incubation with -20°C methanol (see appendix 2). Following fixation, the cells were rinsed 
with PBS, 2 x 1 minutes. Coverslips were then returned to PBS. Each coverslip was 
incubated with 300pl blocker containing normal serum from the animal species used to 
prepare the secondary antibodies (2% BSA, 10% normal goat serum and 5% normal horse 
serum in PBS) for 1 hour at room temperature. The blocker was removed with a disposable 
pasteur pipette and the sections were covered with the two optimally diluted primary 
antibodies (the concentrations used are outlined in individual studies). Antibodies were 
diluted in 1% BSA and 1.5% normal serum in PBS. The coverslips were incubated with the 
two primary antibodies overnight at 4°C. Following the overnight incubation, the coverslips 
were rinsed thoroughly in PBS for 3 x 5 minutes. The cultures were incubated with 
fluorochrome-conjugated antibodies directed against the immunoglobulins from the species 
used to prepare the primary antibodies for 1 hour in the dark at room temperature. 
Fluorochromes used in this thesis were fluorescein and texas red (Vector; 1:100), which can 
be visualised by their green and red fluorescence, respectively. The coverslips were rinsed 
again in PBS for 3 x 5 minutes and mounted onto slides using a polyvinyl alcohol-based 
mountant containing an anti-bleaching agent (protocol in appendix 2). All slides were stored
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in the dark at 4°C and viewed under the microscope within a week of staining to avoid loss 
of fluorescence.
2.6 Assessment of neuronal damage
2.6.1 Lactate dehydrogenase efflux assay for cell damage and death
Two separate protocols for the assessment of lactate dehydrogenase (LDH) efflux 
were used in this thesis as a proportion of the LDH assays were carried out at Lilly 
Research Centre, Eli Lilly and Company. Both methods are described.
Cytotoxicity detection kit
The Cytotoxicity Detection Kit (Boehringer Mannheim) is a sensitive colourimetric 
assay for the quantification of cell death based on the measurement of LDH activity released 
from the cytosol of damaged cells into the supernatant. LDH activity is determined by an 
enzymatic test: In the first step NAD+ is reduced to NADH and FT by the LDH catalysed 
conversion of lactate to pyruvate. In the second step, the catalyst (diaphorase) transfers 
H/H+ from NADH and H+ to the tetrazolium salt INT (2-[4-iodophenyl]-3-[4-nitrophenyl]~ 
5-phenyltetrazolium chloride) which is reduced to formazan (figure 2.7). This colour 
reaction is then measured spectrophotometrically. An increase in the amount of dead or 
damaged cells results in an increase of LDH activity in the culture supernatant. This increase 
in the amount of enzyme activity directly correlates to the amount of formazan formed. 
Thus, the amount of colour formed in the assay is proportional to the number of lysed cells.
Following the harvesting of supernatants for the assessment of LDH efflux, lOOpl of 
supernatant was transferred, in duplicate, into clear 96 well flat bottomed microtitre plates 
(Falcon). The reaction mixture was prepared immediately prior to use; 11.25ml of the dye
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Figure 2.7 Diagrammatic representation of the enzymatic reaction used in the
solution was added to 250pl of the catalyst solution mixed. lOOpl of the reaction mixture 
was then added to each of the wells and the plates were incubated in the dark for 15 
minutes. Absorbance of the samples were measured at 490 nm using an ELISA plate reader, 
with a reference wavelength of 650 nm.
Lactate dehydrogenase kit
This procedure for determining LDH efflux (Sigma Diagnostics) is based on the 
spectrophotometric method of Wroblewski and LaDue (1955). The activity of LDH is 
measured by monitoring the rate at which the substrate pyruvate is reduced to lactate. The 
reduction is coupled with the oxidation of NADH which is followed spectrophotometrically 
in terms of the rate of decrease in absorbance at 340 nm (figure 2.8).
Following the harvesting of supernatants from astrocytes cultured in 75cm2 flasks, 
the volume of supernatant was concentrated from 10ml to approximately 0.5-lml using 
Centriplus™ concentrators (Centriplus-3, Amicon). Supernatants were centrifuged at 3000g
Cytotoxicity Detection Kit.
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for 6V4 hours at 4°C, and the retentate supernatant was recovered by an inverted spin at
2000g for 4 minutes at 4°C. The concentrated volumes of supernatant were used for the
assessment of LDH efflux. Firstly, the temperature controlled cuvet compartment of the 
spectrophotometer was set at a known temperature between 20° and 39°C. In triplicate, 
2.85ml phosphate buffer and 50pl of the supernatant sample were added to a NADH vial 
and mixed. This was left to incubate in a water bath at 25°C for 20 minutes. The solution 
was brought to the temperature of the cuvet compartment and 0 .1ml sodium pyruvate 
solution was added to the vial and mixed. The contents of the vial were then transferred to a 
cuvet of 1cm lightpath. The absorbance at 340nm was read and recorded at 30 second 
intervals for 3 minutes, versus water as reference. The period when the decrease in 
absorbance produced was linear with time was selected, and the AA per minute for this 
period was determined. LDH activity was then calculated from:
LDH (units/ml) = AA per minutes x TCF
0.001 x 0.05 x lightpath (cm) 
where 0.001 = A A equivalent to 1 unit of LDH activity in a 3 ml volume with 1cm lightpath 
at 25°C
0.05 = sample volume in cuvet (ml)
TCF = temperature correction factor (Table 2.1; 1.0 at 25°C)
Therefore, if a lightpath of 1cm is used, the following equation is derived:
LDH (units/ml) = A A per minutes x 20,000 x TCF 
One unit of LDH activity is defined as the decrease in A340 by 0.001 per minute at 25°C in a 
3ml reaction mixture in a cuvet of 1cm lightpath.
Pyruvate +  N A D H  ^ ^  Lactate +  N A D  
(h igh  A 340) (lo w  A 340)
Figure 2.8 LDH assay of Wroblewski and LaDue (1955): Enzymatic reaction.
Table 2.1 Temperature Correction Factors for calculating LDH activity.
Cuvet temperature 
(°C)
TCF Cuvet temperature 
(°C)
TCF
20 1.45 30 0.73
21 1.37 31 0.69
22 1.25 32 0.65
23 1.16 33 0.62
24 1.06 34 0.58
25 1.00 35 0.55
26 0.93 36 0.53
27 0.88 37 0.51
28 0.82 38 0.48
29 0.78 39 0.46
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2.6.2 Measurement of DNA fragmentation
DNA fragmentation was quantified using a nucleosome ELISA immunoassay kit for 
measurement of mono- and oligo-nucieosome formation in cell extracts (Calbiochem). Free 
mono- and oligo-nucleosomes are captured on pre-coated DNA binding proteins. They are 
then detected following the binding of a biotin-labelled antibody (Anti-histone 3) to the 
histone component of the nucleosomes and streptavidin-linked horseradish peroxidase 
conjugate. The resultant colour reaction produced in the assay is proportional to the number 
of nucleosomes in the sample. The Nucleosome ELISA kit includes all the necessary 
reagents required for carrying out the procedure.
Following induction of in vitro neurotoxicity, samples were prepared for the 
Nucleosome assay. The culture media from the cells cultured in 24 well plates were 
carefully removed and each well replaced with 1ml of lysis buffer containing 0.2mM 
phenylmethylsulphonyl fluoride (PMSF). The cells were vortexed and incubated for 30 
minutes on ice. The plates were then centrifuged at 3000 rpm for 30 minutes at 4°C and 
frozen for at least 18 hours at -20°C before proceeding any further in the assay. Samples 
were thawed and components of the Nucleosome ELISA were brought to room 
temperature. In order to measure the free nucleosomes in unknown sample supernatants, a 
standard curve of known nucleosome concentration was prepared. The Nucleosome 
Standard was prepared to a concentration of 30 nucleosome units per ml (30 U/ml) with 
distilled water and lysis buffer. The standard was further diluted with lysis buffer to 
concentrations of 10, 3.3, 1.1 and 0.366 U/ml by making three-fold serial dilutions. Lysis 
buffer was used as a background control (0 U/ml).
All samples were diluted in lysis buffer containing PMSF (1:10). Samples and 
standards were then added to the microtitre plate, 100pl into each well in duplicate. The 
plate was covered with a plate sealer and incubated at room temperature for 3 hours.
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Following this incubation time, the wells were washed thoroughly 3 times with IX wash 
buffer (25ml of 20X wash buffer to 475ml distilled water). Any residual buffer was removed 
by tapping onto a paper towel after each wash. lOOpl of the detector antibody, biotinylated 
polyclonal anti-histone 3 antibody, was added into each well. Again the plate was covered 
with a plate sealer, and the plate was incubated at room temperature for 1 hour. The wells 
were washed three times with IX wash buffer as before. Each well was incubated with 
lOOpl of IX streptavidin conjugate (400X streptavidin horseradish peroxidase conjugate 
diluted 1:400, mixed and filtered with a 0.2pm syringe), the plate covered with a plate 
sealer, followed by incubation at room temperature for 30 minutes. The wells were washed 
twice with IX wash buffer as before, then the whole plate was flooded with distilled water, 
the contents removed, and any residual water tapped off the plate onto paper towel. The 
chromogenic substrate solution was added, lOOpl to each well in the plate and incubated in 
the dark for 30 minutes at room temperature. Following substrate incubation, lOOpl of stop 
solution ( 2.5M sulphuric acid) was added to each well, in the same order as the previously 
added substrate solution. Finally, the plate was read on a spectrophotometric plate reader at 
dual wavelengths of 450/595 nm. The average absorbance value was obtained from the 
duplicate standard and sample readings. A standard curve was constructed (figure 2.9) by 
plotting absorbance for each standard versus concentration of each standard (U/ml), and the 
nucleosome concentration of each sample was determined by interpolation from the 
standard curve.
2.7 Western blot analysis
Western blot analysis was carried out in astrocytes cultured in 75cm2 flasks. Cells 
were treated according to the study being carried out, and the supernatants collected into 
Centriplus™ concentrators (Centriplus-3) for concentration into a smaller volume without
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Figure 2.9 Representative standard curve for the measurement of nucleosomes in 
unknown samples.
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losing any protein. To the supernatants, 1% FCS was added to keep any proteins stable. 
The supernatants were centrifuged at 3000g for 6V4 hours at 4°C and the retentates 
recovered by an inverted spin of 2000g for 4 minutes at 4°C. The flasks containing the cells 
were rinsed in sterile PBS and treated with 1ml lysis buffer/flask (see appendix 2) containing 
0.2mM PMSF (prepared in ethanol). Flasks and concentrated-supernatants were then frozen 
at -70°C until required for protein determination. Before the determination of protein, the 
samples were removed and thawed at room temperature. The astrocytes were removed 
from the flasks into eppendorf tubes using a cell scraper, while the supernatants were 
similarly transferred to eppendorfs. The cell samples and supernatants were then 
homogenised using a hand-held homogeniser (Anachem) and placed on ice.
2.7.1 Protein determination of unknown samples
In order to measure the protein concentration from unknown samples, a standard 
curve using Bovine Serum Albumin (BSA) of known concentration was prepared. The Bio- 
Rad protein assay was used to determine protein concentration.
BSA was prepared at 1 mg/ml in lysis buffer and a standard curve was prepared in 
duplicate (table 2.2). A representative standard curve is shown in figure 2.10.
Table 2.2 Standard curve for protein determination
PROTEIN CONCENTRATION 
(pg/ml)
BSA VOLUME (pi) WATER VOLUME (pi)
0 0 800
1 1 799
2 2 798
5 5 795
10 10 790
15 15 785
20 20 780
25 25 775
100
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Figure 2.10 Representative standard curve for the measurement of protein in 
unknown samples
The unknown samples were diluted 1:10, and 1 Ojul of each of the diluted samples was added 
to 790pl of water in duplicate. 200pl of the Bio-Rad protein assay solution was then added 
to all the tubes and mixed. Spectrophotometric absorbance readings were made at 595nm 
and a standard curve of absorbance versus protein concentration (pg/ml) was produced. 
From the mean absorbance of the unknown samples, the protein concentrations were 
determined from the standard curve.
2.7.2 SDS-PAGE electrophoresis
Gel plates and spacers were cleaned in water followed by ethanol and assembled in 
the gel setter, ensuring that there were no leaks. An 8% resolving gel was prepared using
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Prosieve-50 (appendix 2) to allow the detection of high and low molecular weight proteins. 
Polymerisation was initiated with 10% ammonium persulphate (APS) and 10% TEMED. 
The gel was poured between the gel plates quickly and carefully, and a layer of distilled 
water was added to the surface of the gel to prevent it from drying out. The gel was 
allowed to polymerise for at least 1 hour at room temperature. Once set, the water was 
removed, and any excess was blotted. A 5% stacking gel (appendix 2) was prepared and 
poured onto the resolving gel, the comb inserted and left to polymerise for a further hour, 
after which the comb was removed and the wells rinsed with running buffer (72g glycine, 
15g Tris, 50ml 10% SDS prepared to a volume of 51 with distilled water). The gels were 
loaded into a vertical electrophoresis unit and the reservoirs filled 3/4 full with running 
buffer. Prior to loading, the protein samples were denatured by boiling with 2X sample 
buffer (appendix 2), 1:1, for 5 minutes. Each sample was then loaded into the gel at a 
protein concentration of 25pg/ml together with Bio-Rad prestained broad-range protein 
standards, 20p.l/lane, using a Hamilton syringe. A note was made of the sample loading to 
aid gel identification later. The gel was then run overnight in cooled running buffer at a 
constant current of 11mA.
2.7.3 Western blotting
Following the gel run, the protein was transferred from the gel to polyvinyl 
difluoride (PVDF) membrane using the method of wet transfer. The top gel plate was 
removed, the stacker gel cut away with a scalpel, and the resolving gel was soaked in 
transfer buffer (72g glycine, 15g Tris, 11 methanol prepared to a final volume of 51) for 15- 
20 minutes. A comer of the gel was cut away to aid orientation. Blotting paper, two sheets 
per membrane, were cut to the same size as the sponges used in the transfer tank. PVDF 
membranes were cut to the same size as the gel (12 x 13 cm). While the gels were soaking
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in transfer buffer, the blotting paper and sponges were thoroughly soaked in transfer buffer, 
while the PVDF membranes soaked in methanol for a few seconds. The membranes were 
then transferred to distilled water to remove the methanol for 1-2 minutes, followed by 
soaking in transfer buffer. For wet transfer of the proteins, a sponge was placed on top of 
the outer mesh. A sheet of blotting paper was laid on top followed by the gel. The PVDF 
membrane was carefully placed on top followed by the second sheet of blotting paper. At 
this stage, any air bubbles that may have formed between the gel and the membrane were 
rolled out carefully. Another sponge was placed on top of the blotting paper and the whole 
apparatus was held in place by attaching the second mesh. The transfer set-up was placed 
into the transfer tank so that the membrane faced the anode, and the proteins were 
transferred for 3 hours at 80V. Following successful transfer of proteins onto the 
membrane, the PVDF membrane was rinsed thoroughly in 0.2% Tween 20-Tris buffered 
saline (T-TBS), pH 7.5 (appendix 2). To block non-specific sites, membranes were 
incubated with 5% Marvel in T-TBS for 1 hour at room temperature. Membranes were 
washed thoroughly in T-TBS, 3 x 10 minutes. Optimised concentrations of primary 
antibodies were prepared in T-TBS and incubated with the membranes overnight at 4°C. 
The primary antibodies were poured off and the membranes were washed in T-TBS for 3 x 
10 minutes. Horseradish peroxidase conjugated secondary antibodies directed against the 
immunoglobulins from the species used to prepare the primary antibodies were prepared in 
3% Marvel/TBS-T, at the required concentration, and incubated with membranes for 1 hour 
at room temperature. The blots were washed with T-TBS thoroughly for 3 x 10 minutes. 
Visualisation of the protein bands was carried out using the enhanced chemiluminescence 
(ECL) method. While the membranes were washing, the ECL reagent was prepared in a 1:1 
solution to obtain a final volume of 0.125ml/cm2 membrane. The membranes were blotted 
of any excess T-TBS and placed onto SaranWrap, proteins facing upwards. Membranes
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were incubated with the ECL reagent for 1 minute precisely. Working quickly, membranes 
were carefully blotted vertically onto a sheet of blotting paper to remove any excess ECL 
reagent. The membranes were then placed protein side down onto SaranWrap (pre-cut). 
The SaranWrap was closed, avoiding any pressure on the membrane, to form an envelope. 
The membranes were placed into film cassettes protein side up, and in the dark, a sheet of 
autoradiography film (Fujifilm) was placed on top of each membrane. The cassette was 
closed and the membrane exposed to the film for 15 seconds initially. The films were 
immediately developed to assess the optimal exposure time required.
Following ECL detection, the same membranes were reprobed with a variety of 
antibodies. The membranes were first stripped of the bound antibodies by submerging the 
membrane in stripping buffer (lOOmM 2-mercaptoethanol, 2% sodium dodecyl sulphate, 
62.5mM Tris-HCl, pH 6.7) and incubated at 50°C for 30 minutes with occasional agitation. 
The membranes were washed in TBS-T, 2 x 1 0  minutes and then blocked in 5% Marvel in 
TBS-T for 1 hour at room temperature. Immunodetection could then be carried out again 
as described above.
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CHAPTER 3
MAPPING BRAIN FUNCTION WITH GROUP II SELECTIVE 
METABOTROPIC GLUTAMATE RECEPTOR AGONISTS
3.1 Introduction
Existing ligands for mGluR2 and mGluR3 have been useful for investigating the 
properties of these receptors in vitro, but their utility as pharmacological tools in vivo has 
been limited for a number of reasons. Previous studies have shown that some so-called 
'selective' mGluR ligands can also activate other classes of glutamate receptors. For 
example, the most widely used mGluR 2/3 agonist to date (2S, l'R, 2'R, 3'R)-2-(2', 3'- 
dicarboxycyclopropyl) glycine, DCG-IV, is also a relatively potent NMDA receptor agonist 
(Wilsch et al., 1994). In addition, none of the existing compounds for mGluR2 or mGluR3 
have demonstrated potent central effects after systemic administration.
The two recently developed mGluR agonists, (lSR,2SR,5RS,6SR)-2- 
aminobicyclo[3.1.0]hexane-2,6-dicarboxylate, LY354740 (Monn et al., 1997) and a 
heterobicyclic amino acid related to this molecule, (lR,4R,5S,6R)-2-oxa-4- 
aminobicyclo[3.1.0]hexane-4,6-dicarboxylate, LY379268 (Monn et al., in press) are novel, 
potent agonists selective for Group II mGluRs. They are the first mGluR2/3 selective 
agonists to be effective when administered systemically (Monn et al., 1996; in press; Bond 
et al., 1997; Schoepp et al., 1997) and their pharmacology are discussed in chapter 8, 
section 8.1. However, the precise action of these ligands centrally is poorly defined. Insight 
into the functional events within individual brain regions is possible by measuring the rates 
of local cerebral glucose utilisation using the [l4C]2-deoxyglucose autoradiographic 
technique (Sokoloff et al., 1977). For the purpose of the present study, the [14C]2-DG 
autoradiographic technique was employed to determine the functional events in the brain 
following the systemic administration of LY3 54740 or LY3 79268.
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3.2 Methods
3.2.1 Animal preparation and [14C]2-deoxyglucose measurement
Forty-three male Sprague-Dawley rats weighing between 300-400g (Harlan Olac, 
Bicester, UK) were used for this study. All animals were allowed to acclimatise to their 
surroundings for at least 5 days before surgery. Rats were housed under natural daylight 
conditions, and food and water were provided ad libitum. On the day of the experiment, the 
animals were anaesthetised and cannulated (section 2.1.1). Following recovery from the 
anaesthetic, rats were placed into individual boxes and body temperature was kept 
normothermic with heating lamps. The [14C]2-DG procedure was then carried out as 
detailed in section 2.1.4.
3.2.2 Drug administration and physiological monitoring
The compounds LY354740 (0.3, 3.0, 30.0mg/kg) and LY379268 (0.1, 1.0, 
lO.Omg/kg) were dissolved in 0.7ml saline (0.9%). An intravenous bolus injection of either 
agent was administered via the femoral vein catheter, 10 minutes prior to the injection of 
[14C]2-DG. Control animals (n = 11) received vehicle (0.9% saline).
Any physiological effects of the agonists were also measured. Mean arterial blood 
pressure was monitored (Gould Instruments) for at least 20 minutes before the pulse of 
[14C]2-DG was administered and then subsequently discontinued. Rectal temperature was 
monitored throughout the experiment. Arterial blood samples were also taken 10 minutes 
before, and 5 and 45 minutes after, drug administration for analysis of pC02, p 0 2 and pH 
levels (n = 40).
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3.2.3 Data analysis
Local rates of glucose utilisation were determined in 43 separate brain regions using 
quantitative densitometric analysis. As the consequences of the systemic administration of 
mGluR agonists on brain function were unknown, brain regions were chosen from the 
rostral to the caudal extent of the brain for analysis. All the data were analysed initially by 
ANOVA to identify brain regions associated with significant alterations in glucose use, 
followed by two-tailed Student's unpaired /-test. A Bonferroni correction factor of 3 was 
applied to the probability values to take into account the comparisons between each control 
and drug treatment groups. Each drug was compared with contemporaneous, randomised 
vehicle treated control animals.
The extent of responsiveness of each of the 43 regions measured to LY3 54740 (0.3, 
3.0, 30mg/kg) and LY379268 (0.1, 1.0, lOmg/kg) was assessed by applying an arithmetic 
function (/). This arithmetic function incorporates all the dose response data available for 
each of the brain regions and enables a ‘rank order of responsiveness’ for each region to be 
obtained. The/ value is derived from:-
/= S ( x c -x Ti)2
where xc is the mean of loge(glucose use) for the control group members, and xn is the 
mean of loge(glucose use) for the Ith dose of the treatment group, T. The reliability of this 
method of data handling has previously been described (Ford et al., 1985). A frequency 
distribution of responsiveness was generated for LY354740 and LY379268.
3.3 Results
3.3.1 Physiological parameters
The intravenous administration of LY354740 (0.3, 3.0, 30mg/kg) and LY379268 
(0.1, 1.0, lOmg/kg) produced no detectable changes in mean arterial blood pressure or
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blood gas levels. However, both compounds induced a small increase in rectal temperature 
45 minutes after the administration of the agonists (tables 3.1-3.2).
Prior to drug administration, all the rats exhibited signs of inquisitive behaviour, 
with intermittent periods of movement and grooming. They all responded to auditory, 
visual, and tactile stimulation. Following the administration of LY3 54740 and LY379268, 
marked changes in the gross behaviour between the two different treatment groups o f  the 
rats were noted. No major overt changes in behaviour of LY354740 treated animals were 
observed, although they appeared less active than the vehicle treated controls. In contrast, 
animals treated with LY379268 (lOmg/kg) appeared especially hypersensitive to auditory 
stimuli. Following the administration of the drug, the rats would appear less active with 
little body movement. However, noises would trigger a noticeable startle response which 
remained for the duration of the experiment. Plasma glucose levels were significantly 
increased 45 minutes after LY3 79268 (10 mg/kg) compared with control levels. Similar 
changes in glucose levels were not detected following LY3 54740 administration.
3.3.2 LY354740 and local cerebral glucose utilisation
The function-related glucose utilisation values associated with LY3 5474(0 are 
presented in tables 3.3-3.7. LY354740 (0.3, 3.0, 30mg/kg) produced anatomically 
widespread changes in glucose utilisation in a dose-dependent manner throughout the CNS. 
Only one region, the superficial layer of the superior colliculus, displayed significant 
increases in glucose use with LY3 54740, while 18 regions displayed significant decreases in 
glucose use. No significant changes in glucose use were detected in any regions in animals 
treated with LY354740 (0.3 mg/kg). However, at LY354740 (3.0 mg/kg), 4 out of the 42 
brain areas measured demonstrated statistically significant changes from the vehicle treated 
controls: red nuclei (-16 %), mammillary body (-25 %), anterior thalamus (-29 %) and the
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superficial layer of the superior colliculus (+50 %). An additional 15 brain regions displayed 
statistically significant reductions in function related glucose use (P<0.05) in animals treated 
with LY354740 (30 mg/kg). Function-related glucose use was significantly reduced in over 
50% of the cortical regions measured in animals treated with LY354740 (30 mg/kg). In 
order to determine whether this depression in glucose use affected all layers of the cortex, 
local rates of glucose utilisation were measured in layers II/III, IV and V/VI in the parietal 
cortex. Table 3 .4 demonstrates that the magnitude of the reductions in glucose use after 
LY3 54740 was similar in all cortical layers examined and did not exhibit any selectivity.
The magnitude of the /  values provides an indication of how pronounced the 
alterations in glucose use were within a particular region across the entire dose-response 
relationship (a high value signifies the most pronounced alterations). Thus the application of 
the/ rank allows the regional responses of LY354740 to be rank ordered (table 3.8) and the 
frequency distribution of responsiveness to be generated. The most pronounced changes 
after LY354740 (i.e. largest /  values) were seen in the anteroventral thalamic nucleus, 
mammillary body, superficial layer of the superior colliculus, anterior cingulate cortex and 
lateral habenular nuclei {f>  0.15). For other regions, the/  values were normally distributed 
around a mean of 0.05 (figure 3.7). This distribution of /  values reflects the relative 
homogeneous effects of LY3 54740 on function related glucose utilisation globally in the 
CNS.
3.3.3 LY379268 and local cerebral glucose utilisation
LY379268 (0.1, 1.0 and 10 mg/kg) produced anatomically circumscribed and dose- 
dependent changes in glucose utilisation (tables 3.3-3.7). Six regions displayed significant 
increases in glucose use after LY3 79268 (the superficial layer of the superior colliculus, 
locus coeruleus, genu of the corpus callosum, cochlear nucleus, inferior colliculus and the
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molecular layer of the hippocampus) and 3 regions displayed significant decreases 
(mammillary body, anteroventral thalamic nucleus, and the lateral habenular nucleus). 
Following LY379268 (0.1 mg/kg), only the locus coeruleus demonstrated a statistically 
significant increase in glucose use from the vehicle treated controls. After LY379268 (1 
mg/kg) significant alterations in glucose use were observed in the superior colliculus 
(+63%), locus coeruleus (+57%), molecular layer of the hippocampus (+14%) and the genu 
of the corpus callosum (+31%). In no region were significant reductions in glucose use 
observed after LY379268 (1 mg/kg). After LY379268 (10 mg/kg) significant alterations in 
glucose use were observed in the superficial layer of the superior colliculus (+81%), locus 
coeruleus (+52%), mammillary body (-34%), anteroventral thalamic nucleus (-28%), lateral 
habenular nucleus (-24%), cochlear nucleus (+26%) and inferior colliculus (+20%). As a 
result of the changes in glucose use demonstrated in cortical regions of animals treated with 
LY3 54740, local rates of glucose utilisation were measured in layers II/III, IV and V/VI of 
the sensory motor cortex (table 3.4). This region was chosen because of the sensory 
changes in behaviour noted in animals treated with LY379268 (10 mg/kg). Glucose use in 
the sensory motor cortex was not significantly altered statistically (the issue of statistical 
analysis is discussed further in appendix 4). However, a demonstrable trend of increasing 
glucose use with increasing LY379268 dose can be seen in the sensory motor cortex (all 
layers), which then returned to levels comparable with vehicle treated controls at the highest 
dose of 10 mg/kg.
The frequency distribution and rank order of responsiveness are presented in figure 
3.7 and table 3.8, respectively. The anatomically circumscribed effects of LY379268 
demonstrated by the numerical data were also apparent from the skewed distribution of /  
values obtained from the dose response data with LY379268. Brain areas in which the most 
pronounced changes were identified; i.e. where / >  0.15 were the superficial layer of the
110
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7
superior colliculus, locus coeruleus, mammillary body and the anteroventral thalamic 
nucleus.
3.3.4 Comparison of LY354740 and LY379268
Both LY3 54740 and LY379268 produced dose-dependent changes in glucose 
utilisation. The numerical alteration in glucose use, the computed /  values and visual 
inspection of the autoradiograms, indicate that there were some similarities in the regional 
response to both metabotropic glutamate agonists, i.e. the increased glucose use in the 
superficial layer of the superior colliculus and the marked reductions in glucose use in 3 
limbic areas (mammillary body, anteroventral thalamic nucleus, lateral habenular nucleus) 
after both agonists (figure 3.1-3.4). Despite these similar effects, the overall patterns of 
glucose use response to the two metabotropic agents were quite dissimilar (figure 3.5). 
LY354740 produced anatomically widespread reductions in glucose use while LY379268 
affected a smaller number of brain regions which displayed increases in glucose metabolism. 
More specifically, following LY3 54740 administration, there were widespread reductions in 
glucose use not just in limbic areas, but also in the cerebral cortex and motor areas 
(substantia nigra, red nucleus). In autoradiograms from animals treated with LY354740, 
there was a loss of anatomical detail and sharpness of image reflecting the widespread 
metabolic depression. Following LY379268, there was no widespread reduction in glucose 
use, with the mean rate of glucose use tending to be greater than in vehicle-treated animals. 
In a number of regions, for example, some auditory relay nuclei and the hippocampus, the 
increased glucose use achieved statistical significance. In contrast to the LY3 54740 
autoradiograms, the autoradiograms from animals treated with LY3 79268 showed excellent 
anatomical detail and sharpness of image.
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Further comparisons of the functional consequences of LY3 54740 and LY3 79268 in 
the brain can be achieved by examination of the /  ranking function. An /  value is generated 
for each brain region independently for the effects of LY354740 or LY379268. By 
inspecting the/  ranking hierarchies of the two agonists (table 3 .8), it can be seen that some 
regions of the brain were extremely sensitive (largest /  values) to both LY3 54740 and 
LY379268. These brain regions were the superficial layer of the superior colliculus, 
mammillary body and the anteroventral thalamic nucleus. At the other end of the spectrum, 
brain regions moderately and minimally responsive to LY3 54740 and LY3 79268 were 
different. Considering the overall pattern of the /  ranking hierarchies, the profiles of the 
agonists in the brain appear to differ. The heterogeneity of the regional responses of the two 
agonists is demonstrated by their different /  value frequency distributions, and in addition, is 
highlighted by the absence of association between the calculated /  values (figure 3.7-8). 
Using Spearman’s rank-order correlations, the overall correlation coefficient for all regions 
generated r = -0.075 (P = 0.65), indicating that the two compounds have selectively 
different sites of action in the brain. However, from both the numerical data and /  values, 
both compounds displayed some similar changes in glucose use in the limbic system. The 
correlation coefficient for limbic areas produced r = 0.44 (P = 0.47), which suggests that 
the effects of the two agonists in the limbic system are slightly more similar.
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MAMMILLARY BODY
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Figure 3.3 mGluR agonists and local cerebral glucose use: homogeneous responses 
to LY354740 and LY379268.
The data are presented as % change in glucose utilisation relative to glucose use in vehicle 
treated control animals (mean ± SEM). In both the mammillary body and anteroventral 
thalamic nucleus, LY3 54740 produces a greater magnitude of glucose use reduction. 
*P<0.05, **P<0.01, ***P<0.001 (ANOVA followed by Student’s /-test with Bonferroni 
correction).
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LATERAL HABENULAR NUCLEUS
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Figure 3.4 mGluR agonists and local cerebral glucose use: homogeneous responses 
to LY354740 and LY379268.
The data are presented as % change in glucose utilisation relative to glucose use in vehicle 
treated control animals (mean ± SEM). While the magnitude of glucose use reductions is 
similar in the lateral habenular nucleus following both LY3 54740 and LY3 79268, note the 
greater potency of LY379268 over LY354740 in the superficial layer of the superior 
colliculus.
*P<0.05, **P<0.01, ***P<0.001 (ANOVA followed by Student’s t-test with Bonferroni 
correction).
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VISUAL CORTEX
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Figure 3.5 mGluR agonists and local cerebral glucose use: heterogeneous 
responses to LY354740 and LY379268.
The data are presented as % change in glucose utilisation relative to glucose use in vehicle 
treated control animals (mean ± SEM). While LY3 54740 produces a significant reduction in 
glucose use in part of the visual system, LY3 79268 produces a significant elevation in 
glucose use in a region of the auditory system.
*P<0.05, **P<0.01 (ANOVA followed by Student’s /-test with Bonferroni correction).
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Figure 3.6 mGluR agonists and local cerebral glucose use: minimal responses to 
LY354740 and LY379268.
The data are presented as % change in glucose utilisation relative to glucose use in vehicle 
treated control animals (mean ± SEM). Both the cerebellar cortex and substantia nigra pars 
reticulata were insensitive to alterations in glucose use by LY3 54740 and LY3 79268.
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Table 3.8 LY354740 and LY379268: Hierarchy of regional responsiveness.
BRAIN REGIONS
LY3 54740 LY379268
Anteroventral thalamic nucleus Superficial layer of superior colliculus
Mammillary body Locus coeruleus
Superficial layer of superior colliculus Mammillary body
Anterior cingulate cortex Anteroventral thalamic nucleus
Lateral habenular nucleus Genu of the corpus callosum
Visual cortex Lateral geniculate body
Mediodorsal thalamus Lateral habenular nucleus
Red nuclei Cochlear nucleus
Deep layer of superior colliculus Sensory motor cortex (layer IV)
Pons Sensory motor cortex (layer VAT)
Parietal cortex (layer IV) Cerebellar white matter
Frontal cortex Sensory motor cortex (layer II/III)
Median raphe nucleus Nucleus accumbens
Genu of the corpus callosum Inferior colliculus
Parietal cortex (layer II/III) Amygdala
Septal nucleus Preffontal cortex
Globus pallidus Caudate
Substantia nigra pars compacta Median raphe nucleus
Corpus callosum Anterior cingulate cortex
Sensory motor cortex (layer IV) Hypothalamus
Vestibular nucleus Auditory cortex
Superior olivary nucleus Internal capsule
Subthalamic nucleus Cerebellar hemisphere
Internal capsule Hippocampus - molecular layer
Nucleus accumbens Mediodorsal thalamus
Parietal cortex (layer V/VI) Substantia nigra pars compacta
Hypothalamus Substantia nigra pars reticulata
Medial geniculate nucleus Ventrolateral thalamus
Hippocampus - molecular layer Septal nucleus
Ventrolateral thalamus Corpus callosum
Caudate-putamen Deep layer of superior colliculus
Auditory cortex Frontal cortex (layer IV)
Preffontal cortex Globus pallidus
Dentate Gyrus Red nucleus
Lateral geniculate body Pons
Inferior olivary body Medial geniculate body
Amygdala Dentate gyrus
Cerebellar cortex Parietal cortex (layer IV)
Inferior colliculus Superior olivary body
Cochlear nucleus Vestibular nucleus
Substantia nigra pars reticulata Visual cortex (layer IV)
Cerebellar white matter Subthalamic nucleus
The sensitivity of each of the 43 brain regions investigated following LY3 54740 and 
LY379268 administration are ranked in order of decreasing magnitude of effect by their 
respective /  values. Regions highlighted in bold font have been arbitrarily classified into a 
group considered the ‘most responsive’, where/ values > 0.15.
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Figure 3.7 Frequency distributions off  values for LY354740 and LY379268.
The /  values obtained from the arithmetic function indicate the responsiveness of individual 
brain regions to the drug treatment. (A) Following LY3 54740, the distribution of /values 
was relatively homogeneous with values being normally distributed around 0.05. (B) 
Following LY3 79268, the response of brain regions was more heterogeneous and the /  
values showed a much more skewed distribution.
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3.4 Summary and technical considerations
In this study, the effects of two new mGluR agonists, LY3 54740 and LY3 79268, on 
local cerebral glucose use were examined. Although mGluRs are currently extensively 
studied and characterised, this was the first time the functional consequences resulting from 
the systemic activation of mGluR2/3 by selective agonists were described.
The results of the study show that the systemic administration of LY3 54740 
produced major changes in the rates of local cerebral glucose utilisation in 19 of the 42 
regions measured, while with LY3 79268, only 9 out of 42 regions were substantially 
affected. The additional use of the ranking function /  provides a system which allows the 
interpretation of data from the entire dose-response relationship. The utility of the /ranking 
function has been previously demonstrated by Kelly et al. (1986). In this present study, by 
using all of the available data, distinct patterns of altered local cerebral glucose utilisation 
were established for both metabotropic agonists and used to supplement percentage 
changes in function-related glucose use, or significance levels in specific regions. 
Irrespective of how the data were analysed, a number of similarities and more obviously, 
dissimilarities were identified in the regional responses of local glucose use to the two 
metabotropic glutamate agonists. Glucose use in a number of anatomically interconnected 
regions of the limbic systems (anteroventral thalamic nucleus, mammillary body, lateral 
habenular nucleus) were sensitive to reduction by both LY354740 and LY379268. Glucose 
use in the superior colliculus (superficial layer) was increased by both metabotropic 
agonists. In contrast, LY3 54740 provoked anatomically widespread reductions in glucose 
use, notably in the cerebral cortex and visual system, whereas LY3 79268 elicited 
circumscribed increases in glucose use in the auditory relay nuclei and locus coeruleus.
One of the central assumptions made in the original derivation of the operational 
equation of the [14C]2-deoxyglucose method requires that plasma glucose concentration
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remains constant throughout the experimental procedure. However, plasma glucose levels 
were significantly increased 45 minutes after LY379268 (10 mg/kg) compared with control 
levels (table 3.2), with plasma glucose levels peaking at their highest levels 10-25 minutes 
into the experimental procedure. This clearly does not satisfy the constraints and thus 
invalidates the operational equation and lumped constant of the [14C]2-deoxyglucose 
method (Schuier et al., 1981). Savaki et al., (1980) developed a method for the 
measurement of the turnover rate constant (or the half-life) of the free glucose content of 
brain. As a result of these studies, the method could be applied to the [14C]2-deoxyglucose 
technique for the measurement of local cerebral glucose utilisation in conditions with 
changing arterial plasma glucose concentrations (for example, in conditions such as stress 
where plasma glucose may fluctuate continuously during the procedure). For this, a new 
operational equation was derived to take into account changing plasma glucose levels, 
based on the original operational equation by SokolofF et al. (1977). Using this method for 
the animals treated with LY3 79268 (10 mg/kg), the final plasma integral in both white and 
grey matter differed by less than 3% compared with the final plasma integral values obtained 
using the original method. Therefore, this difference would have negligible effects on the 
final outcome of local rates of glucose utilisation.
The results of this study are discussed in chapter 8, section 8.2.
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CHAPTER 4 
FUNCTIONAL MAPPING FOLLOWING 
LIMBIC SYSTEM MANIPULATION
4.1 Introduction
The [14C]2-DG technique has been applied extensively to characterise the functional 
consequences associated with the pharmacological manipulations of specific receptor 
populations, such as glutamate receptors. Past studies have successfully contributed to our 
understanding of the anatomical circuits influenced by ionotropic glutamate receptor activity 
(Nehls et al., 1988; McCulloch & Iversen, 1991; Browne & McCulloch, 1994). Similarly, 
the study carried out in chapter 3 has revealed selective circuits influenced by group II 
mGluR activity and augmented our current understanding of the functional consequences of 
systemic glutamatergic manipulations.
In contrast to the widespread changes in glucose utilisation following the systemic 
administration of agents, the [14C]2-DG technique has also been successfully used to 
explore the functional consequences following more selective and localised manipulations of 
the CNS. While investigations of NMD A receptor activity have been carried out using 
direct intracerebral injections of selective antagonists, no such studies have been performed 
for AMPA receptors and mGluRs. Therefore the aim of this study was to explore the 
consequences of cerebral function following selective AMPA and mGluR manipulation of 
the hippocampus.
Local rates of function-related glucose use were assessed in animals during and 
following the intrahippocampal infusion of the selective AMPA/KA receptor antagonist 
LY326325. Unfortunately, this study was limited to the investigation of AMPA receptor 
manipulation. At the time this study was carried out, LY3 54740 was under clinical 
development and LY3 79268 was being considered for clinical use. Company policy 
restricted their use in research, and for this reason, LY3 54740 and LY3 79268 could not be 
used in this study. LY326325 is a different salt of the better known decahydroisoquinoline 
compound LY293558 (Ornstein et al., 1993; Schoepp et al., 1995b). LY326325 was
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chosen to inactivate the hippocampus because it has previously been demonstrated to be 
systemically active and to reduce glucose utilisation homogeneously throughout the brain 
(Browne & McCulloch, 1994). In addition, LY326325 is water soluble, which avoids the 
use of solvents such as dimethyl sulphoxide (DMSO) and the possible brain damage 
associated with its use. An advantage of this type of study is the unique opportunity it 
provides to simultaneously complement and combine other studies, such as the effects of 
intrahippocampal LY326325 infusion in behavioural and electrophysiological studies .
4.2 Methods
4.2.1 Stereotaxic surgery
Adult male hooded-Lister rats (Harlan Olac, Bicester, UK) weighing between 200- 
250g (n=19) were used for this study. All animals were allowed to acclimatise to their 
surroundings for at least 5 days before any surgery under normal housing conditions. 
Animals were first anaesthetised with 5% halothane and anaesthetic was maintained by i.p. 
injection of Avertin (tribromoethanol, lOml/kg). Stereotaxic surgery was carried out as 
described in section 2.2. Animals were implanted bilaterally with 7 day minipumps 
containing either LY326325 or aCSF (artificial cerebrospinal fluid). Following surgery, 
animals were returned to their normal housing conditions and checked regularly until they 
were used for the autoradiographic procedure.
4.2.2 [14C]2-deoxyglucose measurements
Local cerebral glucose utilisation measurements were carried out in conscious, 
freely moving animals using [14C]2-DG autoradiography as described in section 2.1. 
Adjacent coronal brain sections to those obtained for autoradiography were taken for H & 
E staining to aid the identification of the cannulae injection site, and any resulting areas of
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brain damage. For this study, as the pharmacological manipulation was localised to 
intracerebral hippocampal injections, the brain regions chosen for analysis reflected 
primarily the hippocampus and it’s anatomical connections. Local rates of glucose use were 
determined in 34 separate brain regions with quantitative densitometric analysis in a blinded 
fashion. All the data were analysed by two-tailed Student’s unpaired /-test.
The [14C]2-DG autoradiographic procedure was carried out 4 days after minipump 
implantation to examine the functional consequences of hippocampal inactivation 
(minipump ran for 7 days), or following 11 days to determine brain function after the 
exhaustion of the drug/vehicle in the minipump.
4.2.3 Drug administration
Artificial cerebrospinal flu id  (aCSF)
To make 11 of aCSF, stock solutions A and B were firstly prepared. For solution A, 
8.66g of NaCl; 0.225g KC1; 0.205g CaCl22H20  and 0.165g MgCl26H20  were added to 
500ml pyrogen-free sterile water. For solution B, 0.115g Na2HPC>4 and 0.025g 
NaH2P04H20  were added to 500ml pyrogen-free sterile water. Solutions A and B were 
then added in equal volumes.
LY326325
LY326325 was dissolved in aCSF to give a 1.5mM stock solution (pH adjusted to 7.2). 
LY326325 was administered at a concentration of 0.375mM via the minipumps and the 
cannulae at a rate of 0.5pl/hour (Drs. J Micheau & G Riedel, personal communication). 
Control animals received bilateral minipump infusions of aCSF.
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4.3 Results
4.3.1 General Observations
Following stereotaxic surgery, recovery from the effects of anaesthesia was slower 
than with halothane as a direct result of the administration route of the anaesthetic (i.p. 
injection rather than a gas mix). Once the animals had regained consciousness, changes in 
behaviour were noticed. All animals were less active than before the surgical procedure. 
This loss of activity remained for the next couple of days together with a loss in weight 
(table 4.1). By 4 days after surgery, weight loss was still evident in animals but they all 
exhibited signs of normal inquisitive behaviour. No changes in behaviour were observed 
between animals at 4 days after surgery and animals at 11 days after surgery.
Gross examination of the autoradiograms revealed that damage had occurred in 
some animals at the cortical level of the brain. This damage was observed usually at the 
level of the frontal/prefrontal cortex and was attributed to either the heat generated from the 
drill-bit used for the stereotaxic surgery, or actual physical damage produced by the screws 
used to keep the stereotaxic assembly in place. Damage caused by the needle tract was 
clearly evident in all brains at the site of the injection. Consequently, brain regions selected 
for densitometric analysis were chosen only if they were free from artefactual damage.
4.3.2 Function-related glucose use 4 days following stereotaxic surgery
The function-related glucose utilisation values associated with LY326325 infusion 
are presented in tables 4.2-4.5. Anatomically circumscribed changes in glucose use were 
measured in animals treated with LY326325 compared with aCSF treated control animals. 
During the period of drug infusion (4 days), a reduction in glucose utilisation of 23% in the 
dorsal hippocampus, stratum lacunosum moleculare, (P<0.002) was evident (bregma -3.30 
mm), while the ventral hippocampus, stratum lacunosum moleculare (bregma = -5.80 mm),
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was minimally affected (figure 4.1). These results reveal a spatially selective response in the 
hippocampus during the period of LY326325 infusion. The intrahippocampal infusion of 
LY326325 after 4 days produced minimal alterations in glucose use in the remaining regions 
of the CNS other than a possible elevation in glucose utilisation in the superficial layers of 
the entorhinal cortex afferent to the hippocampus (table 4.3 and figure 4.1).
4.3.3 Function-related glucose use 11 days following stereotaxic surgery
The results at 11 days after LY326325 infusion, a time when the drug was 
exhausted, are presented in tables 4.2-4.5. At 11 days after LY326325 infusion, glucose 
utilisation in the dorsal hippocampus stratum lacunosum moleculare returned to levels 
comparable to that observed with aCSF treated animals. The alteration in glucose use in the 
entorhinal cortex measured after 4 days LY326325 infusion was also not evident after 11 
days. Function-related glucose use in these regions of LY326325 treated animals were 
indistinguishable from the aCSF treated animals. However, a 17% reduction in glucose 
utilisation was observed in the red nucleus of LY326325 treated animals at 11 days after 
drug infusion (table 4.4). A comparison of the data generated from both the time points of 4 
days and 11 days after drug infusion reveal a generalised reduction in glucose utilisation in 
all brain regions in the 4 day treatment group.
4.3.4 Glucose utilisation in the hippocampus
Tables 4.2-4.5 illustrate the subtle changes in glucose use in the brains of animals 
treated with an infusion of LY326325. The most significant reduction in function-related 
glucose use was demonstrated in the stratum lacunosum moleculare of the hippocampus in a 
selective manner, affecting the dorsal but not the ventral hippocampus. This selective
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Figure 4.1 LY326325 and local cerebral glucose use.
The data are presented as % change in glucose utilisation relative to glucose use in aCSF 
treated control animals (mean ± SEM).
**P<0.002 (Student’s unpaired /-test)
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reduction initiated further analysis of the changes in glucose metabolism in the hippocampus 
in order to explore the extent of the reduction. To investigate the extent of hippocampal 
inactivation, as many densitometric readings were made in the hippocampus (stratum 
lacunosum moleculare) as were possible. However, to demonstrate these changes in the 
hippocampus quantitatively, several factors were taken into consideration. The injection site 
(placement of the stainless steel cannulae) was chosen as a reference point by which all the 
readings in each animal could be normalised. The injection site reference point was chosen 
on a separate occasion from the densitometric readings from the corresponding H & E 
sections in which the needle tract had reached the most ventral point in the hippocampus. 
Also, in order to overcome any issues of left-right asymmetry in the cut of the brain, the left 
and right hemispheres were initially considered separately. No demonstrable differences in 
glucose utilisation in the hippocampus between the left and right hemispheres were 
observed and so the data were pooled together (see appendix 5 for all left-right data). The 
results are presented in table 4.6 and illustrated in figure 4.2. Figure 4.2A illustrates that the 
maximal reduction in function-related glucose in the stratum lacunosum moleculare of the 
hippocampus was observed adjacent to the cannula implant site. In addition, the degree of 
hippocampal inactivation was greater along its dorsal axis relative to the implant site. 
Glucose utilisation in the hippocampus measured at 11 days after drug infusion (minipump 
exhausted) was indistinguishable from aCSF treated animals, although a disparity in glucose 
use was noted at the most dorsal portion of the hippocampus in aCSF treated animals 
compared with the LY326325 group (figure 4.2B). Figure 4.2C demonstrates that glucose 
use values were similar in the molecular layer of the hippocampus following aCSF treatment 
after 4 and 11 days. Figure 4.2D illustrates that a reduction in glucose use was observed in 
the hippocampus 4 days after LY326325 minipump implantation compared with 
hippocampal glucose use values after 11 days.
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Figure 4.2A Extent of the reduction of glucose use in the stratum lacunosum 
moleculare of the hippocampus: 4 days (minipump active).
The data are presented as mean ± SEM. The dotted line represents the site of injection 
(chosen from H & E stained sections). All data points to the left of the dotted line represent 
glucose use in the hippocampus at distances rostral to the injection site, while data points to 
the right of the dotted line represent glucose use in the hippocampus at distances caudal to 
the injection site.
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B. 11 days: minipump exhausted
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Figure 4.2B Extent of the reduction of glucose use in the stratum lacunosum 
moleculare of the hippocampus: 11 days (minipump exhausted).
The data are presented as mean ± SEM. The dotted line represents the site of injection 
(chosen from H & E stained sections). All data points to the left of the dotted line represent 
glucose use in the hippocampus at distances rostral to the injection site, while data points to 
the right of the dotted line represent glucose use in the hippocampus at distances caudal to 
the injection site.
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c . bilateral aCSF treatment
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Figure 4.2C Extent of the reduction of glucose use in the stratum lacunosum
moleculare of the hippocampus: comparison of aCSF treated groups at 
4 days and 11 days.
The data are presented as mean ± SEM. The dotted line represents the site of injection 
(chosen from H & E stained sections). All data points to the left of the dotted line represent 
glucose use in the hippocampus at distances rostral to the injection site, while data points to 
the right of the dotted line represent glucose use in the hippocampus at distances caudal to 
the injection site.
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D. bilateral LY326325 treatment
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Figure 4.2D Extent of the reduction of glucose use in the stratum lacunosum 
moleculare of the hippocampus: comparison of LY326325 treated 
groups at 4 days and 11 days.
The data are presented as mean ± SEM. The dotted line represents the site of injection 
(chosen from H & E stained sections). All data points to the left of the dotted line represent 
glucose use in the hippocampus at distances rostral to the injection site, while data points to 
the right of the dotted line represent glucose use in the hippocampus at distances caudal to 
the injection site.
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Figure 4.3 Measurement of glucose use in the stratum lacunosum moleculare 
of the hippocampus: representative coronal line diagrams.
DH = dorsal hippocampus; VPM = ventral posteromedial thalamic nucleus; TH = 
temporal hippocampus; MG = medial geniculate body.
MG ";-T- TH
Figure 4.3 Measurement of glucose use in the stratum lacunosum molecular of 
the hippocampus: representative coronal line diagrams.
(As an aid to figure 4.2) The coronal line diagrams are presented to provide anatomical 
landmarks at various points of the hippocampus where glucose use was measured, 
a) the approximate site of injection (as recognised from the H & E stained brain sections), 
bregma = -4.52mm; b) the hippocampus at approx 1.6mm rostral to the injection site 
and c) the hippocampus at 1.6mm caudal to the injection site.
4.4 Summary and technical considerations
The results of this study demonstrate that the infusion of the AMPA receptor 
antagonist LY326325 produced selective and localised changes in the rates of local cerebral 
glucose utilisation in the brain. Specifically, the infusion of LY326325 reduced function 
related glucose utilisation in the stratum lacunosum moleculare of the hippocampus in a 
spatially selective manner; glucose utilisation was markedly affected in the dorsal aspect, 
with relatively little effect in the ventral portions of the hippocampus. In addition, the 
[14C]2-DG data reveals that the functional response measured in the dorsal hippocampus 
during LY326325 infusion returns to levels comparable with aCSF treated animals after the 
infusion period. At 11 days after LY326325 infusion, the red nucleus showed a significant 
reduction in glucose utilisation compared to aCSF counterparts. Why this nucleus should be 
affected is not known. The data generated at both 4 days and 11 days after drug infusion 
revealed a generalised reduction in glucose utilisation in all brain regions in the 4 day 
treatment group. This non-specific alteration in glucose use reflects the response of the 
brain to the considerable trauma of the stereotaxic surgery itself (Kelly et al., 1982; Kelly & 
McCulloch, 1984).
The energetic requirements of the brain are obtained almost exclusively from the 
aerobic oxidation of glucose. However, there are three other possible energy-generating 
substrates to glucose; the accumulation of lactate, the use of glycogen, and the use of 
ketone bodies, which are all important to the interpretation of [14C]2-DG experiments. 
While lactate accumulation is well recognised in experimentally induced seizures, it is not 
normally associated with neuropharmacological manipulations (Siesjo, 1978). Levels of 
glycogen in the CNS are very low (less than 1% of the liver) and would only be able to 
support metabolic activity for a few minutes. In this instance, neither lactate accumulation 
nor glycogen utilisation would have affected the rate of glucose metabolism. The use of
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ketone bodies as an alternative source of energy however, is capable of replacing glucose 
catabolism. Levels of ketone bodies in well-nourished animals are very low, and thus in 
normal situations, the contribution of ketone bodies to oxygen and energy metabolism is 
negligible. However, when animals are deprived of food, the levels of ketone bodies in the 
blood rise rapidly, such that their contribution to oxygen consumption has increased from 
less than 1% to greater than 20% (Ruderman et al., 1974). Thus the disruption of the 
normal feeding behaviour of animals will lead to a greater contribution of ketone bodies to 
the energy generation in the CNS, and consequently the close coupling between the rate of 
glucose metabolism and functional activity will be compromised. Although the physiological 
data demonstrate that at 4 days after stereotaxic surgery the animals were continuing to lose 
weight, the animals were not deprived of food and thus it is predicted that ketone body 
metabolism would not have altered the outcome in glucose metabolism significantly in this 
study. For example, in the dorsal hippocampus, levels of glucose utilisation after 4 days 
aCSF treatment were seen to be indistinguishable from the 11 day aCSF treatment group. If 
ketone bodies were being used as an alternative source of energy, one would have expected 
much lower rates of glucose utilisation in the 4 day aCSF group.
In summary, this present study has revealed that a localised infusion of LY326325 
directly into the hippocampus can reduce synaptic activity (i.e. function related glucose 
utilisation) in the dorsal stratum lacunosum moleculare of the hippocampus in a reversible 
manner. The significance of the results obtained from this study are discussed in section 8.3.
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CHAPTER 5 
THE EFFECTS OF THE SELECTIVE GROUP II 
METABOTROPIC GLUTAMATE RECEPTOR AGONIST 
LY354740 IN A RAT MODEL OF PERMANENT ISCHAEMIA
5.1 Introduction
The ionotropic glutamate receptors have been demonstrated to play a central role 
mechanistically in glutamate neurotoxicity. Therefore it is not surprising that metabotropic 
glutamate receptors are similarly thought to play an important role in the modulation of 
glutamate induced neurotoxicity (Nicoletti et al., 1996). It has been generally assumed that 
the activation of group I mGluRs leads to increased neuronal excitation and excitability, and 
thus may have a contributing role in excitotoxic damage, while activation of group II or III 
mGluRs may be neuroprotective. It has been postulated that the neuroprotective effects of 
group II or III mGluR moderated ligands are mediated possibly through their ability to 
inhibit glutamate release presynaptically (Bruno et al., 1995a). The aim of this study was to 
investigate whether the activation of group II mGluRs in the CNS by the bioavailable 
agonist LY3 54740 was neuroprotective following 24 hour permanent middle cerebral artery 
(MCA) occlusion in the rat.
5.2 Methods
5.2.1 Preparation of animals and MCA occlusion
Male Fischer 344 rats weighing between 250-300g were used in this study (Harlan 
Olac, Bicester, UK). Prior to experiments, animals were housed in cages of groups of 4 or 5 
under natural daylight conditions, at a room temperature of approximately 21°C. Food and 
water were available ad libitum. Animals were anaesthetised initially with 5% halothane in a 
nitrous oxide: oxygen mix (70:30) until the righting reflex was lost. Animals were 
subsequently artificially ventilated following oral intubation, and anaesthetic was maintained 
with 1.5% halothane. Focal ischaemia was induced using an adapted method of Tamura et 
al. (1981) as described previously (section 2.3). The time of the diathermy was taken as the
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exact time of the MCA occlusion. The anaesthetic was discontinued and the animals were 
allowed to recover for 24 hours. Once consciousness was regained, the animals were placed 
into individual cages lined with post-operative absorbent pads together with a small amount 
of rat chow softened with water. They were returned to their normal housing conditions and 
were examined regularly to check their status.
5.2.2 Drug administration
The animals received two subcutaneous doses of LY354740 (0.3, 3.0 or 30.0 
mg/kg), or vehicle (0.9 % saline) in a volume of 0.5ml saline. The first injection was 
administered 30 minutes prior to the MCA occlusion under anaesthesia, while the second 
was administered three hours after the occlusion. All administrations of the drug/vehicle 
were performed in a blinded manner.
5.2.3 Histology and quantification of lesion size
Twenty four hours following the MCA occlusion, the animals were sacrificed with 
an overdose of halothane and decapitated. The brains were carefully removed and frozen in 
isopentane at -42°C. The brains were mounted and embedded in Lipshaw matrix and were 
cut into 20 pm thick serial coronal cryostat sections at -22°C. Sections were mounted onto 
microscope slides and stained with H & E (appendix 3). Areas of ischaemic damage and 
brain swelling were assessed by an observer blinded to the treatment groups at 8 pre­
selected coronal levels per animal, from anterior 10.5 mm to posterior 1.02 mm (Osborne et 
al., 1987) using the MCID computer based image analysis system. The approximate 
volumes of ischaemic damage for each animal were obtained by the method previously 
described (section 2.3.4). All the data were analysed for statistical significance using 
ANOVA.
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5.3 Results
During the initial period of recovery, all animals appeared less active than before the 
surgical procedure with very little movement or signs of inquisitive behaviour. The 
behaviour of all animals was greatly improved by the next morning; all animals had taken 
soft diet, and they all exhibited signs of inquisitiveness. None of the animals exhibited any 
adverse signs of suffering, and the mortality rate was zero.
Following 24 hour permanent MCA occlusion, ischaemic damage was observed 
within the territory supplied by the occluded MCA. The histopathological appearance 
between ischaemic brain tissue in animals treated with LY3 54740 and vehicle were 
indistinguishable. A typical lesion produced by the permanent occlusion of the MCA is 
represented in figure 5.1. The area of ischaemic damage can be identified as the area of 
pallor in the H & E stained sections.
The effects on LY354740 on infarct volume are presented in table 5.1. At 24 hours 
after MCA occlusion, figure 5.2 illustrates that there were no significant decreases in infarct 
volume following treatment of LY354740 at any of the doses, F = 0.04 (df 3, 29). The 
distribution of the areas of ischaemic damage are also presented in figure 5.3. The difference 
between the volumes of the ipsilateral and contralateral hemispheres provided a measure of 
brain swelling. Figures 5.4-5.5 show that no significant differences in the volumes of brain 
swelling between animals treated with LY3 54740 and vehicle-treated control animals were 
identified, F = 0.3 (df 3, 29). In addition to generating absolute infarct volumes and volumes 
of brain swelling, the percentage infarct volumes for each animal were also obtained (figure 
5.6). Figure 5.7 illustrates that brain swelling, as a result of ischaemia, is directly 
proportional to infarction volumes in all animals, irrespective of whether they received 
vehicle or drug (r = 0.75, P< 0.01).
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Figure 5.1 Focal ischaemic lesion.
A representative rat brain at the 8 pre-selected coronal levels stained with haematoxylin 
and eosin illustrating a typical lesion produced 24 hours after the permanent occlusion 
of the MCA. The region of ischaemic damage is identified as an area of pallor, affecting 
the ipsilateral striatum and cortex. Note also the swelling in the ipsilateral hemisphere 
compared with the contralateral hemisphere.
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Figure 5.2 Volumes of infarction.
Areas of infarct were measured in H & E stained coronal sections from anterior 10.5 mm to 
posterior 1.02 mm. The volumes of ischaemic damage were obtained by integrating each of 
the areas measured with the known stereotaxic co-ordinates of the level. The data are 
presented as a scatter plot, each point representing an individual animal with the mean value 
presented as a horizontal bar. There were no differences in infarct volume between vehicle 
and any of the LY3 54740 drug treated groups (ANOVA).
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Figure 5.4 Volumes of brain swelling.
Ipsilateral and contralateral hemispheric areas were measured in H & E stained coronal 
sections from anterior 10.5 mm to posterior 1.02 mm. The respective volumes were 
obtained by integrating each of the areas measured with the known stereotaxic co-ordinates 
of the level and the difference between the volumes provided a measure of brain swelling. 
The data are presented as a scatter plot, each point representing an individual animal with 
the mean value presented as a horizontal bar. There were no differences in brain swelling 
between vehicle and any of the LY3 54740 drug treated groups (ANOVA).
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Figure 5.6 Percentage of ipsilateral hemisphere with ischaemic damage.
The percentage o f ischaemic damage in each group was determined by measuring the area 
o f the contralateral hemisphere and the area o f non-infarcted tissue in the ipsilateral 
hemisphere (i.e. area o f non-pallor) in H & E stained coronal sections from anterior 10.5 
mm to posterior 1.02 mm. The respective volumes were obtained by integrating each o f the 
areas measured with the known stereotaxic co-ordinates o f the level and the percentage 
ischaemic damage was generated as described in the text. The data are presented as the 
mean ± SEM for vehicle controls (n=10); LY354740, 0.3mg/kg (n=5); LY354740, 
3.0mg/kg (n=5) and LY3 54740, 30mg/kg (n=10). Analysis o f the data by ANOVA revealed 
that there were no differences in the percentage infarct volume between vehicle and any o f 
the LY354740 drug treated groups F=0.2 (df 3,29).
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Figure 5.7 The relationship between the volume of infarction (mm ) and the 
volume of ipsilateral hemispheric swelling (mm ) in vehicle and 
LY354740 treated animals.
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5.4 Summary and technical considerations
One of the fundamental problems involved with the determination of infarct volumes 
from experimental models of cerebral ischaemia is the enlargement of tissue by oedema 
which can vary from brain to brain. By using the method for measuring the percentage brain 
infarct volume described by Swanson and colleagues (1990), the potential error that is 
introduced by swelling is minimised. Irrespective of whether the data are analysed in 
absolute terms, or in percentage terms, the results from this study show that LY3 54740 
failed to reduce ischaemic damage in the brain following a 24 hour permanent MCA 
occlusion model of cerebral ischaemia at any of the doses investigated.
In any neuroprotection study in which a drug has failed to alter the outcome, the 
adequacy of the dosing regimen must be taken into consideration. Levels of LY3 54740 in 
the brain were not determined in this study, but previous studies have demonstrated that the 
doses of LY3 54740 used in this study would be above levels needed to activate group II 
mGluRs in vitro (Battaglia et al., 1997). Moreover, LY3 54740 administered at 10 mg/kg 
(i.v. and p.o), was shown to provide effective brain levels for more than 3 hours (Bond et 
al., 1997). In addition, the [14C]2-DG autoradiographic studies described in Chapter 3 
demonstrated dose dependent changes in brain function (measured by glucose metabolism) 
following the systemic administration of LY354740 at the same doses used in this study. 
Post hoc power calculations indicated that the sample sizes and variance of the present 
study would have been capable of detecting changes of approximately 20 % (a  = 5 %, P = 
80 %). Therefore, it is unlikely that the failure of LY354740 to reduce tissue damage can be 
attributed to the dosing regimen, or the inadequate power of the study.
Another factor which may influence the outcome in neuroprotection studies is the 
strain of animal used. It is well recognised that there are differences among rat strains in the 
hemispheric volumes of infarction. In 5 rat strains studied (Duverger & MacKenzie, 1988),
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only the Fischer-344 strain demonstrated a consistent and sizeable infarcted volume 
following cerebral ischaemia. However, it could be possible that while the infarct size is 
consistent (compared with the variability seen in the Sprague-Dawley strain), the existence 
of penumbral tissue, and consequently the amount of salvageable tissue, may be 
compromised.
In summary, despite compelling evidence which suggest that group II metabotropic 
glutamate receptor agonists are neuroprotective (Buisson & Choi, 1995; Maiese et al., 
1995; Chiamulera et al., 1992; Bruno et al., 1996; Miyamoto et al., 1997), LY354740 
failed to demonstrate any neuroprotective effects after this model of permanent MCA 
occlusion in the rat. In direct contrast, a recent study demonstrated that LY3 54740 was able 
to substantially reduce damage in CA1 hippocampal neurones in a gerbil model of global 
ischaemia (Bond et al., 1998). The findings of this study and consequently the potential 
involvement of group II mGluR agonists in neurodegenerative conditions such as ischaemia 
are considered in section 8.4.
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CHAPTER 6
INFLUENCE OF THE GROUP II METABOTROPIC 
GLUTAMATE RECEPTOR AGONIST LY379268 IN CEREBRAL 
ISCHAEMIA: A NEUROPATHOLOGIC ASSESSMENT
6.1 Introduction
The study carried out in chapter 5 with the mGluR2/3 selective agonist LY3 54740 
revealed that this agent was unable to reduce the volume of ischaemic damage in the rat 
brain following a 24 hour permanent MCA occlusion model of focal cerebral ischaemia. The 
findings from the [14C]2-DG study (chapter 3) revealed that although LY354740 and 
LY3 79268 are structurally similar, they appear to produce different functional responses in 
the brain. The aim of this study was to investigate whether LY3 79268, because of its 
different profile centrally, was neuroprotective following a 24 hour permanent MCA 
occlusion in the rat. A dose of lOmg/kg was chosen on the basis of its bioavailability in the 
brain as demonstrated in chapter 3. In addition to examining infarct size measurements, an 
attempt was also made to gain insight into the neuropathology of the ischaemic lesion in 
animals treated with LY379268. Thus, brain sections subjected to MCA occlusion were 
assessed for cellular changes using immunohistochemical endpoints. With the recent interest 
in the role of cytokines and white matter protection in cerebral ischaemia (chapter 1, section 
1.5.2) immunohistochemical markers used in this instance included antibodies for TGFP-1 
and TGF0-2 and APP. Given the recent evidence for the reduction of cell death following 
global ischaemia, the actions of group II mGluR agonists may be influenced by the 
mechanisms by which cells die. Therefore an antibody for the detection of DNA 
fragmentation was also used. Finally, an antibody for mGluR2/3 was used to investigate any 
possible changes in the receptors.
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6.2 Methods
6.2.1 Preparation of animals and MCA occlusion
Male Fischer 344 rats weighing between 250-300g were used in this study (Harlan 
Olac, Bicester, UK). Prior to experiments, animals were housed under the normal 
conditions and food and water were available ad libitum. On the day of surgery, animals 
were anaesthetised initially with 5% halothane in a nitrous oxide: oxygen mix (70:30) until 
the righting reflex was lost. Animals were subsequently artificially ventilated following oral 
intubation, and anaesthetic was maintained with 1.5% halothane. Focal ischaemia was 
induced using an adapted method of Tamura et al. (1981) as described previously (section 
2.3). The time of the diathermy was taken as the exact time of the MCA occlusion. The 
anaesthetic was discontinued and the animals were allowed to recover for the next 24 hours. 
Once consciousness was regained, the animals were placed into pre-prepared individual 
cages together with softened diet. They were returned to their normal housing conditions 
and were examined regularly to check their status.
6.2.2 Drug administration
All animals received two subcutaneous doses of LY379268 (10.0 mg/kg), or vehicle 
(0.9 % saline) in a volume of 0.5ml saline. The first injection was administered 30 minutes 
prior to the MCA occlusion under anaesthesia, while the second was administered three 
hours after the occlusion. All administrations of the drug/vehicle were performed in a 
blinded manner.
6.2.3 Tissue processing and quantification of lesion size
Twenty four hours following the MCA occlusion, the animals were re-anaesthetised 
with 5% halothane and perfused transcardially with 4% paraformaldehyde (appendix 3).
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Following fixation, animals were decapitated and the heads post-fixed in fresh 4% 
paraformaldehyde overnight at 4°C. The brains were removed and processed for paraffin 
embedding. Brains were cut into 6 |iim thick serial coronal sections on a microtome and 
mounted onto poly-l-lysine coated slides. The sections were then left at room temperature 
overnight to dry. The 8 pre-determined coronal levels (chapter 2, figure 2.3) necessary for 
the assessment of volumetric measurements of infarction were selected for each animal and 
stained with H & E. Areas of ischaemic damage were assessed by an observer blinded to the 
treatment groups using the MCID computer based image analysis system. The approximate 
volumes of ischaemic damage for each animal were obtained by the method previously 
described (section 2.3.4). The data were analysed for statistical significance using two-tailed 
unpaired Student’s r-test.
6.2.4 Immunohistochemistry
Immunohistochemical analyses were carried out in adjacent sections to those used 
for the quantification of the ischaemic damage at the stereotaxic level of the septal 
nuclei/caudate (anterior co-ordinate = 7.19mm). All antibodies were individually titred to 
obtain the optimal working concentration. The subsequent antibodies were used at the 
following concentrations: 
rabbit anti-mGluR2/3 1:75
rabbit anti-TGF-pl 1:100
rabbit anti-TGF-(32 1:400
mouse anti-APP 1:50
All staining was carried out as described in section 2.5.1. Staining for the amyloid 
precursor protein (APP) did not require enzymatic treatment. Antigen unmasking for 
mGluR2/3, TG F-pl and TGF-|32 proteins required 0.4% pepsin treatment. Following
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immunohistochemical labelling, all stained sections were cleared in histoclear and mounted 
using synthetic mounting medium, DPX. The slides were left to dry for 24 hours at room 
temperature before analysis under the microscope.
Subsequent quantification of the stained material was carried out using two different 
approaches. The APP stained coronal rat brain sections were analysed according to the 
semi-quantitative method of Yam et al., (1998b). This method makes use of an arbitrary 
scoring system from 1-3. Thus, a score of one would indicate a low level of APP 
accumulation, a score of two intermediate/moderate level o f  APP accumulation, while a 
score of three reflects the greatest level of APP accumulation. The remaining material for 
the other protein markers were analysed by counting the number of cells stained selectively 
with the antibody within a 1 cm2 counting grid. Figure 6.1 illustrates the method by which 
this was carried out. By reference back to the line diagrams generated for the quantification 
of the volume of ischaemia, the boundary of the lesion, i.e. border of dead or alive cells, 
could be ascertained. Once the boundary of the lesion was located, using the corpus 
callosum as an anatomical landmark, the grid counter was placed in such a manner so that it 
was aligned parallel with the border of the ischaemic damage. Four separate areas were 
counted; outwith the boundary of the ischaemic lesion, and then three consecutive adjacent 
areas progressing further into the ischaemic lesion. The cell counts were carried out three 
times and performed in a blinded fashion. The data were analysed at each level for statistical 
significance using two-tailed unpaired Student’s /-test.
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Figure 6.1 Analysis of immunohistochemical labelling of TGF(3-1, TGF(3-2 and 
mGluR2/3 for cell counting
Schematic representation o f the brain areas analysed for staining with immunohistochemical 
markers. The 1 cm2 grid used corresponds to an area o f 0.5 mm2 as a result o f the 
magnification o f the section.
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6.3 Results
6.3.1 Effect of LY379268 on the size of the ischaemic lesion
All animals were again less active during the first few hours of recovery compared 
with their behaviour prior to the surgical procedure. Very little movement or signs of 
inquisitive behaviour were exhibited. However, by approximately 3-4 hours after MCA 
occlusion (coinciding with the second administration of the drug), marked changes in the 
general behaviour of LY379268 (lOmg/kg) treated animals were noted. It was apparent that 
some of the animals (drug and vehicle treated) were experiencing a slight discomfort at 
having another s.c. injection, for example, moving around the cage and whimpering. 
LY379268 (lOmg/kg) treated animals appeared to be especially hypersensitive to tactile and 
auditory stimuli and were very jumpy. By the next morning, the behaviour of all the animals 
were similar; they had taken soft diet, and they all exhibited signs of inquisitiveness. 
Important physiological parameters known to directly affect the variability in outcome were 
monitored. The values for these parameters are presented in table 6.1. No significant 
changes were identified in any of the parameters measured before or after the ischaemic 
insult (two-tailed paired Student’s f-test). None of the animals exhibited any adverse signs 
of suffering, and the mortality rate was zero.
From the H & E stained sections of the rat brain, ischaemic damage was apparent 
within the territory supplied by the occluded MCA. The histopathological appearance 
between ischaemic brain tissue in animals treated with LY379268 and vehicle were 
indistinguishable, with a relatively even proportion of small and large areas of ischaemic 
damage. The effects on LY379268 on infarct volume are presented in table 6.2. A typical 
lesion produced by permanent occlusion of the MCA in this study is illustrated in figure 6.2 
(for an actual H & E section, see appendix 6). At 24 hours after MCA occlusion, figure 6.3 
illustrates that there were no significant decreases in infarct volume following treatment of
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LY379268 (10 mg/kg). The distribution of the areas of ischaemic damage are also 
presented in figure 6.4.
6.3.2 Analysis of immunohistochemical labelling
A P P
APP-specific staining was localised selectively at the borders of the ischaemic lesion 
in the subcortical white matter and in the myelinated fibre tracts within the caudate nucleus. 
Background non-specific staining was not evident in either the contralateral hemisphere or 
ipsilateral cortex. Varying levels of APP accumulation were seen in the animals and none of 
the animals displayed an absence of APP accumulation. The scores allocated to each of the 
animals (vehicle and LY379268 treatment) at the stereotaxic level of the septal/caudate 
nuclei are presented in table 6.3. It is clear that both treatment groups exhibit varying levels 
of APP accumulation and there is no separation between high and low scores of APP 
accumulation between the two groups. Examples of low (score of 1), moderate (score of 2) 
and high (score of 3) levels of APP accumulation are presented in figures 6.5-6.6. In 
addition, figure 6.7 illustrates that there is no correlation between APP accumulation and 
the volume of ischaemia.
F r a g m e n t  e n d  l a b e l l i n g  o f  D N A
The immunohistochemical labelling of nucleosomal DNA fragments with terminal 
deoxynucleotidyl transferase (TdT) produced highly selective staining seen only in the 
region of the ischaemic lesion. Very little or no staining was evident in the contralateral 
hemisphere. Both the vehicle treated control group and the LY379268 treated group 
displayed a general increase in the number of labelled cells with increasing progression into
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Table 6.1 Physiological variables monitored before and after MCA occlusion.
PARAMETER VEHICLE LY379268
before surgery after surgery before surgery after surgery
Body temperature 37 ±0.1 38 ±0.2 37 ±0.1 38 ±0.1
Brain temperature 36 ±0.1 37 ± 0.2 36 ±0.3 36 ±0.3
MABP 105 ± 2.7 94 ±2.8 100 ±3.4 97 ±1.6
Plasma glucose 12 ±0.9 10 ± 0.2 10 ±0.4 9 ±0.32
pC02 37 ±0.7 37 ±0.7 36 ±0.8 36 ±1 .0
p0 2 155 ±4.8 154 ±5.3 161 ±3.7 155 ± 4.0
pH 7.5 ±0.01 7.5 ±0.01 7.5 ±0.00 7.5 ±0.01
Number of animals 10 10
Data are presented as mean values ± SEM.
There were no significant differences between parameters measured before or after the 
ischaemic insult in LY379268 treated animals or vehicle treated controls (Student’s paired 
r-test).
Table 6.2 LY379268 and the volume of ischaemic damage (mm3) following
permanent MCA occlusion.
VOLUME (mm3) VEHICLE LY379268 (lOmg/kg)
Infarct:
Hemispheric 101 ± 8 97 ±11
Cortex 68 ± 8 63 ± 9
Caudate 26 ±0.5 27 ± 1
Number of animals 9 9
The data are presented as mean ± SEM (mm3). LY379268 (lOmg/kg) or vehicle (saline) 
were administered by 2 s.c. injections 30 minutes before and 3 hours after the MCA 
occlusion. There were no significant differences in volume of infarct between vehicle or 
LY379268 treated animals (Student’s unpaired r-test). Only 9 animals from each group 
were available for analysis due to cutting artefacts.
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Figure 6.2 Focal ischaemic lesion.
A representative rat brain illustrating the distribution of the ischaemic damage produced 
24 hours after the permanent occlusion of the MCA. The histopathological assessment 
of damage is mapped at the 8 stereotaxic levels, with the damaged areas highlighted in 
black.
150-i
0 - 1-------------------------------------------------------------------
vehicle LY379268 
LY379268 (mg/kg)
Figure 6.3 Volumes of infarction.
Areas of infarct were measured directly from the line diagrams of the stereotaxic levels from 
anterior 10.5 mm to posterior 1.02 mm. Areas were then calculated to take into account the 
magnification factor of the diagrams. Volumes of ischaemic damage were obtained by 
integrating each of the calculated areas with the known stereotaxic co-ordinates of the level. 
The data are presented as a scatter plot, each point representing an individual animal with 
the mean value presented as a horizontal bar. There were no differences in infarct volume 
between vehicle and the LY379268 treated group (Student’s unpaired f-test)
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Table 6.3 APP accumulation and volumes of ischaemic damage.
GROUP APP SCORE VOLUME OF ISCHAEMIC DAMAGE (mm3)
hemisphere cortex caudate
Vehicle 2 ±0.26 100.5 ± 8.0 67.9 ± 7.5 25.9 ±0.5
LY379268 1.7 ±0.26 97.3 ± 10.8 63.0 ±9.4 27.0 ±0.9
number of animals 10 9 9 9
Summary table of APP score at one stereotaxic level (anterior 7.19 mm) and volumes of 
ischaemic damage in vehicle and LY379268 treated groups.
Data are presented as mean values ± SEM.
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Figure 6.5 APP immunoreactivity: method of scoring.
Representative examples (x200) of a) low level of APP accumulation - allocated score 
of 1; b) moderate APP accumulation - score of 2; c) dense APP accumulation - score 
of 3.
Figure 6.6 APP immunoreactivity: method of scoring.
Representative examples (x400) of a) low level of APP scoring; b) moderate APP 
accumulation; c) dense APP accumulation.
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o •#  o
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Infarct volume (mm3)
•  vehicle
o  LY379268 (10 mg/kg)
Figure 6.7 No relationship between the volume of infarction (mm3) and the level of 
APP accumulation in vehicle and LY379268 treated animals.
APP scoring was only taken at one stereotaxic level (anterior 7.19 mm). The solid line 
corresponds to vehicle treated control group, while the dashed line corresponds to the 
LY379268 treatment group.
178
the ischaemic tissue (table 6.4). Cell counts taken outwith the border of the ischaemia show 
an apparent reduction in the number of positively labelled cells following LY379268. This 
reduction just failed to reach statistical significance (t = 1.763). However, at the boundary 
and at the core of the ischaemic lesion, significant reductions in the number of TdT labelled 
cells were demonstrated. At the boundary of the lesion, LY379268 treated animals 
displayed a 41% reduction in TdT labelled cells, while at the core a 28% reduction in 
labelled cells was seen. Figure 6.8 illustrates representative TdT labelled sections at the 
boundary and core of the lesion.
T G F - p i
Immunohistochemical labelling for TGF-pi produced widespread staining 
throughout the tissue. Cells were also counted in the contralateral hemisphere in one area 
that approximated to the boundary of the ischaemic tissue in the ipsilateral hemisphere. This 
area was included in order to gauge the level of TGF-pl-positive cells present in 
undamaged tissue (previous histology for the quantification of infarct volume confirmed that 
the morphology cells in the contralateral hemisphere to be undamaged) and therefore act as 
an internal control. Table 6.4 shows that there were no differences in the number of TGF- 
pl-positive cells between the vehicle treated control and LY379268 treated groups in the 
contralateral hemisphere. No differences in the number of immunoreactive cells were seen 
between counts taken in the area outwith the boundary of the ischaemia and the 
contralateral hemisphere. Both treatment groups also display a general reduction in the 
number of cells positively stained for TGF-pl, with increasing progression into the 
ischaemic tissue. Animals treated with LY3 79268 appear to contain marginally less stained 
cells than the vehicle treated controls (not statistically significant). Cell counts taken within
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the core of the infarct show that the number of TGF-pi-positive cells following LY379268 
was significantly reduced (-18%).
TGF-P2
TGF-02 immunoreactivity was evident throughout both hemispheres. Again, TGF- 
p2-positive cells in the contralateral hemisphere were counted at a level approximating the 
boundary of the ischaemic lesion. Table 6.4 shows that no differences were observed in the 
number of immunoreactive cells on the contralateral hemisphere. However, in the ipsilateral 
hemisphere, cell counts taken outwith the boundary of ischaemic damage revealed TGF-p2 
immunoreactivity to be increased by 25% following LY379268 treatment (just failed to 
reach statistical significance). With both the vehicle treated controls and the LY379268 
treated groups, the number of TGF-p2-positive cells decreased with further progression 
into the area of ischaemic tissue. In addition, tissue from LY379268 treated animals showed 
higher counts of immunoreactivity than vehicle treated controls. TGF-P2 immunoreactivity 
is presented in figure 6.9.
mGluR2/3
Immunohistochemical labelling for mGluR2 and mGluR3 in this study showed 
widespread immunoreactivity throughout both hemispheres. The number of immunoreactive 
cells in the contralateral hemisphere did not differ significantly in either the vehicle treated 
or LY379268 treated groups. Also, numbers of mGluR2/3-immunoreactive cells in the 
ipsilateral hemisphere outwith the boundary of the ischaemia were not significantly altered 
from the counts obtained from the contralateral hemisphere. In contrast to the results 
obtained with fragment end labelling of DNA and TGFP-1 and -2 immunoreactivity, cell 
counts of immunoreactivity taken within the area of ischaemic damage did not differ
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Figure 6.8 Fragment end labelling of DNA by TdT: reduction in the number of 
immunoreactive cells.
Representative photographs (x200) illustrating the changes in cell immunoreactivity 
a) the boundary of the ischaemic lesion and b) the core of the lesion. Contralateral 
staining is also illustrated c).
Figure 6.9 Cell immunoreactivity for TGF-(32 : alterations in the number of 
immunoreactive cells.
Representative photographs illustrating the changes in cell immunoreactivity a) outwith 
the ischaemic lesion and b) at the core of the lesion, c) represents TGF-(32 
immunoreactivity in the contralateral hemisphere.
Figure 6.10 mGluR2/3 immunoreactivity.
Representative photographs showing immunoreactivity in the a) contralateral hemisphere 
and b) ipsilateral hemisphere following 24 hour permanent focal ischaemia. Note the 
less intense staining of the ipsilateral hemisphere.
markedly from the contralateral hemisphere (table 6.4) following either vehicle or 
LY379268 treatment. Although the number of positively stained cells did not differ, 
mGluR2/3 immunoreactivity appeared more faint in the ischaemic ipsilateral hemisphere 
than the non-ischaemic contralateral hemisphere (figure 6 .10).
6.4 Summary and technical considerations
From a histological neuroprotection viewpoint, LY379268 (lOmg/kg) failed to 
reduce ischaemic damage in the brain following 24 hour permanent MCA occlusion model 
of cerebral ischaemia. Again, questions that address the adequacy of the dosing regimen 
must be answered. At lOmg/kg (s.c.), LY379268 has been demonstrated to provide 
effective brain levels for the activation of mGluR2 and mGluR3 for greater than 3 hours 
(Dr. D. Schoepp, personal communication - see chapter 8, figure 8.1). Also, the results 
from autoradiographic studies in chapter 3 clearly demonstrate that LY3 79268, at the same 
dose, was able to effect selective changes in brain function. Post hoc power calculations 
indicated that for this study, the sample sizes used and the variance would have been 
capable of detecting changes of approximately 20% (a=5%, P=80%). Consequently, it is 
unlikely that the inability of LY379268 to reduce tissue damage can be attributed to the 
dosing regimen, or inadequate power of the study.
Although the use of histological endpoints alone has not provided any evidence to 
suggest that LY379268 is neuroprotective (reduction in volume of ischaemia) in this rat 
model of permanent focal ischaemia, the use of immunohistochemical markers in this study 
may hint at the neuroprotective effects of LY379268, as analysis of the tissue resulted in 
some interesting data. In this study, 24 hour permanent focal cerebral ischaemia has 
revealed that the number of TGFP-1 immunoreactive cells in the ipsilateral hemisphere in 
both groups is similar to that seen in undamaged contralateral hemisphere, and following
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LY379268, a significant reduction in the number of immunoreactive cells is observed in the 
core of the damaged tissue. In contrast, treatment with LY3 79268 resulted in an apparent 
increase in the number of cells displaying TGF0-2 immunoreactivity in a circumscribed area 
just outwith the boundary of the ischaemia. This increase in the number of immunoreactive 
cells is not seen in any of the other areas investigated. The data obtained from fragment end 
labelling of DNA with the TdT enzyme also displayed significant changes in the number of 
immunoreactive cells in the drug treated groups. LY3 79268 treated animals showed marked 
reductions in the number of positive TdT stained cells in and around the boundary of the 
ischaemic lesion, with reductions also evident in the core. Staining for immunoreactive 
mGluR2/3 cells in this study demonstrated that there are no changes in the number of 
immunoreactive cells, but there may be a reduction in the intensity of the stain in 
immunoreactive mGluR2/3 cells.
The method of analysis used in this study differed from that used for the 
quantification of ischaemic damage described in chapter 5 with LY3 54740. Because of the 
study’s requirements for immunohistochemical analysis of the tissue, the brain material had 
to be fixed and paraffin embedded. This however, raises problems such as shrinkage of 
tissue as a result of fixation and the subsequent re-hydration of the tissue, all processes that 
are uncontrollable and inconsistent (Stowell, 1941). Such changes were clearly evident in 
the brain tissue used in this study, and are discussed further in appendix 6 . Therefore, the 
method used to measure infarct size excludes the contribution of swelling that could lead to 
an overestimation of the size of the lesion (Osborne et al., 1987). This method requires the 
delineation of the area of ischaemia at the pre-determined levels which is then transcribed 
onto coronal scale diagrams (4x actual size) drawn from the atlas of Konig & Klippel 
(1963).
186
The method by which APP accumulation was assessed was straightforward but not 
without its limitations. A major problem is the narrow range of the scoring system from 1 to 
3 which places constraints upon the staining observed. For example APP accumulation 
could have been seen diffusely but extensively along the boundary of the ischaemia, and may 
have been allocated a low score compared to a dense accumulation of APP in circumscribed 
zones along the boundary. In addition, because only one level was assessed in this instance, 
a maximum score of 3 is only possible in each group. Although analysis of all 8 levels may 
have provided more insight into the distribution of APP, the limitation associated with the 
fixed maximum score still holds true. In theory, one could arbitrarily produce a scoring 
system ranging from 1-5 or 1-10 etc. to assess levels of staining. However, this would 
introduce the added problem of subjectivity and reproducibility; the use of scores from 1-3 
limits this problem and the method is reproducible. In addition, the small variance in lesion 
sizes in rats and the small number of levels assessed makes the separation of APP scores 
between different treatment groups difficult. This has led to the development of APP 
quantification using stereological methods (Yam et al., in preparation). This involves using 
a transparent fine, regular square array point-grid system. The grid is placed over an image 
of the section and the number of points overlying areas of APP immunoreactivity are 
counted. The advantage of this technique is that it is totally quantitative and sensitive. The 
authors were able to measure APP scores between coronal levels ranging from 1-177.
The use of immunohistochemistry is notoriously subjective, and unless the 
immunoreactive response is very selective and intense, changes in staining are difficult to 
discern objectively. Therefore whether the difference between the intensity of mGluR2/3 
staining observed in ischaemic tissue following LY379268 compared with vehicle treated 
controls is a ‘real’ observation is not known. However, the staining pattern observed should 
not be interpreted purely on face value. It is known that immunohistochemical staining
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carried out at in different batches at different times will produce variable responses in the 
intensity of staining depending on the length of time the tissue has been exposed to the 
chromogen. Thus, interpretation of such data is always carried out in blocks so that tissue 
samples stained at the same time are also analysed together. Needless to say, within any 
batch of tissue stained, one cannot definitively say that each sample was exposed to the 
chromogen for exactly the same time. An interesting study to carry out would be to use 
Western blotting analysis to compare the levels of the mGluR2/3 protein in ischaemic tissue 
from vehicle and LY379268 treated animals.
The results of this study are discussed in detail in chapter 8, section 8.4.
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CHAPTER 7
PROTECTIVE MECHANISMS OF LY354740 & LY379268 
FOLLOWING IN VITRO NEUROTOXICITY?
7.1 Introduction
In vivo neuroprotection studies are limited in one respect in that they provide, on the 
whole, observational data. Thus, the in vivo studies carried out in chapters 5 and 6 
demonstrated that the administration of LY3 54740 and LY3 79268 were not capable of 
reducing the size of the ischaemic lesion. In vitro models of cerebral ischaemia may provide 
valuable information about the cellular mechanisms of injury not possible in vivo. For 
example, the systems allow the possibility of selecting the type of cells cultured (e.g. 
neurone enriched cultures, astrocytes, oligodendrocytes, endothelial cells), and also cells 
from specific brain regions. Cell culture systems have been used extensively, and recent 
work has shown that the activation of group II or group III metabotropic receptors is 
neuroprotective against a variety of insults such as NMD A-induced excitotoxicity (Bruno et 
al., 1994, 1995a; Buisson et al., 1996), hypoxia/hypoglycaemia (Buisson & Choi, 1995), 
nitric oxide (Maiese et al., 1995) and staurosporine (Koh et al., 1994).
The aims of this study were to assess the neuroprotective actions of LY3 54740 and 
LY3 79268 in in vitro models of neuronal cell death. By using different models of 
neurotoxicity together with Western blot analysis of astrocyte cultures to investigate the 
production of neurotrophic factors, the issues of the possible protective mechanisms of 
LY3 54740 and LY3 79268 were addressed. Neurotoxicity was induced by the deprivation 
of glucose and oxygen, and by the application of staurosporine.
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7.2 Methods
Part of the work described in this chapter (neurotoxicity studies) was carried out 
over 8 weeks at Eli Lilly, Windlesham, Surrey. The neurotoxicity studies described use both 
staurosporine and hypoxia/hypoglycaemia models of cell death, neither of which were in use 
at the laboratories at Eli Lilly. Therefore, initial experiments were carried out in order to 
optimise the conditions for neurotoxicity. However, because of time constraints, only a 
limited number of experiments could be carried out. So, although the majority of the 
experiments carried out in this study were performed by myself, Dr. Ann Kingston (Eli 
Lilly), kindly agreed to generate additional material on the basis of the initial optimisation 
experiments. These results are included in this chapter.
7.2.1 Cell culture
Neurone-enriched cultures
Neurone-enriched cultures were prepared from embryonic rat neocortex according 
to the method of Rose et al. (1993). Briefly, neocortices from embryonic rats at day 18 of 
gestation were dissociated using trypsin and mechanical disruption. Cells were plated in 
Neurobasal medium (containing 10% heat inactivated FCS and glutamine lmM) and plated 
in 15mm 24 well plates previously treated with poly-D-lysine, at a density of 3 x 105 cells 
per well and kept at 37°C in a humidified 5% CO2 atmosphere. Non-neuronal cell division 
was halted after 2 days in culture, by exposure to cytosine arabinoside (5pm) for 3 days. 
The medium was part-replaced at 3-5 day intervals and the cells used after 10-14 days in 
culture.
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Pure astrocyte cultures
Astrocytes were cultured from the cortices of day 0-3 rat neonates as described in 
chapter 2, section 2.4.1. Cortices were enzymatically and mechanically dissociated and cells 
were plated down in DMEM containing 20% FCS and ImM glutamine at a final density of
1.5 x 106 cells/ml (2 x 105 cells/cm2) into 75 cm2 flasks (total volume lOmls). The medium 
was exchanged after 3 days (DMEM with 10% FCS) and subsequent changes made twice a 
week. Once the cells reached confluence after 10-12 days in culture, they were purified 
according to the method of McCarthy & de Vellis (1980). Experiments were performed on 
cultures after 21 days in vitro.
Mixed neuronal-astrocyte cortical cultures
Mixed cultures of neurones and astrocytes were obtained by plating the neocortical 
cell suspension on a previously established monolayer of type I cortical astrocytes 
(established in vitro for 2 weeks). Astrocytes were prepared and maintained as above and 
plated at a final density of 15 x 104 cells/well into poly-D-lysine treated 24 well plates. 
Dissociated cortical neuronal cells were then added (3 x 105 cells/well) directly onto the 
astrocytes and treated with cytosine arabinoside from day 0 of culture. Cultures were again 
used after 10-14 days in vitro (with respect to neuronal cultures).
7.2.2 Induction of staurosporine-induced neurotoxicity
For staurosporine-induced neurotoxicity, cells were incubated with Neurobasal 
medium (serum and glucose free with 1% HEPES, 1% glutamine and 10pM glycine) and 
staurosporine for 24 hours. Supernatants from the cultures were then collected for the 
assessment of neurotoxicity. The data were analysed for statistical significance using two- 
tailed Student’s t-test.
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7.2.3 Glucose and oxygen deprivation
Glucose and oxygen deprivation was induced in 24 well cultures by incubating the 
cultures in deoxygenated balanced salt solution (glucose free) containing 1% HEPES in a 
5% 02/5% CO2 environment. Following the incubation, the medium was exchanged with 
serum free Neurobasal medium and incubated in a 5% CC>2/90% air atmosphere for the 
remainder of the 24 hour incubation before the evaluation of cell damage and death. The 
data were not analysed for statistical significance because of the small number of 
experiments carried out.
7.2.4 Drug administration
LY354740 and LY379268 were prepared as 0.1M stock solutions in 0.1M NaOH. 
Working concentrations of the two agonists were prepared at 100X the final concentration 
just before use at various doses. Treatment of the cultures used in the different models of 
neurotoxicity are described below.
Staurosporine induced neurotoxicity: Cells were pre-incubated with LY3 54740 or
LY379268 for 15 minutes before the addition of staurosporine to the cultures.
Glucose and oxygen deprivation: LY3 54740 and LY3 79268 were added to the
cultures for the duration of the insult and additionally for the post-insult normoxic 
incubation.
7.2.5 Assessment of neuronal cell injury
Lactate dehydrogenase efflux assay
Cell death was assessed 24 hours after the insults using the measurement of lactate 
dehydrogenase (LDH) release from damaged or dead cells. Supernatants were harvested
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from the cultures in duplicate (see chapter 2, section 2.6.1), and LDH was measured using a 
spectrophotometric assay (Cytotoxicity detection kit, Boehringer-Mannheim).
DNA fragmentation
DNA fragmentation was quantified by using an immunoassay kit for measurement of 
mono- and oligo-nucleosome formation (Calbiochem/Novabiochem). The protocol is 
described in detail in chapter 2, section 2 .6 .2 .
7.2.6 Characterisation of astrocytes by immunofluorescence and Western blot
analysis
Astrocytes cultured in 75cm2 flasks were incubated with LY354740 or LY379268 
overnight. Following the incubation, the drugs were washed out, the media replaced with 
fresh DMEM (high glucose) and incubated for the remainder of 24 hours. The cells were 
harvested in lysis buffer (appendix 2) and the medium from each flask was collected and 
concentrated into a smaller volume (refer to section 2.7). All the samples were homogenised 
and loaded onto gels (25pg/lane). Proteins were separated on 8% SDS-PAGE overnight at 
11mA. Proteins were then transferred to PVDF membranes and incubated with 5% Marvel 
in TBS-T for 1 hour. Membranes were incubated overnight with a primary antibody. On the 
basis of the results in chapter 6, antibodies used in this study were: 
mouse Anti-GFAP, 1:30 000 
rabbit Anti-mGluR2/3, 1:1000 
goat Anti-TGF~P2, 1:500
All the primary antibodies had been previously titrated at a variety of dilutions to obtain the 
optimised working solution. Following incubation with the appropriate horseradish 
peroxidase conjugated secondary antibody (Promega peroxidase coupled anti-mouse and
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anti-rabbit IgGs were used at 1:5000; Vector peroxidase coupled anti-goat IgG was used at 
1:1000) for 1 hour, detection was performed using ECL. Depending on the amount of 
target protein on the membrane, exposure of the membrane to the autoradiography film 
varied from 15 seconds to 1 hour. In this study, the membranes labelled for the different 
proteins were exposed to the film for:
GFAP - 15 seconds 
mGluR2/3 - 1 hour 
TGF-P2 - 15 seconds
For the detection of the remaining antibodies, the PVDF membranes were stripped of the 
bound antibodies and reprobed according to the method described in section 2.7.
As glial cultures had never been cultured before in our laboratory, astrocytes were 
characterised and assessed for their purity by immunofluorescence. Astrocytes were fixed 
and permeabilised using 4% paraformaldehyde followed by incubation with -20°C methanol. 
Cells were washed, blocked with serum and BSA, and incubated with the primary antibody 
overnight at 4°C. Cells were washed three times and the secondary antibody was added 
(Vector fluorescein- or Texas red- conjugated secondary antibodies were used at 1:100) 
and incubated for 1 hour in the dark. The coverslips were rinsed in PBS and water and 
mounted onto microscope slides using an aqueous polyvinyl alcohol-based mountant.
7.3 Results
7.3.1 Establishing staurosporine-induced neurotoxicity
Initial experiments were carried out to assess the optimal dose of staurosporine to 
be used to cause neuronal death. Staurosporine (5pl) was added to neurone-enriched 
cultures in log-doses ranging from lOnM to lOpM for 24 hours. Control groups were given 
5pi of the culture medium. Supernatants were removed for quantification of LDH levels
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Figure 7.1 Assessment of neuronal cell injury.
Neuronal cell death was assessed by measuring levels of LDH efflux. Cell viability 
can also be visualised with fluorescent techniques, (a) control neuronal cultures, and 
(b) non-viable neurones following an excitotoxic insult of NMDA. The green 
fluorescence (fluorescein) denotes viable cells. Fluorescein diacetate is taken up into 
healthy cells and becomes hydrolysed by esterases to generate free fluorescein. The 
red fluorescence corresponds to propidium iodide staining of DNA in dead cells. Note 
the substantial increase in propidium iodide staining in cells treated with NMDA.
(Courtesy o f  D r  Ann Kingston; Eli Lilly)
control 0.01 0.1 1.0 10.0
Staurosporine (pM)
Figure 7.2a. Effect of staurosporine on LDH release.
Staurosporine-induced neurotoxicity was induced in cortical neurone-enriched cultures (12 
days in culture) at a variety of doses for 24 hours. Results represent the LDH release in OD 
units (mean ± SEM of 1 experiment using quadruplicate culture replication). Maximal LDH 
release were similarly demonstrated by 1 and lOpM staurosporine.
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Figure 7.2b Neuroprotective effects of LY379268 on staurosporine-induced 
neurotoxicity.
LY379268 is effective at reducing LDH release in staurosporine treated cultures (lpM). 
LY3 79268 was added to the cultures and incubated for 15 minutes prior to the addition of 
staurosporine to the cultures. Results represent the % reduction in LDH release (mean ± 
SEM of 3 experiments using quadruplicate culture replication).
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Table 7.1 LY354740 and LY379268 protect against staurosporine-induced LDH
release.
COMPOUND % NEUROPROTECTION AGAINST
(lfiM) STAUROSPORINE TREATMENT
LY354740 -I- g ***
LY379268 60 ± 4  ***
E l8 cortical neuronal cells (days in vitro =12) were pre-incubated with the agonists for 15 
minutes prior to the addition of staurosporine (l|uM). Cultures were incubated for 24 hours 
before the assessment of neuronal damage by measurement of LDH release from cells. 
Results represent % reduction in LDH release (mean ± SEM of 3-4 experiments using 
quadruplicate culture replication.
***p<0 ooi for statistical comparison between agonist and staurosporine treated cultures 
(two-tailed Student’s unpaired /-test).
% Neuroprotection = 100 X [1 - (OD test - OD control)/OD staurosporine treated - OD 
control)]
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released from the cells (fluorescent visualisation of damaged neurones following an 
excitotoxic insult is shown in figure 7.1). LDH release into the culture medium was seen to 
increase with an increasing dose of staurosporine (figure 7.2a). Staurosporine had little 
effect at 10 and lOOnM, with LDH release at levels comparable with control groups. At the 
highest doses of staurosporine, LDH release was twice that seen in control cultures. As 
minimal differences in LDH response were observed between lpM  and 10pM 
staurosporine, lpM  staurosporine was chosen for all the subsequent neurotoxicity 
experiments.
7.3.2 Effects of LY354740 and LY379268 on staurosporine-induced neurotoxicity
Figure 7.2b presents the effects of various doses of LY379268 (log-doses from 
lOnM to lOpM) on lpM  staurosporine induced LDH release from enriched cortical 
neuronal cultures. It is clear that with an increasing dose of LY3 79268, the greater the 
reduction in neuronal toxicity. A maximum 70% reduction in LDH release was seen 
following lOpM LY379268. From these results, the near-maximal dose of lpM  was chosen 
for subsequent studies. A dose of lpM  was also chosen for LY3 54740 on the basisof 
previous studies with NMDA excitotoxicity in which LY3 54740 demonstrated a similar 
profile of neuroprotection to LY379268 (Kingston et al., in press).
In rat cortical neuronal cultures (days in vitro = 12), LY354740 and LY379268 (1 
pM) significantly reduced neuronal toxicity against cell damage and death, as measured by 
LDH efflux, caused by staurosporine (1 pM). Table 7.1 shows that both agonists can 
protect against staurosporine-induced neurotoxicity with similar potencies of effects.
Preliminary experiments investigating DNA fragmentation was also assessed in 
cultures following exposure to staurosporine-induced neurotoxicity. Due to lack of time, 
the results shown below were assessed in neuronal cultures used for an optimisation
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experiment, which accounts for the difference in the dose of staurosporine used and the time 
of incubation. The results on nucleosome formation are shown in table 7.2. Both LY3 54740 
and LY379268 demonstrated reductions in the production of DNA fragmentation in the 
mixed glial-neuronal cultures. The percentage reductions of nucleosome formation were 
32% and 50% for LY379268 and LY354740, respectively. However, these results were not 
statistically significant. No substantial changes in nucleosome formation were noted in 
neurone-enriched cultures. However, it should be noted that prior to staurosporine 
treatment, the neurone-enriched cultures did not appear entirely healthy morphologically. 
The cells did not plate down well during the initial culture and the resulting density of the 
neurones appeared very low compared with normal cultures. This finding is perhaps 
reflected in the increased nucleosome formation in the control cultures of neuronal cultures 
compared to the low level seen in the mixed glia-neuronal cultures.
7.3.3 Establishing glucose and oxygen deprivation
Initial experiments were carried out to determine the time required to cause neuronal 
death following glucose/oxygen deprivation. Cultures were exposed to a glucose/oxygen- 
deprived environment for 1 hour and 6 hours. Following the incubation in HBSS, the 
culture medium was replaced with Neurobasal medium for the remainder of the24 hours. 
The next set of experiments used the same time points, but in order to remove any dissolved 
oxygen in the medium prior to incubation in the 5% O2 incubator, the medium was 
ultrasonicated for 10 minutes followed by direct gassing with N2 for at least an hour. The 
resulting measurements of LDH are presented in figure 7.3. These results indicate that 
neuronal cell death is greatly enhanced following a 6 hour insult compared with a 1 hour 
insult. Also, the physical removal of dissolved O2 from the medium prior to the insult 
further increased the neurotoxicity of the insult. Additional experiments were carried out in
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mixed glial-neuronal cultures using N2-gassed PBS Dulbecco’s balanced salt solution, as it 
was noticed that the HBSS contained a low level of glucose (1000mg/l). Figure 7.3 shows 
that there appears to be no difference between cultures exposed to glucose/oxygen 
deprivation in HBSS or PBS Dulbecco’s at 6 hours. However, this data should be 
interpreted with caution because of the different types of cultures used. Unfortunately, 
neurone-enriched cultures exposed to glucose/oxygen deprivation in PBS Dulbecco’s 
medium were not carried out due to the poor nature of the cultures obtained.
Experiments investigating the neuroprotective effects of LY3 54740 following 
glucose/oxygen deprivation were not carried out due to the lack of time. The 
neuroprotective effects of LY379268 on glucose and oxygen deprived cultures were tested 
only at each of the time points used for the glucose/oxygen time deprivation course 
investigation. Unfortunately, LY3 54740 was not assessed. The results are presented in table 
7.3. These preliminary data suggest that LY379268 may reduce LDH release from cultures 
subjected to glucose/oxygen deprivation of 6 hours. Without considering the background 
LDH release expected from normal neuronal cultures, a maximal 25% reduction in LDH 
release was measured in cultures exposed to a 6 hour insult.
7.3.4 Characterisation and purity of astrocytes cultures
Using the most commonly used and widely accepted marker for astroglia, glial 
fibrillary acidic protein (monoclonal anti-GFAP, 1:15 000), cells cultured from the cortices 
of day 0-3 neonates were established as astroglia (figure 7.4). In addition to the expression 
of GFAP, morphologically they appeared to represent type 1 astrocytes as defined by their 
irregular morphology with one or more thick processes. This contrasts to type 2 astroglia 
which are defined as process-bearing, like neurones. This was further established through 
the use of the monoclonal antibody A2B5, which distinguishes between the two types of
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astroglia. Figure 7.6 illustrates that the astrocytes cultured in this study were GFAP positive 
and A2B5 negative, indicative of cerebral type 1 astrocytes. Astrocytes were also assessed 
for the presence of mGluR2/3 (1:75) using double-labelling immunofluorescence. A low 
level of autofluorescence was seen, but no detectable mGluR2/3-specific fluorescence was 
observed in the cultured cells.
The purity of the astrocytes was assessed by labelling the cells for markers of other 
contaminating cell types commonly seen. Cultures were labelled against two other cell 
markers, ox42 (1:1000) for the presence of microglia, and galactocerebroside (1:200) for 
the presence of oligodendrocytes. As figures 7.5 and 7.6 show, cultures were composed 
primarily of astrocytes, with no detectable presence of oligodendrocytes and only a small 
proportion of microglial contamination. Astrocytes were not counted to assess the % purity 
of the cultures, as the purification step via the shaking procedure eliminated the majority of 
the contaminating cell types. However, it has been previously documented that microglia 
may represent up to 5% of the total cells in purified cultures of astrocytes (Giulian & Baker, 
1986).
7.3.5 Expression of TGF-P in astrocytes following treatment with Group II mGluR
agonists
Astrocytes previously treated with LY3 54740 or LY3 79268 at doses of 1 pM and 
10 fj.M were used for Western blot analysis. Protein extracts from treated astrocyte cultures 
together with their supernatants were characterised initially with an antibody against GFAP 
and mGluR2/3. Figure 7.7 illustrates that an intense 50kDa band corresponding to GFAP 
was detected at a high level in all the cellular protein extracts, confirming the identity of the 
cultures. As expected, no GFAP stained bands were seen to be expressed in the culture 
medium of the corresponding cell extracts. In agreement with the immunofluorescence
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Figure 7.4 Characterisation of primary astrocyte cultures.
Representative photographs of astrocyte cultures (3 weeks in culture) immunolabelled 
with a monoclonal antibody against GFAP, 1:15000 (a) x200 magnification (b) x 400 
magnification. GFAP positive astrocytes visualised using fluorescein.
Figure 7.5 Contamination of astrocytes with other cell types: microglia.
Representative photographs (x400) of astrocyte cultures (polyclonal GFAP, 1:500, 
visualised with texas red), a) antibodies against ox42 stain microglia (fluorescein), but 
do not stain astrocytes, b) simultaneous localisation of astocytes and microglia in primary 
astrocyte cultures.
Figure 7.6 No contam ination of astrocytes with type 2 astrocytes or 
oligodendroglia.
Representative photographs of astrocyte cultures visualised with a polyclonal antibody 
against GFAP together with (a) an antibody against A2B5 selective for type 2 astrocytes 
(b) an antibody against galactocerebroside selective for oligodendrocytes. Only non­
specific autofluorescence can be seen with these two antibodies.
experiments, no protein bands corresponding to mGluR2/3 were detected in any of the 
samples (figure 7.8). The continued presence of the prestained protein standards on the 
membranes demonstrated that this observation was not due to a reduction in protein levels. 
Western blot analysis with an antibody directed against TGF-P2 resulted in the detection of 
a 25kDa band corresponding to the molecular weight of TGF-p2. This signal was easily 
detected both in the cell culture media of the control and drug treated astrocytes and also 
faintly in the astrocytic cellular extract (figure 7.8).
In order to ascertain whether this TGF-P2 response was due to the direct activation 
of mGluR2/3, astrocyte cultures were incubated simultaneously with either the agonists 
LY354740 or LY379268, together with the selective mGluR2/3 antagonist LY341495. 
Figure 7.8 illustrates that despite the absence of a protein band corresponding to mGluR2/3 
in cultured astrocytes treated with mGluR2/3 agonists, the secretion of TGF-P2 into the 
culture medium from astrocytes is abolished following concomitant treatment with the 
selective antagonist LY341495. Therefore, TGF-P2 production and secretion from 
astrocytes is selectively mediated through mGluR2/3. To ensure that the reduction in the 
TGF-p2 signal was not due to the toxic effects of LY341495, the antagonist was also tested 
for neurotoxic effects by measurement of LDH efflux. LDH efflux was measured using the 
method of Wroblewski & La Due (1955). Table 7.4 demonstrates that the doses of 
LY341495 used in this study were not toxic to astrocytes.
7.4 Summary and technical considerations
In vitro model systems provide an environment to examine the mechanisms of 
neuronal injury in a controlled setting without the complex biological processes associated 
with whole animal studies. However, the limitations of in vitro systems are widely 
recognised as the experimentally advantageous simplicity of these systems also reflect their
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Figure 7.7 Western blot analysis with cultured rat cortical astrocytes treated 
with LY354740 and LY379268.
Cells were incubated with either LY354740 or LY379268 overnight. The drugs were 
washed out and the cells returned to the incubator for the remainder of the 24 hour 
incubation. Supernatants from each of the cultures were also concentrated down and 
used to investigate the possible secretion of proteins into the medium from the astrocytes. 
The intense 50KDa protein band which corresponds to the deduced weight of GFAP 
was detected after a very short exposure to autoradiographic film. GFAP is seen 
selectively in the cellular extract, with no detectable signal in the medium.
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Figure 7.8 Western blot analysis with cultured cortical astrocytes; Secretion of 
TGFB2 by astrocytes is an mGluR2/3 mediated event.
a) Protein bands corresponding to mGluR2/3 were not detected in cortical astrocyte 
cultures, b) A 25KDa protein band corresponding to the deduced weight of TGF-(32 
was detected in the culture medium following treatment with the agonists LY354740 
and LY379268. The presence of the TGF-P2 protein band is reduced/abolished following 
the simultaneous incubation with LY341495. This suggest that TGF-(32 secretion results 
from mGluR2 or mGluR3 activation.
Table 7.4 The selective mGluR2/3 antagonist LY341495 is not toxic to astrocytes 
at the doses used.
TREATMENT LDH RELEASE (U/ml)
Control (no treatment) 51.0
LY341495 3pM 47.6
LY341495 lOpM 63.8
LY341495 30pM 55.1
LY341495 lOOpM 26.0
The antagonist LY341495 was incubated with astrocyte cultures for 6 hours at 37°C in a 
5% CCVair atmosphere. Following the incubation, the antagonist was washed out and 
replaced with DMEM. LDH release from cells was measured in the supernatants of the 
cultures 24 hours after the initial incubation.
Results represent the mean LDH released (U/ml) from one experiment carried out in 
triplicate. LDH was calculated using the equation: AA per minute x 20,000 x temperature 
correction factor (1 at 25°C).
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differences from the intact brain. For example, in vitro systems lack most obviously the 
three-dimensional architecture of the intact brain. Other major differences include the 
absence of the cerebral vasculature which has a central role in cerebral function and the 
phenotype of cells removed from embryos and postnatal rats may be different to the adult 
counterparts in the brain in vivo.
In this study, the effects of the group II mGluR agonists LY3 54740 and LY3 79268 
were investigated in two models of neurotoxicity. Staurosporine-induced neuronal death is 
considered to be mediated primarily through the activation of apoptotic pathways (Koh et 
al., 1995). In direct contrast, neuronal cultures subjected to glucose and oxygen deprivation 
are generally considered to die by necrosis (Goldberg et al., 1997). Both LY354740 and 
LY3 79268 were similarly demonstrated to significantly reduce neuronal cell death caused 
by staurosporine and reduced nucleosome formation in mixed neuronal-astrocytic cultures. 
Preliminary experiments investigating the effects of group II mGluR agonists following 
glucose/oxygen deprivation indicate that LY3 79268 at least, may reduce neuronal cell 
death. However, this requires further investigation. Given more time, a comprehensive and 
systematic time-course study on the effects of glucose and oxygen deprivation on neuronal 
LDH release would have been undertaken using neurone-enriched cortical cultures. Once 
the conditions were optimised, a direct comparison could then be made with mixed 
neurOnal-astrocytic cultures.
Characterisation of the glial cultures using GFAP established the cells as astrocytes, 
with little or no contamination with microglia or oligodendrocytes. To investigate the 
presence of group II mGluRs in astrocytes, immunofluorescence and Western blot analysis 
were performed using a commercially available polyclonal antibody against mGluR2/3. 
mGluR2/3-specific fluorescence was not detected in the cultures. In addition Western blot 
analysis of purified cortical astrocyte cultures did not reveal any immunoreactive band in
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protein extracts. This finding has been shown by others (Bruno et al., 1997). They found no 
detection of mGluR2/3 in protein extracts from either rat or mouse cortical astrocytes, 
while mGluR3 mRNA levels were only detectable in cultured rat astrocytes following RT- 
PCR. This suggests that the amount of mGluR2/3 protein expressed by cultured astrocytes 
is below detection level either by Western blot analysis or by immunofluorescence. These 
negative findings in this study also raises the possible issue of lack of specificity of the 
mGluR2/3 antibody. However, the same antibody was used successfully in chapter 6 to 
detect mGluR2/3-immunoreactive cells in rat brain sections using immunohistochemistry. In 
order to determine the use of this antibody in immunofluorescence, the staining procedure 
carried out on the astrocyte cultures was repeated with fresh frozen sections of rat brain 
(fluorescein as fluorochrome). Controls were also generated by omitting the incubation with 
the mGluR2/3 antibody in order to gauge the level of background autofluorescence. 
Differences in fluorescence was observed between the control sections and sections treated 
with the mGluR2/3 antibody. Specifically, the control sections emitted a pale yellow-green 
autofluorescence while treated sections gave a much stronger green signal. The strongest 
signal was noted in the corpus callosum. However, photographs have not been included due 
to the rapid photobleaching of the fluorescence, with the signal fading within seconds. Thus 
it appears likely the levels of mGluR2/3 in astrocyte cultures were below levels detectable 
by immunofluorescence or by Western blot analysis.
The findings from this study are discussed in chapter 8, section 8.4.
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CHAPTER 8 
DISCUSSION
8.1 LY354740 and LY379268 are selective agonists for mGluR2/3
Previous studies have shown that the two agonists LY3 54740 and LY3 79268 are 
highly potent and selective for group II mGluRs (mGluR2 and mGluR3). By using 
recombinant mGluRs expressed in non-neuronal cells, Monn et al. (in press) demonstrated 
that LY3 54740 suppressed forskolin-stimulated cAMP with nanomolar potency (mGluR2 
EC50 = llnM; mGluR3 EC50 = 38nM) and displaced the high affinity binding of 
[3H]LY341495 at low concentrations (mGluR2 K; = 75nM; mGluR3 Ki = 93nM). 
LY379268 showed even greater agonist potency on the mGluR2 (EC50 = 3nM) and 
mGluR3 (EC50 = 5nM) cloned receptors together with a higher affinity to the receptors 
(mGluR2 Kj = 14nM; mGluR3 Kj = 6nM).
Further in vitro studies using recombinant human mGluRs have demonstrated that 
LY3 54740 has no activity at group III receptors (mGluR4 and mGluR7) up to 100 pM, or 
at group I (mGluR 1 and mGluR5) receptors at 300 pM or more. However, agonist 
responses have been demonstrable at mGluR6 and mGluR8 at the low pM dose range 
(Monn et al., in press). In addition, the application of 100 pM of LY354740 alone on 
recombinant AMPA and kainate receptors produced only negligible currents, while binding 
assays confirmed that the agonist (up to 100 pM) did not have any NMDA activity (Monn 
et al., 1997). Similarly, LY379268 did not produce any effects (agonist or antagonist) in 
cells expressing recombinant mGluRl, mGluR5 or mGluR7 at concentrations up to 100 
pM, and again no NMDA activity was measured at concentrations up to 100 pM. In 
contrast to LY3 54740, LY3 79268 has been shown to have higher affinity at mGluR6 
(inhibition of forskolin stimulated cAMP EC50 = 0.04 pM), mGluR4 (21 pM) and mGluR8 
(2 pM) (Monn et al., in press). In rat cortical slices, LY354740 has also demonstrated the 
inhibition of forskolin-stimulated cAMP formation (EC50 = 55nM) with no phosphoinositide 
stimulation (Monn et al., 1997), which indicates that it has similar group II mGluR
215
selectivity in rat tissue as in recombinant cells. In vitro binding of [3H]LY3 54740 in rat 
brain has also confirmed the selectivity of this agonist to group II mGluRs (Schaffhauser et 
al., 1998). In agreement with the previous findings, NMDA, AMPA/KA and a group I 
mGluR selective agonist did not inhibit [3H]LY3 54740 binding in cortical membranes. It 
binds to at least two populations of receptors that are thought to correspond to mGluR2 
and mGluR3 on the basis of the reported affinity of LY3 54740 on cloned receptors.
8.2 Functional consequences of mGluR2/3 activation
The [14C]2-deoxyglucose autoradiographic technique provides a reliable method in 
which the functional events of the brain can be mapped simultaneously following specific 
receptor manipulations. In the past, this technique has been used successfully in revealing 
the anatomical pathways associated with the manipulation of specific receptor populations 
(McCulloch, 1982). Until now, the functional events in the brain resulting from group II 
mGluR activation have not been documented because of the lack of good pharmacological 
tools. In this thesis, [14C]2-deoxyglucose autoradiography was employed to assess the 
effects of two recently developed mGluR2 and mGluR3 receptor agonists, LY3 54740 and 
LY379268.
LY3 54740 and LY3 79268 are structurally similar and are constrained analogues of 
glutamate (chapter 1, figure 1.5). While LY354740 is approximately equipotent at mGluR2 
and mGluR3, LY3 79268, although more potent than its heterobicyclic analogue for both 
receptors (16X at mGluR3, 5X at mGluR2), has a higher affinity for mGluR3 (Monn et al., 
in press). This may explain both the different responses measured in the brain regions and 
the contrasting behaviour elicited following the administration of the two drugs. At the 
levels of LY3 54740 and LY3 79268 used in this study, the concentration of both 
compounds in the brain would definitely have been sufficient to activate the group II
216
Ta
bl
e 
8.1
 
Ef
fe
ct
s 
of 
LY
35
47
40
 
an
d 
LY
37
92
68
 
on 
se
co
nd
 
m
es
se
ng
er
 
re
sp
on
se
s 
in 
a 
sta
bl
e 
m
am
m
al
ia
n 
ce
ll 
lin
e 
co
-tr
an
sf
ec
te
d 
wi
th
 
a 
gl
ut
am
at
e 
tr
an
sp
or
te
r 
(R
GT
 
ce
lls
) 
ex
pr
es
sin
g 
re
co
m
bi
na
nt
 h
um
an
 
mG
luR
 
su
bt
yp
es
.
WCO
+1
00
3
3
g
8r-"
3h3
3
6
VO
P43
5s
8
m
P43
3s
8
23
3
E
m
3
3
B
23
3
s
8
23
3
E
T333OQ,
Bo
U
8  §  
+l +1 
I  s^  VO
OOo
oo
ooo
oo
A A
O<N1—H
+1
O 
in
+1 
P oO  ■OV O'
<N
OOo
oo
m
ooo
oo
A A
ooo
oor ^
A
VO
00
+1
(N
t'- r^o  p
m O
+1 +1
O  00
00 ^  co rf-
* 8  
^  o'
+l +1
© V^O
OOo
oo
ooo
oo
A A
00
VO(NOvin  t"- m m >1 ><
J  kj
C/5
Ui
Q
•os
8
23
o
g■ws33
3
#S
*8
k.-D
k.
V
GO
k.o
Q.©
©
k.
as
3
5
g
OX)#s
■3(8
2
■a38OX
■o8
k.
3O
00
VO2  .Os Vi t" s
2  8 
J  H
5 . s
-a
' T  W5IXJ M fO £
^  «• J  *E « © ^  
GQ Q4
W .5
w s
n
oo*
S
8
H
WCO
+1
WCO
+1
in
Ov
TT
cn
•J
m
Ov
8-m
>JI
K
CO
3
3s
m
OvTf
Ti­en
I*i—I
23
5
s
tC'3
i-Hx>
TD3
3Oa,
goO
r--
(N
^  VO
^  d  
+' +1 
^  00
s  *
Ov 
+1 +1 
Ov **-i
ti- ^t"- ^
VO
00 Tf 
+1 +1 
Tf in 
m  i—i <N
oTf 00VOC- <N 
tJ- Ov 
in  r - m m 
^  JH kj —1 (D
rs.
 J 
M
on
n 
& 
D 
Sc
ho
ep
p,
 p
er
so
na
l 
co
m
m
un
ic
at
io
n)
|iM 
in 
D
ia
ly
sa
te
l.OO-i
LY354740 (lOmg/kg s.c.)
LY379268 (lOmg/kg s.c.)
60 2 3 4 51
Time (hours)
Figure 8.1 Brain levels of LY354740 and LY379268.
(Figure courtesy o f Dr. D Schoepp, Eli Lilly)
mGluRs in the brain (figure 8.1). However, LY379268 (10 mg/kg) could possibly have 
produced non-selective effects due to mGluR6 or mGluR8 activation, which are thought to 
be implicated in sensory function (Schoepp et al., unpublished data). The behavioural 
changes elicited following the administration of LY354740 and LY379268 may reflect this 
difference in receptor selectivity. While the acute administration LY3 54740 (lOmg/kg) did 
not produce any notable changes in behaviour, LY379268 (lOmg/kg) produced a 
substantial hypersensitivity reaction to auditory stimuli. This response was not observable at 
LY379268 (1 mg/kg). The sensitivity of the locus coeruleus to LY379268, as demonstrated 
by the substantial changes in glucose utilisation, appears to substantiate this behavioural 
response.
The additional use of the ranking function /  illustrates that although a number of 
similarities in function-related glucose utilisation were apparent following both agonists, the 
regional responses of local glucose use to the agonists were dissimilar. Similar responses in 
glucose use were identified in a number of anatomically interconnected regions of the limbic 
system; the anteroventral thalamic nucleus, mammillary body and the lateral habenular 
nucleus. Glucose use in the superior colliculus (superficial layer) was also increased by both 
metabotropic agonists. In contrast, LY3 54740 provoked anatomically widespread 
reductions in glucose use, notably in the cerebral cortex and visual system, whereas 
LY3 79268 elicited circumscribed increases in glucose use in the auditory relay nuclei and 
locus coeruleus. However, the /  rank function fails to address alterations in cerebral 
function in discrete nuclei where they are masked by the more global changes in the brain. 
For example, following LY3 54740, reductions in glucose use were affected in visual regions 
with the majority of brain regions assessed in this system significantly affected. In fact, the 
only regions seemingly unaffected were the lateral geniculate bodies. This is also reflected in 
the hierarchy of responsiveness where the lateral geniculate bodies have been placed at the
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bottom end of the responsiveness scale. However, visual inspection of the autoradiograms 
in animals treated with LY3 54740 (30mg/kg) showed that although the majority of the 
brain displayed a general depression in function, the lateral geniculate bodies were clearly 
evident and glucose levels were relatively unchanged across the treatment groups. This 
suggests that the lateral geniculate bodies are trying to compensate the reduction in activity 
in the visual system by ‘switching on’. However, this response cannot be demonstrated 
because of the general reduction in metabolism in the rest of the brain.
The patterns of glucose alterations seen in this study could simply reflect the 
distribution of mGluR2 and mGluR3 in the CNS. In situ hybridisation, 
immunohistochemical and in vitro binding studies have been carried out to examine the 
distribution of these receptors in the rat brain (Ohishi et al., 1993a & b, 1994; Neki et al., 
1996a & b; Petralia et al., 1996; Schaffhauser et al., 1998). These studies demonstrated the 
differential distribution of the receptors, illustrating that even though mGluR2 and mGluR3 
are seen throughout the rat brain, mGluR3 are distributed more widely in forebrain 
neurones, glia and white matter. The elevation in local cerebral glucose utilisation in the 
genu of the corpus callosum following LY3 79268 administration, which is more selective 
for mGluR3, substantiates this difference. The sensitivity of the superficial layer of the 
superior colliculus to LY354740 and LY379268 can most probably be the result of the 
direct actions of these agonist on the neuronal pathways associated with vision. As already 
mentioned, LY3 79268 appears to have a strong agonist activity at mGluR6, which are 
located in the retina. Recent evidence also shows that mGluR2 are present in subsets of 
amacrine cells located at the border of the plexiform layer of the retina (Hartveit et al., 
1995). While the distribution of local cerebral glucose utilisation changes following the 
administration of the drugs displayed a general relationship to the topography of group II 
mGluR localisation, discrepancies were also evident. Substantial alterations in glucose use
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were measured in the red nuclei and the inferior colliculus with LY3 54740 and LY3 79268 
respectively, but the presence of mGluR2 and mGluR3 in these brain areas are not 
substantial. The brain regions demonstrating substantial alterations in glucose use also do 
not appear to be randomly distributed. As dynamic alterations in glucose use appear to 
reflect mostly the activity in axonal terminals of neuronal pathways (Schwartz et al., 1979), 
alterations in local rates of glucose use are not restricted to the regions rich in group II 
mGluRs, but also in neuronal pathways connected to the receptor-rich areas.
The [14C]2-deoxyglucose autoradiographic technique has been widely employed to 
investigate changes after a wide range of neuropharmacological manipulations (for review, 
see McCulloch, 1982). The anatomical patterns of response to the two metabotropic 
agonists in the present study do not resemble those described previously for glutamate 
receptor blockade (NMDA), or modulators of presynaptic glutamate release, such as k  
receptor agonists (Mackay & McCulloch, 1994). NMDA receptor blockade using the non­
competitive and use dependent antagonist MK-801 (Nehls et al., 1988) produced 
widespread increases throughout the limbic system, with the greatest changes (greater than 
50%) effected in the Papez circuit (posterior cingulate cortex, entorhinal cortex, 
hippocampus, mammillary body). CPP, a competitive NMDA antagonist however, evoked 
minimal alterations in glucose use in the limbic system (Nehls et al., 1988). Previous work 
has revealed that the K-opioid agonist CI-977 results in relatively homogeneous reductions 
in cerebral glucose utilisation (Mackay & McCulloch 1994). The findings from these studies 
contrast with the reductions observed in these similar brain areas following LY3 54740 and 
LY3 79268. The patterns of response to mGluR2/3 activation are also very different to 
those reported following AMPA antagonism. By using NBQX and LY293558, Browne & 
McCulloch (1994) demonstrated widespread reductions in glucose use in nearly all brain 
regions examined. In contrast to this study, the superficial layer of the superior colliculus
221
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was minimally affected following the AMPA antagonists. The findings demonstrated in the 
limbic system following the systemic manipulation of NMDA, AMPA and mGluR2 and 
mGluR3 receptor systems are presented in table 8.3.
The group II mGluRs are known to have a modulatory role pre- and peri- 
synaptically (Forsythe & Bames-Davies, 1997). Here they can exist either as autoreceptors 
at glutamatergic synapses, or as heteroreceptors at GABAergic synapses. Previous [14C]2- 
DG studies (Kelly & McCulloch, 1982; Ableitner et al., 1985; Kelly et a l., 1986) using 
GABAergic agonists (muscimol and THIP) and the benzodiazepine receptor agonist 
diazepam elicited reductions in glucose use. While nearly all brain regions were seen to be 
affected following diazepam, a more heterogeneous response was observed following 
GABA agonists, with anterior thalamic and cortical areas, extrapyramidal and limbic 
systems predominantly affected. Similar reductions in glucose use were also observed in 
these areas with LY3 54740 (albeit with greater heterogeneity), and to a lesser extent with 
LY3 79268. It may be that the observed changes result from the activation of presynaptic 
heteroreceptors. In addition, the activation of presynaptic autoreceptors that function as 
negative feedback receptors would inhibit any further release of glutamate onto 
postsynaptic receptors, leading to a decrease in glucose use. Indeed, evidence that 
LY3 54740 plays a role in the presynaptic negative modulation of glutamate release has been 
reported. Battaglia et al. (1997) recently demonstrated that LY3 54740 completely 
prevented veratridine-evoked release of glutamate and aspartate in the striatum. 
Furthermore, recent electrophysiological studies have shown the presynaptic inhibitory 
action of LY3 54740 in the medial and lateral perforant pathway of the hippocampal dentate 
gyrus (Kilbride et al., 1998). Thus, the reductions in glucose utilisation observed following 
LY3 54740 may be due to its preferential action on pre-synaptically located mGluR2 
receptors. From a more general standpoint, the reductions in glucose use could also be a
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direct result of the possible negative modulation of group II mGluRs on VSCCs and K+ 
channels. It is thought that this mechanism results from the activation of mGluR2 (Kilbride 
et al., 1998).The tendency for elevations in glucose utilisation following LY379268 could 
be attributed to the possible action of the ligand on post-synaptic receptors or non-selective 
cation channels.
There is recent evidence to suggest that mGluR2 are localised in perisynaptic areas 
which could permit activity-dependent receptor activation (Scanziani et al., 1997), 
suggesting their involvement in the suppression of over-excited systems. While this study 
has demonstrated more general reductions in glucose utilisation following LY3 54740 (but 
not LY3 79268), the exact sites of action of this agonist in the brain could be more fully 
exploited. By increasing glucose metabolism (i.e. exciting neuronal systems), one may well 
observe clear and specific reductions in brain metabolism directly related to the activation of 
mGluR2 as a direct result of their modulatory role peri-synaptically. In fact, behavioural 
evidence for the involvement of mGluR2 in suppressing glutamatergic disruptions was 
demonstrated recently (Modghaddam & Adams 1998). They presented evidence to suggest 
that LY3 54740 was capable of suppressing PCP-induced behaviours. A recent study by 
Schoepp et al. (personal communication) have also indicated LY3 79268 acts similarly.
Glutamate is the major excitatory neurotransmitter of the perforant pathway which 
projects from the entorhinal cortex and terminates in the hippocampus and dentate gyrus. 
Petralia et al. (1996) demonstrated that the hippocampus, and in particular, the terminals of 
axons located in the hippocampus originating from the entorhinal cortex, was the region 
richest in mGluR2 and mGluR3. In this study, the molecular layer of the hippocampus was 
substantially affected with both compounds, but did not show the most significant changes 
in local cerebral glucose use. However, this would be an expected finding, since the 
metabolic effect of the activation of these receptors would be expected downstream at the
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next synapse of that pathway. The mammillary body is an important efferent area of the 
hippocampal region, while the mammillary body in turn projects onto the anterior thalamus 
via the mammillothalamic projection. These structures form the main components of the 
circuit described by Papez (1937); entorhinal cortex —» hippocampus —» mammillary body 
—» anterior thalamus —» cingulate cortex. Local rates of glucose utilisation were 
substantially altered in the majority of these structures in this study.
In summary, this present study has demonstrated utility of the [14C]2-deoxyglucose 
technique in discerning the responses of the two selective agonists in the brain. The actions 
of LY354740 and LY379268 in the brain do not resemble the responses previously 
demonstrated with other glutamate receptor ligands, and their sites of action are selectively 
mediated by the mGluRs. The findings from this study reveal the important functional 
involvement of the limbic system in response to the activation of mGluR2 and mGluR3 with 
LY3 54740 and LY3 79268. Aside from the mutual change produced in the limbic system, 
the two agonists produce essentially different CNS effects following systemic 
administration. These central effects shown following systemic administration demonstrate 
their usefulness as pharmacological tools, especially with their different affinities to the two 
receptor subtypes, and that they may be of potential therapeutic use in conditions where 
there is an apparent overactivity of the limbic system.
8.3 The significance of limbic system manipulation
The [14C]2-DG autoradiographic technique has been used successfully in the past to 
map the functional changes following local intracerebral administration of various agents 
(Kelly & McCulloch, 1984; Lothman et al., 1985). With respect to glutamatergic 
hippocampal manipulations, studies have previously examined the functional consequences 
following the NMDA receptor antagonist MK-801, but no such studies have been
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performed with AMPA receptors or mGluRs. This present study was performed in order to 
investigate the functional consequences in the CNS during and following local bilateral 
intrahippocampal administration of LY326325.
In this thesis, reductions in glucose utilisation were restricted to the hippocampus. 
Reductions in glucose use were more predominant in the dorsal aspect of the hippocampus 
over the ventral hippocampus. An unexpected surprise was the very subtle nature of the 
changes in glucose utilisation seen following the intrahippocampal injections of LY326325. 
No significant changes in glucose metabolism were observed in any other regions directly 
connected with the hippocampus, and no diffusion effects of the drug were detected. A 
similar study using MK-801 injected directly into the hippocampus demonstrated that 
alterations in glucose metabolism were also restricted to the hippocampus (albeit increases 
in glucose utilisation) with no significant changes noted in regions connected with the 
hippocampus (Kurumaji & McCulloch, 1990). However, the alterations were found in the 
ventral portion of the hippocampus rather than the dorsal hippocampus. A comparison of 
the consequences in brain function following MK-801 and LY326325 is presented in table 
8.4.
The most important and novel finding from this present study is the nature of the 
inactivation. The reductions in glucose utilisation of the hippocampus are reversible as 
levels of glucose metabolism following the infusion of the drug return to levels comparable 
with aCSF treated animals. In essence, infusions of LY326325 is able to selectively ‘switch 
off the dorsal hippocampus for the duration of the infusion period, and then ‘switch on’ 
again. The reduction in function of the hippocampus as demonstrated with [14C]2-DG was 
also demonstrated electrophysiologically (figure 8.2). Dentate gyrus field-potentials to 
perforant path stimulation were monitored daily over a period of over two weeks. The data 
revealed an abrupt decrease in fast synaptic transmission which remained throughout the
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Table 8.4 Changes in glucose utilisation in the CNS following intrahippocampal 
glutamatergic manipulation: comparison between NMDA and AMPA 
receptor systems.
BRAIN REGION GLUCOSE UTILISATION (% CHANGE 
FROM CONTROLS)
MK-801 LY326325
Entorhinal cortex +19% +14%
Ventral hippocampus 
(molecular layer)
+31% +5%
Ventral dentate gyrus +44% +13%
Posterior cingulate cortex +8% -17%
Sensorimotor cortex 0% +12%
Glucose use changes in selected brain regions following the intrahippocampal administration 
of the non-competitive NMDA antagonist MK-801 and the selective AMPA antagonist 
LY326325, used in this thesis. 
aKurumaji & McCulloch, 1990.
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Figure 8.2 The AMPA receptor antagonist LY326325 blocks fast synaptic 
transmission at perforant path/granule cell synapses.
Representative aCSF and LY326325 micropump-implanted animals show a reduction 
in fast synaptic transmission during 7 days of infusion and no change in the aCSF 
control. Means for slope and population spike.
MP = minipump
(From Riedel et al., submitted)
infusion period of LY326325, which suddenly returned to baseline levels within one day of 
the exhaustion of LY326325 from the minipumps (Riedel et al., submitted). In this study, 
the level of glucose utilisation in the dorsal hippocampus during LY326325 infusion was 
similar to that after the suppression of synaptic transmission (flat EEG) induced by 
pentobarbital (Crane et al., 1978; Astrup et al., 1981). Increasing the dose of LY326325 
may have reduced function-related glucose metabolism in the hippocampus even further, but 
this is associated with the risk of increasing extra-hippocampal diffusion and functional 
changes elsewhere.
Reversible infusions of this kind that selectively inactivate the hippocampus may 
provide invaluable insight into memory processes. Studies of brain dysfunction have 
provided substantial evidence for the involvement of glutamate receptors and the 
hippocampus in various types of learning and memory (Squire, 1992; Gaffan, 1994; Vargha- 
Khadem et al., 1997; Riedel et al., 1994; Ohno & Watanabe, 1996). In addition, the 
involvement of the dorsal hippocampus, but not the ventral hippocampus, has been shown 
to be important in various types of learning (Moser et al., 1995).
Each of these types of memory is thought to consist of a series of interdependent 
memory processes, namely encoding, storage, consolidation and retrieval. The conventional 
neurotoxic lesions used at present cannot categorically dissociate between these different 
processes due to their permanent nature. For example, lesions made prior to the training 
(learning the task) would affect the later retrieval of the task were they to disrupt any of the 
memory processes. Similarly, lesions made after the training period could disrupt the 
storage of the information or processes associated with consolidation processes and 
retrieval. Thus, using this method of reversible inactivation of the hippocampus would 
enable the contribution of the hippocampus to the different memory processes to be 
independently studied. This novel method of synaptic inactivation has been put to use for
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the study of memory processes recently. Seminal studies by Morris and colleagues 
(submitted) have provided the first direct evidence for the involvement of the hippocampus 
in the distinct memory processes of one type of memory, spatial memory. Rats were trained 
using a variant of the open-field watermaze in which an escape platform is raised only if the 
animal searches at the correct location persistently (Morris, 1981; Spooner, 1994). 
Inactivation and reactivation of the hippocampus by LY326325 at different times made it 
possible to investigate the involvement of the hippocampus in these processes. The studies 
revealed a marked deficit in spatial learning during the training period (encoding) in animals 
with abnormal hippocampal neural activity. In the same set of experiments, retrieval of 
spatial memory following training was also revealed to be affected following manipulation 
of hippocampal function. Animals treated with LY326325 during training not only failed to 
learn where the platform was located but also failed to acquire the ‘search and dwell’ 
strategy needed for this type of test. In contrast, animals trained under aCSF were able to 
learn the strategy, but when tested later at the retrieval stage with LY326325 could not 
recall where to search for the platform and were demonstrated to search and dwell in the 
inappropriate quadrant. Subsequent studies showed that the hippocampus is also involved in 
maintaining storage of certain memory traces or consolidation processes in circuits 
elsewhere in the brain.
Although the group II mGluR ligands were not used in this study, the use of 
selective mGluR ligands to produce this type of reversible inactivation of the hippocampus 
would provide great insight into the involvement of these G-protein coupled receptors in 
memory and learning. Recent electrophysiological studies and studies using trangenic 
animals have provided much evidence for the important role of mGluRs, particularly of 
group I mGluRs in LTP (O’Connor et al., 1995; Zheng & Gallagher, 1992) and 
behaviourally in spatial learning (Balschun & Wetzel, 1998). It would be of great interest to
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start to look at their potential role in the different processes involved in memory. Together 
with other technologies used for the study of memory, such as functional imaging 
approaches, this type of temporary inactivation of synaptic transmission will undoubtedly 
help unravel and increase our understanding of the complexities of cognitive function.
8.4 mGluR agonists as potential neuroprotective agents?
Various problems have been associated with the use of ionotropic glutamate 
receptor antagonists as neuroprotective agents. For example, inhibition of these receptors 
can compromise fast excitatory synaptic transmission and can have serious side effects. The 
most obvious problem associated with ionotropic glutamate receptor antagonists in recent 
years has been the realisation that these agents show no therapeutic benefit in human stroke. 
None of the agents selected for clinical trials have proved successful. This has paved the 
way for exploring the potential of mGluRs for the therapy of neurodegenerative disorders. 
The mGluRs are similarly distributed throughout the CNS, but because they have more 
subtle effects on neurotransmission at synapses, it is believed that they will have fewer side 
effects than the antagonists developed for the ionotropic glutamate receptors.
In this thesis, contrary to the evidence in the literature that group II mGluR agonists 
are neuroprotective, LY3 54740 and LY3 79268 failed to demonstrate a reduction in the size 
of the infarct volume following 24 hour permanent cerebral ischaemia in the rat. Unlike the 
existing ligands for group II receptors, LY3 54740 and LY3 79268 are both orally active, 
and are currently the most potent agonists (in terms of the inhibition of forskolin-stimulated 
cyclic AMP formation) available for mGluR2 and mGluR3.
Various factors have to be taken into consideration in order to understand the 
possible neuroprotective role of group II metabotropic glutamate receptors in cerebral 
ischaemia. Firstly, it has been demonstrated that the choice of ischaemia model determines
231
the severity of damage. Secondly, the mechanisms participating in the evolving damage in 
the different models are different (Macrae et al., 1992). Interestingly, Bruno et al. (1997) 
recently proposed that neuroprotection mediated by group II mGluRs in vitro requires new 
protein synthesis and involves an interaction between neurones and astrocytes, an event 
distinct from their actions on reducing synaptic activity. It may be possible that studies using 
focal models of permanent ischaemia will not protect against neuronal damage due to the 
rapid evolvement of damaged tissue, but a more slowly progressing infarct would allow this 
neuroprotective mechanism to take place.
APP
In addition to protecting neuronal elements, the protection of myelinated white 
matter tracts should also be considered. Recently, APP has been used a marker for assessing 
axonal damage after an ischaemic insult. Previous studies have demonstrated the larger the 
volume of the ischaemic lesion, the greater the extent of increased APP immunoreactivity 
(Yam et al., 1998b). A marker for APP was used in this thesis to investigate any changes in 
APP accumulation following focal cerebral ischaemia and intervention with LY379268. No 
positive correlation between APP and infarct size was revealed; in fact infarct size and APP 
in the LY379268 treated group appeared slightly negatively correlated. No firm conclusions 
can be drawn from this data, as only one level out of the possible 8 was investigated. 
However, it may suggest that LY3 79268 may protect axons against cerebral ischaemia 
using a non-synaptic mechanism. This contrasts with the neuroprotective agent MK-801, 
which failed to protect axons even though a 30% reduction in ischaemia was demonstrated 
(Yam etal., 1998).
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TGFp
The subsequent studies of Bruno et al. (1998) claim that the neuroprotection is in 
fact mediated by TGF-p, as antibodies that selectively neutralised the actions of TG Fp-1 or 
TGFp-2 prevented any neuroprotective activity. TGF-Ps form a group of homodimeric 
proteins of 25 kDa that are secreted in latent forms made up of a TGF-P active dimer 
associated with a set of proteins that need to be activated in order to become functional. 
They exert their effects by binding to one of three cell surface receptors - TPR-I, -II or -HI. 
Activation of the receptors leads to the phosphorylation of effectors (SMAD proteins) 
eventually resulting in changes in transcriptional responses such as modulation of genes in 
the cell cycle (Vivien et al., 1998). From the immunohistochemistry studies carried out in 
this thesis, the results provide tentative evidence to substantiate the findings of Bruno and 
colleagues (although only one stereotaxic level was assessed).The pattern of the changes 
seen following TGFp2 and TdT immunohistochemistry confirm that the area at the 
periphery of the infarcted tissue is salvageable unlike the ischaemic core, and that the 
vulnerable cells in this area may be promoting cell survival. The reduction in TdT labelled 
cells displayed following LY3 79268 in and around the boundary of the ischaemic lesion may 
result from the activation of mGluR2 and mGluR3 in the penumbra which activate 
intracellular signalling pathways, such as the production of trophic factors such as TGFp-2 
to prevent further cell death. An increase in the number of cells displaying TGF-p 1 
immunoreactivity following LY379268 however, was not demonstrated in this thesis. TGF- 
pi mRNA immunoreactivity in the normal rat brain has been shown previously to be 
confined to the meninges and choroid plexus only (Unsicker et al., 1991). This may explain 
the low level TGF-P 1 response observed in this thesis. However, TGF-p 1 and TGF-P2 
mRNA has been previously demonstrated to be dramatically increased at 24 hours and 3 
days after focal ischaemia in the mouse (Vivien et al., 1998). It may be possible that an
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increased TGF-P 1 immunoreactive response would have been observed in this thesis at a 
later time point than 24 hours.
Group II mGluRs: neuroprotection against delayed neuronal death?
It has been recognised that neuroprotection by new protein synthesis and neuronal- 
glial signalling may not be efficient against all types of excitotoxic insults in vitro. For 
example, the activation of group II mGluRs has not been shown to protect mixed cortical 
cultures exposed to AMPA (Buisson et al., 1996). This ‘selective’ protective mechanism 
appears also to extend to in vivo paradigms. In this thesis, LY354740 and LY379268 did 
not demonstrate a reduction in the size of the ischaemic lesion following a 24 hour model of 
focal cerebral ischaemia. Interestingly, a similar finding is demonstrated with LY3 54740 
following the endothelin-1 model of focal cerebral ischaemia (O’Neill, unpublished 
observations). In contrast, studies using the gerbil model of global ischaemia have indicated 
that LY3 54740 is effective in significantly reducing the damage to CA1 hippocampal 
neurones, which is seen to develop over several days (Bond et al., 1998; Kingston et al., in 
press). However, this neuroprotective effect was temporally dependent. A mild three minute 
insult reduced the damage to the CA1 neurones significantly, while a more severe insult 
attenuated the neuroprotection.
In view of the delayed nature of the neuronal cell death observed following global 
ischaemia and the idea that cell death pathways are dependent upon the insult severity and 
[Ca2+]i (Choi, 1995), it may be that global ischaemia is associated with an apoptotic 
component of cell death. In contrast to the cell swelling and disintegration of cell 
architecture seen in necrosis, apoptosis is recognised to result from the execution of finely 
regulated genetic programs. Apoptosis leads to chromatin aggregation and compaction, a 
progressive loss of cell volume and the extrusion of membrane-bound cytoplasmic
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fragments known as apoptotic bodies. However, the criteria for defining apoptosis are still 
not absolute. In recent years, it has been popular to use DNA breakdown, such as agarose 
DNA ladders, as a marker for apoptosis. However, it should be mentioned that the 
detection of DNA breakdown by TdT-mediated end labelling can also occur in cells 
undergoing necrosis (as in cases of incomplete triggering of apoptosis).
In comparison to the slowly evolving cell death seen after global ischaemia, the 
severe regional cell death associated following focal ischaemic insults seems an unlikely 
setting for apoptosis. Apoptosis may follow focal ischaemia as an event distinct from 
ischaemia induced excitotoxicity. Thus it has been estimated that around 4% of cells are 
thought to become apoptotic following focal ischaemia, and that the number reaches a 
maximum at 24-48 hours after the insult (Linnik, 1996). Studies have demonstrated DNA 
laddering (Linnik et al., 1993) while other studies have revealed that the molecular systems 
linked to the generation of apoptosis can be manipulated, e.g. bcl-2, bax genes, which can 
alter the outcome of focal ischaemia (Martinou et al., 1994; Linnik et al., 1995). Consistent 
with these observations, the use of fragment end labelling of DNA by TdT in this thesis has 
revealed that there is substantial reduction in the number of apoptotic-like cells in the area 
of the ischaemic lesion following LY379268 compared with vehicle treated controls.
Chopp & Li (1996) have previously characterised the cell types exhibiting apoptotic 
morphology following two hours MCA occlusion and 24 hours reperfusion. They claim that 
90-95% of the cells displaying apoptotic morphology were neurones with astrocytes 
comprising around 5-10% and endothelial cells less than 1%. Interestingly, comparable to 
the distribution seen for APP in this thesis, they found the vast majority of the apoptotic 
cells were located along the inner boundary of the ischaemic lesion (Chopp & Li, 1996). 
The finding that the number of TdT immunolabelled cells is reduced following permanent 
MCA occlusion suggests an important intracellular event involved in the cascade of
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apoptotic cell death is being selectively targeted following the activation of group II 
mGluRs by LY3 79268 - possibly through the actions of the less vulnerable astrocytes. 
Despite the absence of a reduction in the size of the ischaemic lesion following LY379268, 
this study supports the view that a broad range of insults, even those that strongly favour 
membrane failure and necrosis, have the potential to cause cells to initiate apoptosis.
Gene Expression
Ischaemia modifies gene expression (for reviews see Koistinaho & Hokfelt, 1997; 
MacManus & Linnik, 1997). Studies relevant to this thesis include previous investigations 
of changes in mGluR mRNA levels following global ischaemia. Using in situ hybridisation, 
levels of mRNA were measured 24 hours after the transient global insult - a time point 
when no neuronal damage can yet be seen morphologically. Iversen and colleagues (1994) 
demonstrated that while mGluR3 mRNA levels were not changed, the mRNA levels for 
mGluR2 were decreased. Whether their eventual translation to protein is reduced too is not 
known. These findings are consistent with previous studies which have shown that mRNA 
encoding the ionotropic glutamate receptors are downregulated following ischaemia 
(Pellegrini-Giampietro et al., 1992; Frank et al., 1995). Interestingly, it has recently been 
observed that protein levels of mGluR2/3 in animals subjected to hypoxia are substantially 
reduced. These animals were subjected to hypoxic and hypobaric conditions for two weeks 
(MacLean et al., 1995) and cortical levels of mGluR2/3 protein were reduced by up to 80% 
(Dr I Mullaney, unpublished observations). Moreover, there was a concurrent reduction in 
the levels of Ga and Gs type G-proteins.
No notable changes in mGluR2/3 immunoreactive cells were demonstrated 
following permanent focal ischaemia in this thesis, which further serves to highlight the 
differences in the mechanistic events following different central insults. Focal cerebral
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ischaemia has been traditionally viewed as producing severe cell damage rapidly; changes 
can be seen in cells as early as 30 minutes after the insult (Garcia et al., 1993).This contrasts 
to the delayed neuronal death seen after transient global ischaemia where cells die over the 
following 48-72 hours and the graduated and milder insult of hypoxia.
Actions o f LY354740 and LY379268following in vitro neurotoxicity
From the speculative in vivo findings observed in this thesis together with the 
existing evidence for the involvement of mGluR2 and mGluR3 in neuroprotection in the 
literature, the idea that mGluR2 and mGluR3 activation are protective in instances where 
the evolving damage is protracted to allow defensive intracellular events to take place 
appears possible. Using in vitro cell culture studies, the actions of LY3 54740 and 
LY3 79268 on cell death were explored using two different models of neurotoxicity with 
different mechanisms of damage. Previous studies have demonstrated that LY3 54740 and 
LY379268 can preserve the viability of cortical neuronal cells under conditions of NMD A- 
induced excitotoxicty in a dose-dependent manner (Kingston et al., in press). This 
neuroprotective response was demonstrated to be specifically mediated through mGluR2/3 
activation, as the addition of the selective group II antagonist, LY341495 (Kingston et al., 
1998) caused a reversal in the neuroprotective response. Neuronal death induced by NMDA 
exposure has been reported to occur predominantly by necrosis (Gwag et al., 1997). 
However, NMDA-treated cortical cells exhibit an increase in nucleosome formation, which 
is effectively reduced following the administration of LY3 54740 and LY3 79268 to cultures. 
This response was demonstrated at low nM concentrations (observed at a much lower 
concentration than that required for LDH release) at doses in accordance with their 
measured receptor affinities in clonal lines (Kingston et al., in press). The authors propose 
that the difference in the ability of the agonists to produce these effects is due to the ligands
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differentiating a population of apoptotic cells within an overall population of dying 
neurones.
Additional evidence to support this anti-apoptotic effect is provided in this thesis by 
the ability of LY3 54740 and LY379268 to protect against staurosporine-induced cell death. 
Nucleosome formation in cultures following the hypoxic-hypoglycaemic insult were not 
measured unfortunately. In view of the hypothesis put forward by Kingston et al., one 
would expect that the application of LY354740 and LY379268 to cultures subjected to 
glucose and oxygen deprivation would lead to a similar reduction in nucleosome formation. 
In addition, the activity of the agonists against staurosporine-induced neurotoxicity also 
appeared to be enhanced in the mixed cultures compared with the neurone-enriched 
cultures. Therefore, this may indicate that glial cells have an important role in the 
neuroprotective mechanism and further supports the findings of Bruno et al. (1997). 
Although no firm conclusions can be drawn from the glucose and oxygen deprivation 
studies due to the inadequate number of experiments performed, the data suggest that 
activation of mGluR2/3 may lead to actions on an apoptotic pathway.
Astroglial involvement in neuroprotection?
Western blot analysis in astrocytes carried out in this thesis corroborate the existing 
evidence that astrocytes are crucial to the mGluR2/3 neuroprotective mechanism and are 
involved in producing neurotrophic factors for neurones. While an immunoreactive protein 
band was not detected for mGluR2/3, a TGF-P2-specific protein band was detected both in 
the astrocyte homogenates and in the cell culture medium, which suggests the expression 
and secretion of TGF-(32 from cultured rat cortical astrocytes. This response was 
demonstrated to be mediated through mGluR2/3 as concomitant treatment of astrocytes 
with the selective antagonist LY341495 reversed this response. Astrocytes in vitro have
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been shown to secrete TGF-(32 and to express TGF-p 1 and TGF-p3 mRNAs, while cortical 
neurones only express TGF-P2 mRNA (Constam et al., 1992; Vivien et al., 1998). The 
recent demonstration that neurones and astrocytes are able to express TGF-P receptors 
(Vivien et al, 1998), which are necessary for the signal transduction of the TGF-Ps, suggest 
that these cytokines play a critical role in the biology of neurones and astrocytes. Again, the 
findings of this study provide further support that neuroprotection by the group II mGluR 
agonists LY3 54740 and LY3 79268 requires the involvement of astrocytes and new protein 
synthesis. It is possible that while cells may be undergoing cell death by necrosis, the 
activation of group II mGluRs can also trigger a specific intracellular pathway that opposes 
the execution of programmed cell death. Investigations should be continued to assess the 
involvement of mGluR2/3 with the intracellular cascades.
Neuroprotective therapy
Neuroprotective drugs of many classes that target various steps of the excitotoxic 
cascade have undergone clinical trials, and none have yet proved successful. The failure of 
these trials has led to a rethink of trial designs for future protocols. Some common themes 
can be seen to underlie trial failures, such as patient recruitment, drug tolerability, and 
systemic toxicity. Some agents may have been simply launched prematurely into clinical 
trials. For example, the mechanism of action of Lubeluzole, an agent entered into clinical 
testing, is still unknown. In light of the negative findings from clinical trials in stroke, the 
predictive value of the animal models used in ischaemia research has also been questioned 
(Hunter etal., 1995). However, the negative results clinically following positive animal data 
should not be regarded as damaging to the usefulness of these models, only indicating that 
certain criteria may have to change. For example, despite the fact that stroke primarily 
affects those of middle or later life, the animals used preclinically are invariably young rather
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than aged. Additionally, one of the most important factors to take into consideration is the 
timing of the treatment in cerebral ischaemia. Agents therefore should be efficacious when 
given after the ischaemic insult and not before to mimic the clinical situation.
The way in which the ischaemia is analysed also needs to be changed. The most 
common method used at present for the assessment of damage following an experimental 
ischaemic insult is usually by histopathological measures of neurodegeneration. However, 
this is not an appropriate option in the clinical setting where measures of functional 
impairment and neurological outcome are measured. Therefore, measures of functional 
impairment and improvement should also be used in experimental stroke models. Various 
types of tasks have been developed to evaluate the functional performance in rats subjected 
to ischaemic insults. Because of the nature of the animal models of ischaemia, functional 
tests have been restricted to sensorimotor and cognitive performance (for review see Hunter 
et al., 1998).The use of functional performance appears to be increasingly important since a 
variety of evidence indicates that neurological deficits and lesion size do not automatically 
correlate (Rogers et al., 1992). The failure of clinical trials show that neuroprotective 
therapies using glutamatatergic agents alone do not appear likely treatments for stroke. 
Future successful treatment of stroke may emerge from a polypharmacy approach as 
reducing infarct volume in the absence of any functional benefit will have little impact on the 
quality of life of the patient. Moreover, it is of paramount importance to protect not just 
grey matter, but white matter also, as it is crucial to the fundamental architecture of the 
brain. Thus agents that can limit the spread of acute damage in the brain, for example, such 
as that seen at the level of the glutamate receptors, together with agents that improve long 
term functional recovery, e.g. anti-inflammatory agents, may result in promising therapeutic 
candidates for stroke.
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8.5 The future of group II mGluRs in therapy...
There is currently much interest in the potential use of mGluR ligands in the therapy 
of neurologic disorders. Aside from their emerging role in neuroprotection following 
ischaemia, agonists acting at group II receptors have also been shown to reverse 
glutamatergic disruptions in an animal model of schizophrenia. Thus, the mGluRs present an 
alternative non-dopaminergic therapeutic strategy for the treatment in schizophrenia 
(Moghaddam & Adams, 1998).
Activation of group I mGluRs in the hippocampus has been shown to facilitate the 
generation of limbic seizures. Consistent with this, various studies have shown that seizure 
activity can be attenuated either by antagonists for group I receptors or by selective agonists 
of group II or group HI receptors. For example, a study using (S)-4C3HPG (antagonist at 
group I and agonist at group II mGluRs) demonstrated anticonvulsant effects in mice 
(Thomsen et al., 1994; Dalby & Thomsen, 1996). mGluRs may serve as important new 
targets for development of novel anticonvulsant agents.
In addition to their involvement in memory, mGluRs also elicit physiologic effects in 
the hippocampus that may enhance cognitive function thus suggesting that mGluR ligands 
may be useful as cognitive enhancing agents. This would be of particular benefit to those 
suffering from memory impairments. Recent work has also implicated the involvement of 
mGluRs in Huntington disease (Cha et al., 1998). By using transgenic mice expressing a 
portion of an abnormal human HD gene, the mutant mice were found to have a reduction in 
mGluRl, mGluR2 and mGluR3. These changes were observed in association with decreases 
in ionotropic glutamate and dopamine receptors, which are thought to be pathologic 
hallmarks of Huntingdon disease. Studies have also implicated group I and II mGluRs in 
transmitting noxious sensory information to the thalamus (Salt & Eaton 1994; Eaton et al.,
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1993).Thus, development of selective ligands for the mGluRs involved in the transmission 
of these signals could potentially be useful in the treatment of acute and chronic pain.
As already mentioned, LY354740 is currently under clinical development. A 
potential clinical use of LY3 54740 could be for the treatment of anxiety (Helton et al., 
1998b). The anxiolytic effects of LY354740 were tested in the fear potentiated startle 
procedure and the elevated plus maze models (Davies, 1979; Lister, 1987), both of which 
have been used for clinically proven anxiolytics such as the benzodiazepine, diazepam and 
the 5HTia agonist, buspirone (Helton et al., 1998b). The study indicates that LY3 54740 
produces benzodiazepine-like efficacy, but is devoid of benzodiazepine-like side effects at 
anxiolytic doses. Moreover, the [14C]2-DG study carried out in this thesis demonstrated that 
LY3 54740 reduced function-related glucose metabolism in the perforant pathway, which is 
known to be important for producing anxiolytic effects (Pratt, 1992). Given the anxiolytic 
profile of LY3 54740, this agent also appears to be efficacious in reducing the symptoms 
associated with nicotine withdrawal during smoking cessation (Helton et al., 1998a). The 
effects of nicotine withdrawal were assessed by measuring the sensorimotor reactivity to an 
auditory startle reflex in rats. The discontinuation of chronic exposure to nicotine in rats 
results in a marked increase in the auditory startle reflex. The administration of LY3 54740 
(6 mg/kg for 12 days) resulted in an attenuation of the withdrawal-enhanced startle 
responses. How it affects nicotine withdrawal however, is not known. The potential of 
LY3 54740 in smoking cessation in humans has yet to be tested. Similarly, LY3 54740 has 
indicated a promising role in attenuating morphine withdrawal symptoms and may be of 
therapeutic benefit in man for the treatment of opiate withdrawal (Vandergriff & 
Rasmussen, 1999). At the time of writing this thesis, LY3 79268 is also undergoing clinical 
development. However, as many aspects of the work carried out with LY3 79268 have not 
been disclosed, they cannot be discussed here. Nonetheless, because of its different central
242
profile and selectivity for the group II mGluRs, its use in the clinical setting will most 
probably be different from LY354740.
Because of the fundamental roles of mGluRs in the brain, the development of 
agonists and antagonists selective for specific mGluR subtypes will provide invaluable tools 
for increasing our understanding of mGluRs. The variety of mGluRs and the differences in 
their localisation suggests that they specialise in their functions. Because of the 
heterogeneity of the subtypes, the potential to develop drugs that are selective for mGluRs 
in specific brain regions for neurologic and psychiatric disorders is great. Much has been 
learnt about the mGluRs in the last decade, and the continuing effort to produce better 
ligands will help us proceed in unravelling the complexity and functional importance of 
these receptors.
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APPENDICES
Appendix 1
Sources of commonly used materials
ABC kit Vector
Amyloid precursor protein A4 IgG, mouse Boehringer Mannheim
Ammonium persulphate (APS) Sigma
B27 supplement GibcoBRL
Biotinylated secondary antibodies Vector
Bio-Rad colour reagent Bio-Rad Labs
Blotting paper Inverclyde Biologicals
Bovine serum albumin (BSA) Sigma
[14C]2-deoxyglucose Amersham Life Science
Collagenase GibcoBRL
Cytosine arabinoside Sigma
Diaminobenzidine (DAB kit) Vector
DABCO Sigma
Dulbecco’s modified Eagle’s medium GibcoBRL
Dimethylsulphoxide (DMSO) Sigma
DNase Sigma
ECL reagent Amersham Life Science
Euthatal Rhone Merieux
Foetal calf serum GibcoBRL
Fluorescein secondary antibody Vector Laboratories
Gentamicin GibcoBRL
Glial fibrillary acidic protein IgG, mouse Sigma
Glial fibrillary acidic protein IgG, rabbit Dako
Glucose (D) Sigma
Glutamine GibcoBRL
Glycerol Sigma
Glycine BDH
Halothane Concord Pharmaceuticals
Hank’s balanced salt solution GibcoBRL
Heparin Leo Laboratories
HEPES PAA laboratories
IBMX Sigma
Isopentane Fisher Scientific
Lysis buffer Calbiochem
mGluR2/3 antibody, rabbit Chemicon International
Neurobasal medium GibcoBRL
Normal goat/horse serum Vector laboratories
Nystatin (10 OOOU/ml) Gibco
Paraffin wax Bayers
Paraformaldehyde Sigma
PBS Dulbecco’s Balanced salt solution (w/o bicarbonate) Gibco
Pepsin Sigma
PMSF Sigma
Poly-D-lysine hydrobromide Sigma
Poly-L-lysine Sigma
Polyvinyl alcohol Sigma
Prestained protein standards (broad range) Bio-Rad
Prosieve-50 Flowgen
Polyvinyl difluoride (PVDF)
Soy bean trypsin inhibitor
Staurosporine
TEMED
Transforming Growth factor-p 1 IgG, rabbit
Transforming Growth factor-p2 IgG, rabbit
Transforming Growth factor-p2 IgG, rabbit
T ertiary-amyl-alcohol
Texas red avidin
Tribromoethanol
Triton X-100
Trypan Blue
Trypsin
Xylocaine antiseptic gel 2%
Boehringer Mannheim
Sigma
Sigma
Sigma
Santa Cruz Biotechnologies 
Santa Cruz Biotechnologies 
Chemicon International 
Sigma
Vector Laboratories
Aldrich
Sigma
Sigma
GibcoBRL
Astra Pharmaceuticals
Appendix 2 
Stock solutions
Buffers
Lysis buffer (100ml)
50mM Hepes pH 7.5 1.192g
150mM NaCl 8.76g
ImMEDTA 37.22mg
2.5mMEGTA 95.1mg
ImMDDT 15.42mg
0.1% Tween-20 lOOpl
10% glycerol 10ml
0. ImM PMSF (125mM stock) 80pl
1 Opg/ml leupeptin (1 mg/ml stock) 1 ml
2pg/ml aprotinin (1 mg/ml stock) 200jal
lOmM P-glycerophosphate 216mg
1 mM NaF (1M stock) 1 OOpl
0.1 mM sodium metavanadate (0.1M stock) 1 OOjul
Prepare lysis buffer in distilled water, pH 8; Aliquot and store at -20°C.
Phosphate Buffer (PB)
Stock solutions A. Sodium dihydrogen orthophosphate (Na2HP042H20 ) 31.2 g/1 
B. Disodium hydrogen orthophosphate (Na2HP042H20) 35.6 g/1 
95ml of stock A. and 405ml of stock B. PB made up to 21, with either distilled water or 
0.9% saline to produce PBS.
Sample buffer for gel loading 
5 X sample buffer: 0.5 M sucro se 43.78g
15% SDS 37.5g 
312.5mM Tris 9.5g 
lOmMEDTA 0.925g
Prepare 5X sample buffer in 225ml distilled water. Heat gently and adjust to pH7 with HC1. 
Final volume of 5X sample buffer should be adjusted to 250ml.
2X working sample buffer solution: dH20  1.5ml
p-mercaptoethanol 50pl
0.1% Bromophenol blue 25pl
5X stock sample buffer 1ml
20 mM Tris Buffered Saline (TBS), 140 mM NaCl pH  7.6 
Stock solutions A. 0.2 M Tris, 24.2g/l
B. 0.2 M Hydrochloric acid 
50ml of stock A and 38.4ml of stock B. Dilute 1:10 with distilled water, and add 882mg 
NaCl/100ml Tris.
10 mM Tris pH  8.0
Using the same stock solutions for TBS above, add 50ml solution A to 26.8ml 
solution B and dilute 1:1 with distilled water. Dilute this 1:10 with dH20.
2XTBS
Add 116.9g NaCl to 40ml 2M Tris/HCl. Make up to 21 with distilled water, pH 7.5. 
20mM TBS-T
To 250ml 2X TBS, add 250ml distilled water and 1 ml Tween 20. Mix thoroughly.
Other Solutions
Astrocyte culture media (100ml)
20% FCS-DMEM 
Heat inactivated 20ml
foetal calf serum 
2mM Glutamine 
(200 mM stock) 1ml
25pg/ml Gentamicin 
(lOmg/ml stock) 250pl
DMEM (1000g/l glucose) 78.75ml
Discard one month after preparation.
Collagenase
2000 U/ml solution of collagenase was prepared in Ca2+/Mg2+ free Dulbecco’s 
Modified Eagles Medium (DMEM-CFMF). The solution was passed through a 0.45pm 
filter, aliquotted and stored at -20°C
Cortical neurone culture media
To Neurobasal medium, 10% FCS (heat inactivated, non-dialysed), 1% glutamine, 
1% gentamicin and 1% nystatin were added. Media was filtered before use and kept for 1 
week only.
100X Cytosine arabinoside
A 5pM working solution was prepared by diluting stock solution 1:100. Stock 
solution of cytosine arabinoside was prepared freshly in water to give a concentration of 0.5 
mM
Heat-inactivated FCS
FCS was thawed and heated to approximately 60°C for at least 1 hour. Aliquot and 
store at -20°C
Gels
8% resolving gel: deionised water 45.6ml
(volume for 2 gels) Prosieve-50 12.8ml
1.5M Tris pH 8.8 20ml
10% SDS 800jul
10% APS 800pl
TEMED 40pl
10% FCS-DMEM 5% FCS-DMEM 
10ml 5ml
lml 1ml
250pl 250pl
88.75ml 93.75ml
5% stacking gel: deionised water
(volume for 2 gels) Prosieve-50
1M Tris, pH 6.8
18ml
2.4ml
3.1ml
240pl
240pl
25 pi
10% SDS 
10% APS 
TEMED
Neurobasal-B27 medium
Medium was prepared by adding 1ml of B27 supplement and 0.5ml 2 mM glutamine 
to 48.5ml Neurobasal medium
4% paraformaldehyde containing 4% sucrose
In a fume hood, approximately 60ml PBS was heated to 56°C. To this, 4g 
paraformaldehyde was added and stirred. 4g sucrose was added and the volume made up to 
100ml with PBS. Once dissolved, the solution was cooled and any residual cloudiness was 
removed by filtration. Store at 4°C. This fixative should be freshly prepared.
Polyvinyl alcohol (aqueous base) mounting media
To 40ml 0.2 M Tris-HCl, pH 8.5, 8g polyvinyl alcohol was added and heated to 
50°-60°C with occasional stirring. After the solution had cooled, 20ml glycerol and 2.5%
1,4 diazoabicyclo[2,2,2]octane (DABCO) were added. This was centrifuged at 5000 rpm 
for 15 min, aliquotted and stored at -20°C.
Soybean trypsin inhibitor-DNase
0.52mg/ml soybean trypsin inhibitor, 0.04mg/ml bovine pancreas Dnase and 
3.0mg/ml BSA were mixed and dissolved in DMEM. Stirring is necessary to aid 
solubilisation. The solution was filtered through 0.22pm and stored at 4°C.
0.25% Trypsin
2.5mg/ml trypsin (bovine pancreas) was dissolved in DMEM-CFMF. Store at 4°C 
after filtration. A 10X solution was also prepared
Appendix 3
Protocols for tissue processing and histology
4% paraformaldehyde fixative
In a fume hood, 4g/100ml PB paraformaldehyde was added to the appropriate 
volume of PB. The solution was heated to 56°C and mixed until the paraformaldehyde had 
totally dissolved. The solution was left to cool, filtered and stored at 4°C. Approximately 
200ml of fixative is required per animal.
Transcardiac perfusion fixation with 4% paraformaldehyde
For transcardiac perfusion fixation, the rat was anaesthetised with 5% halothane in a 
perspex anaesthetic chamber until the rat was deeply anaesthetised (no righting reflex, and 
breathing is slow and deep). Once deeply anaesthetised, 1ml euthatal was injected i.p. and 
the animal transferred to a fume hood and placed into the deep tray. Using forceps and large 
scissors, the skin was cut from below the sternum and up towards the throat. Holding the 
breast bone in place with forceps, the muscle layer was cut in the same direction as the 
diaphragm. The cartilege between the ribs was cut upwards towards the lungs on both sides 
and the breast bone was clamped in place. With forceps the heart was gently held in place 
and a small cut was made into the left ventricle. A stainless steel catheter attached to a 
bottle of heparinised saline (50 U/ml saline) was passed into the heart, up into the aorta and 
secured with clamps. Saline was introduced and a small incision was made in the right 
atrium. The pressure of saline flow was maintained at ~ 100 mmHg, and saline introduction 
was continued until the fluid expelled became clear (usually ~ 150-200 ml). Saline was 
stopped and paraformaldehyde fixative introduced into the animal, maintaining the pressure 
-lOOmmHg. After ~200-250mls fixative, the fix was discontinued. Animals were 
decapitated and heads were post-fixed in fresh 4% paraformaldehyde overnight at 4°C.
Processing o f tissue for paraffin embedding
Following the 24 hour post-fix, the brain was removed carefully (the post-fix should 
not exceed 24hr as this may produce artefacts in immunostaining), washed under running 
water and placed in 50 mM phosphate buffer (PB; for no longer than 7 days) at 4°C. The 
brains were then cut into coronal blocks using a rodent brain matrix (ASI instruments Inc., 
distributed by Bilaney). Each block was placed into an embedding cassette (Surgipath 
Medical Industries Inc.), caudal side up. The cassettes were placed into a container 
containing fresh PB and the cassettes were processed for embedding.
The cassettes were placed into:
1. Running water 30 min
2. 70% ethanol 2 x 30 min
3. 90% ethanol 2 x 30 min
4. 100% ethanol 2 x 30 min
5. xylene 2 x 30 min
6. paraffin wax 60°C, 1 - lV2hr
7. paraffin wax 60°C, overnight
Stainless steel moulds were cleaned in xylene. Wax was poured into one of the 
moulds carefully and placed onto a hotplate. Taking a cassette from the paraffin wax, the 
processed tissue (again caudal face up) was placed into the mould. The mould was then 
removed from the hotplate, and allowed to cool slightly. Once the base of the inside of the 
mould appeared slightly opaque, the cassette (without the lid) was pressed in place over the 
mould. The paraffin was allowed to cool a little while longer, then the mould was topped up 
with more paraffin. This process was repeated with all the remaining tissue.
The moulds are cooled at room temperature for at least 4 hrs before removing the 
mould. The wax blocks are now ready for cutting in a microtome.
Haematoxylin and Eosin histochemistry
1. Remove wax from sections, incubate in histoclear 10 min.
2. Dehydrate in absolute ethanol, 2 x 5  min.
3. Transfer into methylated spirits quickly, 1 min.
4. Wash sections in water, 1 min.
5. Stain with haematoxylin, 2 min
6. Rinse in water.
7. Transfer to 1% HC1 in methanol, 30 sec-1 min.
8. Rinse in water.
9. Transfer to Scots Tap Water Substitute, 2 min.
10.Rinse in water.
11. Stain with eosin (aqueous) for approximately 3 min.
12.Rinse well in water.
13.Dehydrate through ethanol (70% and 90%), 5 min each.
14. Transfer into absolute ethanol, 2 x 5  min.
15.Transfer into histoclear, 2 x 5  min.
16.Mount coverslips with DPX mountant.
17. Allow to dry for 24 hours.
Counter staining with haematoxylin following immunohistochemistry 
Following the production of the colour reaction with DAB, and the rinse with water, 
counterstaining with haematoxylin was carried out by following steps 5-9 above. The 
sections were then dehydrated and mounted by following steps 13-17 of the protocol.
Appendix 4
[14C]2-DG measurements following LY379268: statistical considerations
Following densitometric measurement of brain regions treated with LY3 79268, it 
was noticed that the glucose utilisation in some brain regions displayed a more 
heterogeneous spread, giving rise to a greater variance in standard deviation (SD), 
particularly in the higher dose treatment groups. A requirement of the ANOVA with post 
tests, in this case Student’s t-test, is a homogeneity in variance. That is, the SD from one 
sample should not be significantly different from the SD from another sample. It follows 
that when a comparison between groups is made and there is a marked change in the mean 
of the test groups, but a greater heterogeneity in variance, the more difficult it will be for 
the data to reach statistical significance. This may lead to an underestimation o f ‘significant’ 
data. Out of interest, the data was analysed post hoc using independent Student’s /-test, to 
compare the individual test groups with the vehicle controls to examine whether any 
significant changes arose. The findings are presented in table A4.1. It is clear that together 
with the original statistically significant reductions in glucose use, a number of additional 
regions demonstrate statistical significance using the alternative test. These regions all 
exhibited marked changes in glucose use following the respective dose of LY3 79268 
(chapter 3, tables 3 .3-3.7), but failed to reach statistical significance because of the greater 
variance in the data.
Table A4.1 Glucose use in animals treated with LY379268: post hoc comparison of data 
using an alternative statistical test.
REGION LY379268 LY379268 LY379268
0.1 mg/kg l.Omg/kg 10 mg/kg
Cerebellar white matter T=2.7, P<0.03
Cochlear nucleus T=3.4, P<0.009 
P<0.01
Cocus coeruleus T=4.4, P<0.004 T=6.0, P<0.0006 7H5.7, P<0.0007
P<0.001 P<0.001 P<0.001
Inferior colliculus T=2.5, P<0.04 
P<0.05
Median raphe nucleus T=2.581, P<0.05
Superficial layer of the superior T=5.9, P<0.0004 T=7.3, P<0.0001
colliculus PO.OOl P<0.001
Hippocampus T=3.3, P<0.01 
P<0.05
Mammillary body T=4.8, P<0.009 
P<0.001
Lateral habenular nucleus T=2.6, P<0.03 
P<0.05
Amygdala T=2.5, P<0.04
Anteroventral thalamic nucleus T=4.6, P<0.002 
P<0.01
Sensory motor cortex (IV) T=3.3, P<0.01 T=3.0, P<0.02
Sensory motor cortex (I/II) T=3.176, P<0.01
Sensory motor cortex (V/VI) T=2.6, P<0.03
Genu T=2.8, P<0.02 
P<0.05
Comparison of results obtained in chapter 3 using ANOVA followed by post tests (Student’s /-test with 
Bonferroni correction factor of 3) with Student’s unpaired t-test. Values indicate the original P values 
obtained from ANOVA and post tests.
Values indicate results obtained using independent Student’s unpaired t-test, comparing between the 
vehicle control group and the individual treatment group.
Appendix 5
Limbic system manipulation with LY326325; hippocampal analyses
Table A5.1 Glucose utilisation at 4 days (minipump active) after LY326325 or 
aCSF infusion in the stratum lacunosum moleculare of the 
hippocampus: left and right hemispheres considered separately.
Hippocampus 4 Days
(mm)
aCSF LY326325
Left Right Left Right
(bregma « -2.3mm) 
2.2
I T 68a
2.0 69a 69a
1.8 61 ± 9 65 ±5 71a 63a
1.6 60 ±3 59 ± 2 55 ±3 57 ± 4
1.4 6 1 + 2 58 ± 1 53 ± 1 52a
1.2 55 ±1 56 ±3 49 ±3 51 ±2
1.0 56 ± 2 54 + 2 44 ±3 46 ±3
0.8 52 ±3 49 ± 2 42 ± 4 41 ±4
0.6 54 ±3 50 ±3 40 ± 1 40 ±2
0.4 51 + 5 47+1 38 ± 2 41 ±3
0.2 55 + 1 52 + 2 38 ± 2 41 ±2
0 (INJECTION) 54 + 3 49 ±3 37 ±3 44 ±2
0.2 53+ 4 49 ±2 43 ±3 44 ±3
0.4 55 ± 6 52 ±5 45 ±5 46 + 0.5
0.6 57 + 4 58 ±3 48 ±3 49 ±3
0.8 58 ±5 57 ±3 53 ±3 56 + 3
1.0 62 + 3 60 ± 4 54 ± 4 57 ±3
1.2 62 ±3 62 ± 4 61 ± 4 64 ± 1
1.4 63 ±3 63 ±3 64 ± 2 63 ±3
1.6 62 ±3 60 ±3 64 ± 2 66 ±3
1.8 64 ± 1 62 ± 1 67 ± 2 66 ± 4
2.0 66 ±4 66 ± 1 66 ± 4 66 + 3
2.2 65 ±2 66 + 4 72a 68 + 1
2.4 63+ 3 65 + 3
(bregma * -7 mm) 
2.6
71a I T
Number of 5 5 5 5
animals
Data are presented as mean ± SEM (|imol/100g/min). The injection site ‘O’ approximates to 
bregma = -4.52 mm (Paxinos & Watson, 1986). 
aDensitometric analysis at this level only possible in one animal
Due to differences in the cut of the sections, densitometric readings carried out at the most 
rostral and caudal points of the hippocampus may only include a couple of the animals 
within each group.
Table A5.2 Glucose utilisation at 11 days (minipump exhausted) after LY326325 or 
aCSF infusion in the stratum lacunosum moleculare of the 
hippocampus: left and right hemispheres considered separately.
Hippocampus 11 Days
(mm)
aCSF LY326325
Left Right Left Right
(bregma «-2.3 mm) 
2.2
54a 74a
2.0 59a 67 + 12 ±
1.8 56a 61 ±3 78a 66a
1.6 62 ±8 65 ± 4 76 + 8 74 ±8
1.4 6 1 + 7 65 ± 6 70 ±3 75 ±5
1.2 60 + 8 64 ± 4 70 ± 2 72 ±2
1.0 61 + 10 63 ± 6 66 ± 4 68 ± 4
0.8 58 ± 11 61 ± 6 64 ± 2 64 ± 2
0.6 54 + 5 57 ±3 63 ± 2 62 ± 2
0.4 59 + 5 54 + 2 58 + 2 57 ±3
0.2 55 ± 4 52 ±3 59 ± 4 56 ±3
0 (INJECTION) 55+ 3 53+ 2 56 ± 4 56 + 4
0.2 61 ±5 57 ±5 56 ±3 58 ± 1
0.4 61 ±4 58 ±3 61 ± 2 65 + 3
0.6 63 ± 4 61 ±3 62 ± 2 62 ±2
0.8 66 ± 4 65 ± 4 66 ±3 67 ± 4
1.0 66 ±4 68 ± 4 67 ± 2 68 ± 4
1.2 66 ± 2 68 ±3 70 ±3 69 + 3
1.4 68 ± 1 71 ± 2 71 ± 1 71+ 3
1.6 70 ± 1 66 + 2 69 ±3 75 + 2
1.8 66 ±2 67+1 72 ±3 71 ±2
2.0 70 ±1 70 ± 4 71 ±4 75 ± 4
2.2 68 ±3 71 + 4 75 ±5 73 + 6
2.4 71 ± 2 73a 78 + 6 73+ 5
(bregma «-7  mm) 
2.6
71a 73a 78 ± 4 67 ±0.1
Number of 4 4 5 5
animals
Data are presented as mean ± SEM (pmol/100g/min). The injection site ‘O’ approximates to 
bregma=-4.52 mm (Paxinos & Watson, 1986). 
aDensitometric analysis at this level only possible in one animal
Due to differences in the cut of the sections, densitometric readings carried out at the most 
rostral and caudal points of the hippocampus may only include a couple of the animals 
within each group.
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Figure A5.1a Extent of the reduction of glucose use in the stratum lacunosum 
moleculare of the hippocampus: 4 days (minipump active).
The data are presented as mean (left/right side) ± SEM. The dotted line represents the site 
of injection (chosen from H & E stained sections). All data points to the left of the dotted 
line represent glucose use in the hippocampus at distances rostral to the injection site, while 
data points to the right of the dotted line represent glucose use in the hippocampus at 
distances caudal to the injection site.
B. 11 days: minipump exhausted
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Figure A5.2b Extent of the reduction of glucose use in the stratum lacunosum 
moleculare of the hippocampus: 11 days (minipump exhausted).
The data are presented as mean ± SEM. The dotted line represents the site of injection 
(chosen from H & E stained sections). All data points to the left of the dotted line represent 
glucose use in the hippocampus at distances rostral to the injection site, while data points to 
the right of the dotted line represent glucose use in the hippocampus at distances caudal to 
the injection site.
Appendix 6
LY379268: Quantification of infarct size following 24 hour permanent 
MCA occlusion
The method of analysis used in chapter 5 for quantification of ischaemic damage 
after MCA occlusion is carried out directly from the histology sections (see methods 2.3). 
Therefore, to remain consistent with the previous study, and with a view to compare the 
two data sets, this same method was initially used to evaluate the changes in infarct size 
after intervention with LY379268. However, because of the negative result demonstrated 
with LY3 54740, a decision was made to investigate other outcome parameters, in this case, 
cellular changes using immunohistochemical markers. For this purpose, it was necessary to 
fix the tissue, as the cell architecture observed in cryostat sections normally taken for the 
quantification of ischaemic damage is very poor, and due to the thickness of cryostat 
sections, they contain multiple cell layers. The volumes of ischaemic damage are 
summarised in table A6.1.
Upon examining the data in more detail, it was noticed that there appeared to be an 
approximate 20% difference in the swelling volume between the vehicle treated and 
LY379268 treated group. In addition, the swelling volumes measured in this study were 
substantially lower that that normally expected following permanent occlusion of the MCA. 
Comparison with the LY354740 data (chapter 5, table 5.1) demonstrates that the volume of 
swelling has reduced markedly from approximately 100 mm3 to less than 35 mm3. Brain 
swelling is a consequence of the ischaemic insult, and is directly proportional to the volume 
of the lesion in animals (see chapter 5, figure 5.7). However, in this study, as figure A6.1 
illustrates, there is no relationship whatsoever between the ischaemic lesion volume and 
swelling (r2=0). From other plots carried out, figure A6.2 reveals there are no correlations 
between the volume of ischemic damage and the volume of the contralateral hemisphere. 
However, figure A6.3 suggests that there is a negative correlation between the volume of 
ipsilateral swelling and the volume of the contralateral hemisphere.
Shrinkage of tissue as a direct result of fixing is recognised (Stowell, 1941). One of 
the problems encountered in the fixation of tissue that has undergone an episode of 
trauma/insult, is the passage of water through the tissue. The fixation process requires all 
aqueous solutions present in the tissue to be substituted with paraffin wax. However, if 
tissue has undergone a traumatic episode, such as ischaemia, a proportion of cells in the 
tissue will be dead and will have lost its normal cell structure. As a result of this, water 
removal and replacement with wax will cause the tissue to shrink. Moreover, once cut, 
microtome sectioned tissue is placed over water to allow the tissue to flatten out and 
remove any creases or folds. Again, because the tissue has undergone damage, water 
entering the tissue
is not controlled as the cells have lost their normal architecture. The changes in the volume 
of swelling in this study can probably be directly attributed to the fixation process. In 
addition, figure A6.3 appears to suggest that there is less swelling present in tissue that 
exhibit a greater contralateral hemispheric volume. This could be an issue of time. It is 
possible that the longer the tissue has spent in the water bath before being picked up onto a 
slide results in a non uniform increase in the size of the tissue. That is, even if a section was 
hypothetically very swollen as a direct result of ischaemia, but spent a protracted time in 
water, any issue of swelling could not be measured. Figure A6.4 demonstrates the 
variability observed in the size of the tissue as a result of the fixation process.
Due to the distortion of the material, a decision was made to analyse the areas of 
ischaemic damage using an alternative approach. This method for measuring infarct size 
excludes the contribution of swelling (Osborne et al., 1987). More specifically, this 
approach requires the delineation and transcription of the ischaemic damage onto scale
diagrams (4 times actual size) of the 8 pre-selected stereotaxic coronal levels of the brain 
drawn from the Atlas of Konig & Klippel (1963). A comparison between the volumes of 
ischaemic damage obtained by the direct histology method and the scale line diagram 
method is presented in table A6.2.
Table A6.1 LY379268 and the volume of ischaemic damage (mm3): direct histology
method.
VOLUME (mm3) VEHICLE LY379268 (lOmg/kg)
Infarct 145 ±13 135 ± 14
Swelling 34 ±3 27 + 4
% Infarct volume3 21 ± 2 19 ± 2
Number of animals 10b 10b
The data are presented as mean ± SEM.
aSwanson et al., 1990. bOne animal from each group only contained 7 of the 8 stereotaxic 
levels. For these animals, the volumes were still calculated, but taking into account the 
missing level.
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Figure A6.1 The relationship between the volume of infarction (mm3) and the
volume of ipsilateral hemispheric swelling (mm3) in vehicle and
LY379268 treated animals
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Figure A6.2 The relationship between the volume of infarction (mm3) and the
volume of the contralateral hemisphere (mm3) in vehicle and LY379268
treated animals.
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Figure A6.3 The relationship between the volume of ipsilateral hemispheric swelling
(mm3) and the volume of the contralateral hemisphere (mm3) in vehicle
and LY379268 treated animals.
Figure A6.4 Artefacts resulting from the fixation and paraffin embedding process.
All the sections underwent the same fixation process a) + b) are sections obtained from 
the study described in chapter 6. c) is a representative example from a different study. 
Note the differences in the size of the tissue.
Table A6.2. Comparison of the volumes of ischaemic damage obtained using the 
direct histology method and the scale line diagram method which 
excludes the contribution of swelling.
ANIMAL VOLUME OF ISCHAEMIC DAMAGE (mm3)
Vehicle:
AMI
AM2
AM6
AM8
AM9
AM10
AMI 1
AM12
AM13
AM19
LY379268:
AM3
AM4
AM5
AM7
AM14
AM15
AM16
AM17
AM18
AM20
direct histology method
186.2
158.9
153.1 
141.8*
81.5
91.0
109.0
148.8
178.4
200.2
127.6
189.4
83.2
191.8
137.9
88.3 
102.7*
150.1
97.8
184.9
scale line diagram method
124.8
108.3
96.1 
n/a
72.4
54.9
95.0
111.8
115.3
125.8
75.9
122.2
40.9
129.4
114.4
99.1 
n/a
115.2
55.1
123.1
* not all 8 levels present
